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“If you can’t explain it simply, you 
don’t understand it enough” 
 
A. Einstein 
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1. Mycotoxins 
1.1. The mycotoxin issue 
A toxin can be defined as a substance that is synthesized by a plant species, an animal, or by 
micro-organisms, which is harmful to another organism. Mycotoxins are secondary 
metabolites produced by fungi, mostly by saprophytic moulds growing on a variety of feed- 
and foodstuffs (Turner et al., 2009). The name mycotoxin is a combination of the Greek word 
for fungus ‘mykes’ and the Latin word ‘toxicum’ meaning poison. Mycotoxin producing fungi 
can be divided in two classes, namely field and storage fungi. Field fungi, such as Fusarium 
species, produce mycotoxins during their growth in the field whereas storage fungi, such as 
Aspergillus and Penicillium species, produce mycotoxins after crop harvesting. Many factors 
can influence mycotoxin production, but temperature and humidity are commonly accepted 
as the most determining factors in the field, as during storage (Filtenborg et al., 1996). 
Mould contamination does not necessarily implicate mycotoxin production. Furthermore, 
some mycotoxins are produced by only a limited number of fungal species, while others may 
be produced by a relative large range of genera. The prevalence of different fungal species is 
region dependent. Fusarium produced mycotoxins are more likely to occur in moderate 
regions, such as Western-Europe and North-America, whereas Aspergillus and Penicillium 
species are more prevalent in (sub-)tropical regions. Nevertheless, ochratoxin A, produced 
by P. verrucosum, can also occur in more moderate regions (Duarte et al., 2010). 
Contamination of feedstuffs with mycotoxins occurs worldwide at a higher level than 
generally assumed. In 2001, the Food and Agricultural Organization (FAO) stipulated that 
25% of feedstuffs worldwide are contaminated (FAO, 2001). In a more recent paper, it was 
shown that one or more mycotoxins could be detected in 82% of European crop samples 
(Monbaliu et al., 2010). In general, more than 50% of European samples are contaminated 
with deoxynivalenol at low levels and 75-100% of the samples are contaminated with one or 
more mycotoxins (Streit et al., 2012). 
Up until now, over 400 mycotoxins with toxic potential have already been described (Kabak 
et al., 2006), however only few of them have distinct toxic effects. The toxicological risk has 
deemed to exist since the beginning of organized agriculture. In the Old Testament, some 
references to ergotism have been found (Schoental, 1984) as well as to T-2 toxin (T-2) and 
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zearalenone (ZON). ZON is thought to be responsible for the decline of the Etruscan 
civilization (Schoental, 1991). Egyptian farao tombs would have contained ochratoxin A 
(OTA), held responsible for the death of archeologists (Pittet, 1998). In the Middle Ages, 
ergotism, due to ergot alkaloids from Claviceps purpureae fungi, was spreading. Ergotism 
was called Saint Anthony’s fire, named after the monks of the Order of St. Anthony who 
would have been successful in treating the symptoms of the ergot alkaloids. It was not until 
the 1960’s that the first cases of mycotoxicosis were demonstrated. In Great Britain, more 
than 100 000 turkeys died due to liver necrosis and biliary hyperplasia (Turkey ‘X’ disease), 
where the etiological agents were aflatoxins (Nesbitt et al., 1962). Since then, a tremendous 
amount of research has been conducted to investigate a variety of mycotoxins, their 
potential toxic effects and how to counteract their effects. 
1.2. Fusarium mycotoxins 
Fusarium fungi are field fungi, commonly occurring in Western-Europe due to its moderate 
climate. They can produce a variety of mycotoxins, however the most toxicological 
important are trichothecenes (including deoxynivalenol (DON) and T-2), ZON and fumonisin 
B1 (FB1). 
Trichothecenes are generally produced by Fusarium spp., however not limited as they can 
also be produced by other unrelated genera, such as Stachybotrys, Trichoderma, 
Cephalosporium and others (Ueno, 1985). Many trichothecene producing Fusarium spp. are 
causal agents of Fusarium Head Blight (FHB), root rot and foot rot in cereals. These include F. 
graminearum, F. poae and F. culmorum (Rocha et al., 2005). The most common ZON 
producing Fusarium fungi are F. graminearum and F. culmorum, but also F. cerealis, F. 
crookwellense, F. semitectum and F. equisiti (Zinedine et al., 2007). Fumonisins are produced 
by F. verticillioides (formerly F. moniliforme), F. proliferatum and other minor species 
including F. nygamai (Thiel et al., 1991). 
Enniatins (ENNs) and beauvericin (BEA) are ‘emerging’ Fusarium mycotoxins which have only 
recently been of interest (Jestoi, 2008). The most important ENNs are enniatin (ENN) A, A1, B 
and B1. They are primarly produced by F. avenaceum but also by other species such as F. 
tricinctum, F. poae and F. culmorum (Logrieco et al., 2002). 
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Next to these Fusarium mycotoxins, also other compounds can be produced by several 
Fusarium spp. A synergistic effect between DON and fusaric acid (FA) has been 
demonstrated by Smith et al. (1997). Acute dosing of swine with FA causes vomiting, 
lethargy and neurochemical changes by altering the serotonin synthesis in the brain, as does 
DON (Smith and MacDonald, 1991). Bacon et al. (1995) observed synergistic effects between 
FA and FB1 (both produced by F. verticillioides) when administered simultaneously to 
developing chicks in ovo. However, FA is not commonly analyzed in feed samples as it is not 
considered a major contaminant by various research labs. At the time being it is still unclear 
what the contribution of FA is in feed-borne mycotoxicosis. 
1.2.1. Deoxynivalenol and T-2 toxin 
Chemical structure 
DON and T-2 are both trichothecenes. They are sesquiterpenoids, consisting of an alkene 
group at C-9, 10, an epoxy at C-12, 12, which is essential for its toxicity (Desjardins et al., 
1993), and a variable number of acetoxy and hydroxyl groups. They have been classified into 
A, B, C and D toxins, depending on their functional groups (Ueno, 1977). Members of group 
A (e.g. T-2 and HT-2 toxin) do not contain carbonyl on C-8. Hydrolysis of ester groups leads to 
the formation of a basic trichothecene moiety with one to five hydroxyl groups. Group B 
(e.g. DON) differs from group A by the presence of a carbonyl group on C-8. Group C 
members (e.g. crotocine) have another epoxy group between the C-7 and C-8 or C-8 and C-9 
positions, respectively. Compounds in group D, also called macrocyclic trichothecenes, (e.g. 
satratoxin G) include a macrocyclic ring between C-4 and C-15 (Wu et al., 2010). 
  
  
Figure 1. Chemical structure of T-2 toxin (T
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The most prominent molecular target of trichothecenes is the 60S ribosomal unit, where 
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activation, DON increases the expression and stability of cyclooxygenase-2 (COX-2) mRNA 
and hence protein content in leucocytes, confirming its role in the inflammatory process 
(Moon and Pestka, 2002). Recently it has been demonstrated that 15a-DON would be a 
more potent activator of MAPK in vitro compared to DON or 3a-DON (Pinton et al., 2012), in 
contrast to what is generally accepted. 
Toxicity in pigs and poultry 
The first symptoms of trichothecene intoxication were observed in the USSR in 1930s where 
consumption of overwintered moldy feed resulted in massive outbreaks of alimentary toxic 
aleukia (ATA) in pigs. Symptoms included vomiting, diarrhea, leucopenia, hemorrhage, shock 
and death (Joffe and Palti, 1974). 
Pigs are the most sensitive species for DON as well as T-2, mainly due to their limited 
metabolic activity (Wu et al., 2010). High exposure of DON or ‘vomitoxin’ to pigs elicits 
abdominal distress, malaise, diarrhea, emesis and even shock or death (Pestka, 2010). The 
emetic effect is thought to be mediated through affection of the serotonergic activity in the 
central nervous system or via peripheral action on serotonin receptors (SCF, 1999). T-2 is 
one of the most acute toxic mycotoxins. Acute mycotoxicosis in pigs is characterized by 
multiple hemorrhages on the serosa of the liver and along the intestinal tract (Weaver et al., 
1978).  
 
Poultry are less susceptible to trichothecenes than pigs, however LD50 values, the acute dose 
at which 50% of the tested animals die within 24 h, are moderate. The LD50 value is 5 mg/kg 
BW for T-2 (compared to 1.2 mg/kg BW for pigs) and 140 mg/kg BW for DON (Chi et al., 
1977; Huff et al., 1981; Schuhmacher-Wolz et al., 2010). Acute intoxication in broiler 
chickens has several consequences including internal hemorrhage, mouth and skin lesions 
(necrohemorrhagic dermatitis), impaired feather quality and neural disturbances (Sokolovic 
et al., 2008).  
 
Chronic exposure to lower doses of DON and T-2 induces growth retardation, weight gain 
suppression and feed refusal in pigs and poultry. The immune system is very sensitive to 
trichothecenes and can be either stimulated or suppressed depending on the time, duration 
 and dose of exposure (Pestka, 2008; Sokolovic et al., 2008)
inflammatory gene expression at mRNA and protein levels, while high concentrations 
promote leukocyte apoptosis. Trichothecenes, especially DON and T
reproductive and teratogenic effects, however 
International Agency for Research on Cancer (IARC) has listed them as group 3 substance
(non-carcinogenic) (IARC, 1993)
 
1.2.2. Zearalenone 
Chemical structure 
ZON is a resorcylic acid, and was given the trivial name 
Giberella zeae (now Fusarium graminearum
of the C-1,2 double bond) and 
(Figure 2). 
Figure 2. Chemical structure of zearalenone (
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allowing the receptor to interact with chromatin and to modulate transcription of target 
genes (Kuiper et al., 1998). Not all compounds have the same affinity for estrogen receptors. 
It has been shown that the metabolites of ZON can express lower or even higher affinities to 
estrogen receptors than the parent compound. Metabolisation of ZON occurs primarily in 
the liver, but a variety of organs show metabolisation activity such as intestine, kidney, ovary 
and testis. ZON is metabolized by 3α- and 3β-hydroxysteroid dehydrogenase (HSD) into α- 
and β-zearalenol (ZOL), respectively. β-ZOL has a 2.5 times lower affinity for the estrogen 
receptor, whereas α-ZOL has a 92 times higher binding affinity compared to ZON. The 
metabolisation to β-ZOL can therefore be regarded as an inactivation pathway, whereas the 
metabolisation to α-ZOL can be seen as an bioactivation pathway (Malekinejad et al., 2006). 
The rate of α- or β-ZOL production, and consequently the susceptibility, is species 
dependent. Pigs are the most sensitive species, which has been confirmed by in vitro data 
demonstrating that pig liver microsomes dominantly convert ZON into α-ZOL. Poultry and 
cattle metabolize ZON to a large extent into β-ZOL, confirming their relative resistance 
(Malekinejad et al., 2006; Zinedine et al., 2007).    
Following or contemporary to these hydroxylation reactions, phase II metabolisation 
reactions take place. ZON and its metabolites are conjugated with glucuronic acid, catalyzed 
by uridine diphosphate glucuronyl transferases (UDPGT) (Olsen et al., 1981). Glucuronidation 
enhances the water solubility of compounds, thus enhancing renal elimination. On the other 
hand, it prolongs the total body residence time due to enterohepatic circulation, which has 
been demonstrated for ZON (Biehl et al., 1993). 
Toxicity in pigs and poultry 
The acute toxicity of ZON is rather low. Oral LD50 values in mice and rat vary from 4000 to 
>20000 mg/kg BW (Hidy et al., 1977). The specific manifestations of ZON in pigs are 
dependent of the dose, age, stage during estrus cycle and pregnancy or not. ZON 
intoxication leads to an estrogenic syndrome and affects primarily the reproductive tract and 
mammary gland. In young gilts, 1-5 mg/kg feed induces clinical signs such as hyperemia, 
oedemateus swelling of vulva and even vaginal or rectal prolaps (Minervini and Dell'Aquila, 
2008). At lower doses (0.05 mg/kg feed) ZON induces vulva redness, swelling of the 
mammary gland and numerous vesicular follicles and some cystic follicles on the ovaries 
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(Bauer et al., 1987). In cyclic animals, nymphomania, pseudopregnancy, ovarian atrophy and 
changes in the endometrium are reported. During pregnancy, ZON can induce embryonic 
death, decrease fetal weight and induce teratogenic effects in piglets characterized by 
various genital abnormalities (D'Mello et al., 1999). In boars, ZON can suppress testosterone 
levels, testes weight and spermatogenesis, while inducing feminization and suppressing the 
libido (Zinedine et al., 2007). 
ZON has little effect on poultry reproduction due to their well developed metabolisation 
pathways. Feeding mature chickens a diet contaminated with ZON up to 800 mg/kg did not 
affect their reproductive performance (Allen et al., 1980; Allen et al., 1981a). Moreover, this 
contamination level does not have negative effects on performance of mature broiler 
chickens or young turkey poults either (Allen et al., 1981b). However, feeding 100 mg 
ZON/kg feed to mature female turkeys, reduced the egg production by 20% (Allen et al., 
1983). 
Next to their major effects on the reproduction and hormone system, ZON and its 
metabolites may also affect other organ systems. ZON was shown to be hemotoxic. It 
disrupts the blood coagulation process, alters hematological parameters (such as hematocrit 
count, mean cell volume and number of platelets) as well as some serum biochemical 
parameters (such as aspartate aminotransferase, alanine aminotransferase, serum creatine 
and bilirubin) (Maaroufi et al., 1996). ZON is also hepatotoxic, shown by altered serum 
biochemical parameters (Zinedine et al., 2007). Genotoxic and immunotoxic effects of ZON 
have also been demonstrated in vitro and in mice (JECFA, 2000). The IARC has classified ZON 
as a non-carcinogenic component (group 3) (IARC, 1999). Nevertheless, more recent data 
demonstrate that ZON stimulates growth of mammary tumors containing estrogen 
receptors, indicating that it can play a role in tumor development upon chronic exposure 
(Ahamed et al., 2001; Yu et al., 2005). 
1.2.3. Fumonisin B1 
Chemical structure 
The chemical structure of fumonisins was first identified in 1988 (Gelderblom et al., 1988). 
Today, more than 28 fumonisin homologues have been identified. Fumonisin B1 is the most 
 thoroughly investigated because of its toxicological importance (Figure 3). Fumonisin B2, B3 
and B4 are less prevalent and differ structurally from FB1 in the number 
hydroxyl groups, i.e. a loss of a hydroxyl group on C
respectively (Voss et al., 2007)
activity of fumonisins. Deamination leads to a significant
2001a). Cleavage of the tricarballylic acid side chains of FB1 leads to a less toxic 
metabolisation product, named hydrolyzed fumonisin B1 (HFB1) 
Figure 3. Chemical structure of fumonisin B1
Mode of action 
Fumonisins competitively inhibit sphinganine N
consequently disrupt the ceramide and sphingolipid metabolism (Figure 4) 
2001; Riley et al., 2001). The inhibition of ceramide synt
accumulation of free sphinganine (Sa), and to a lesser extent of sphingosine (So), and 
decrease of complex sphingolipids formation. The increase of free Sa leads to an increased 
Sa:So ratio in tissues and body fluids, whi
biomarker for fumonisin exposure in mammals and avian species 
increase is dose and time dependent and is 
2007). The increased concent
ceramide concentration all contribute to the apoptotic, cytotoxic and growth inhibitory 
effects of fumonisins (Merrill et al., 2001)
itself appears to contribute to the cellular effects of FB1 as well 
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Figure 4. Mode of action of fumonisins (Voss et al., 2007) 
Toxicity in pigs and poultry 
Signs of acute fumonisin intoxication include non-species specific symptoms such as 
hepatotoxicity and renal failure, as well as species specific symptoms on target organs. The 
well described pathology in horses is called equine leukoencephalomacia (ELEM), where the 
brain is targeted. In pigs, primarily the heart tissue is affected, leading to cardiac 
insufficiency and consequently to pulmonary edema, called porcine pulmonary edema (PPE). 
FB1 as causal agent of PPE was first identified in 1992 (Osweiler et al., 1992). Thousands of 
pigs died in the USA due to consumption of corn contaminated with F. verticillioides. 
Symptoms of this intoxication are reduced feed intake at first, followed by respiratory 
distress and cyanosis a couple of days later and finally death caused by hydrothorax and 
acute pulmonary edema (Haschek et al., 2001). Poultry are quite resistant to fumonisin 
toxicity. Nevertheless, they are at risk because the major part of their diet consists of maize, 
which can be highly contaminated (Diaz and Boermans, 1994). High doses (up to 300 mg/kg 
feed) are needed to induce clinical toxicity including decreased weight gain and liver failure 
in broiler chickens (Ledoux et al., 1992). In general, high doses are needed to induce toxicity 
as fumonisins have a very low oral bioavailability (Martinez-Larranaga et al., 1999). Turkeys 
are also quite resistant to fumonisin toxicity, however they are still more susceptible 
compared to chickens (Weibking et al., 1994).  
 In mammals and poultry, immunosuppression has been demonstrate
fumonisin exposure. This is economically important as adverse effects on the immune 
system can lead to increased pathogen susceptibility and lowered vaccinal response 
al., 2007). Next to their effect on heart, liver and immune func
reproductive, teratogenic and carcinogenic effects in laboratory animals 
2001; Riley et al., 2001; Voss et al., 1996a; Voss et al., 1996b)
a group 2B compound (possibly carcinogenic to 
1.2.4. Enniatins and Beauvericin
Chemical structure 
BEA and ENNs are cyclic hexsadepsipeptides consisting of alternating D
and amino acid units. In BEA the three amino acid residues are aromatic N
phenylalanines, whereas in ENNs they are aliphatic N
subunits are linked with peptide bonds and intra
depsipeptide (Figure 5) (Jestoi, 2008)
 R1 R2
BEA phenylmethyl phenylmethyl
ENN A sec-butyl sec
ENN A1 sec-butyl sec
ENN B iso-propyl iso
ENN B1 iso-propyl iso
Figure 5. The chemical structures of beauvericin (BEA) and enniatin (ENN) A, A1, B 
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Mode of action 
ENNs and BEA are of interest because they can exert antibacterial, antifungal and phytotoxic 
effects (Jestoi, 2008; Meca et al., 2010; Meca et al., 2011). On the other hand, they can also 
be toxic for mammalian cells. Their main mode of action is based on their ionophoric 
properties (Ivanov et al., 1973). They are capable of transporting cations through the cell 
membrane, leading to toxic actions by disturbing the normal physiological level of cations in 
the cell (Jestoi et al., 2009). Next to their ionophoric properties, ENNs exhibit other effects, 
such as inhibiting acyl-coenzyme A:cholesterol acyl transferase (ACAT) and 30,50-cyclo-
nucleotide phosphodiesterase enzymes (Tomoda et al., 1992), causing mitochondrial 
dysfunction (Tonshin et al., 2010), and the inhibition of multidrug resistance associated 
protein-1 (ABCG2) and P-glycoprotein (ABCB1) efflux pumps (Dornetshuber et al., 2009). 
Toxicity in pigs and poultry 
ENNs and BEA have not been thoroughly investigated because they have not been 
associated with clinical mycotoxicosis yet. Therefore, most research focused on other, more 
toxic compounds as those described in this thesis. Nowadays, the role of mycotoxins in 
subacute or subclinical toxicology is of greater concern in animal nutrition. Subclinical 
mycotoxicosis can lead to reduced feed consumption and growth, poorer reproductive 
capacities and altered immunological response which causes increased susceptibility for 
infectious disease (CAST, 2003). ENNs and BEA have been found to be common co-
contaminants of feedstuff, the reason why they became of interest. In a study on Finnish 
grains, BEA, ENN A, A1, B and B1 were detected in 95, 95, 74, 100 and 100% of the samples, 
respectively, at concentrations ranging from trace levels up to 18.3 mg/kg (Jestoi et al., 
2004). 
Cytotoxicity of ENNs and BEA has been demonstrated in vitro on various cell types (for 
review see Jestoi, 2008). Data on their in vivo toxicity is, however, lacking. Feeding studies 
performed on chickens or turkeys did not show any negative effect of these mycotoxins 
(Leitgeb et al., 1999; Leitgeb et al., 2000; Zollitsch et al., 2003). However, contamination 
levels tested in these studies were rather low (1.4 -12.0 mg BEA/kg feed and 2.5 mg ENNs/kg 
feed), especially when one bears in mind that detected concentrations of BEA and ENNS are 
up to 520 and 18 mg/kg, respectively (Jestoi et al., 2004; Ritieni et al., 1997).  
 1.3. Aspergillus and Penicillium
 
Aspergillus and Penicillium 
mycotoxins. Toxicologically, the most important ones are OTA and aflatoxin B1 (AFB1). 
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produced during storage by 
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bombycis and A. pseudotamari, 
 
1.3.1. Ochratoxin A 
Chemical structure 
OTA consists of a dihydroisocoumarin subunit, linked to phenylalanine by a peptide 
(Mally and Dekant, 2009) (Figure 6). Cleavage of the dipeptide bound induces the formation 
of ochratoxin alpha (OTα), a nontoxic metabolite. Other major, but less toxic, ochratoxins 
are ochratoxin B and C, which vary from OTA by loss of the chlorine on C
formation on the carboxyl function at
Atoui, 2010; Wu et al., 2011). 
 
Figure 6. Chemical structure of ochratoxin A
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Mode of action 
OTA does not act through a single well-defined mechanism but disturbs cellular physiology in 
multiple ways (Marin-Kuan et al., 2008). It seems that the primary effects are associated 
with inhibition of the enzymes involved in the synthesis of the phenylalanine tRNA-complex, 
thus interfering with phenylalanine metabolism. In addition, it stimulates lipid peroxidation 
(Bennett and Klich, 2003). OTA is also considered carcinogenic amongst laboratory animals, 
IARC Class 2B (IARC, 1993), although the mode of action has not been well described yet 
(Mally, 2012). The suggested molecular targets are histone acetyltransferases (HATs). These 
enzymes are critical in the regulation of a diverse range of cellular processes, including gene 
expression, DNA damage repair and mitosis through posttranslational acetylation of histone 
and nonhistone proteins (Czakai et al., 2011; Mally, 2012). 
Toxicity in pigs and poultry 
Dietary human exposure to OTA has long been suspected to be involved in Balkan endemic 
nephropathy (BEN) occurring in the 1950s although no direct proof can be put forward 
(Pfohl-Leszkowicz, 2009). The first report of OTA intoxication in animals was in the 1960s and 
1970s in Denmark where mycotoxic porcine nephropathy (MPN) has been correlated with 
OTA ingestion (Krogh et al., 1973). The kidneys are the main target organ of OTA. 
Considerable species differences in sensitivity towards acute OTA toxicity have been 
demonstrated (O'Brien and Dietrich, 2005). Pigs are particularly sensitive to OTA because of 
the long serum half-life and tissue accumulation. This is sustained by high protein affinity 
and enterohepatic and renal recirculation. Poultry species eliminate OTA faster than 
mammals, leading to a lower accumulation level. The half-life of OTA in pig plasma is 20-30 
times longer than that in poultry plasma leading to a higher OTA contamination level and 
incidence in pigs (Duarte et al., 2011). This difference is also demonstrated by the difference 
of LD50 value in pigs and poultry: an oral LD50 value of 1.0 mg/kg BW for pigs versus 3.3 
mg/kg BW for chickens and 5.9 mg/kg BW for turkeys (El-Sayed et al., 2009; Peckham et al., 
1971). 
Following chronic exposure to lower levels of OTA, the kidneys are again primarily affected, 
causing mycotoxic nephropathy in pigs as well as in chickens (Stoev et al., 2010). Several 
 pathological changes can be observed, varying from desquamation and focal degeneration 
of tubular epithelium cells to peritubular fibrosis and thickening of the basal membrane 
(O'Brien and Dietrich, 2005). This leads to renal insufficiency, but not to tumor promotion in 
poultry and mammals. In addition, OTA is hepatotoxic, teratogenic and immunotoxic 
et al., 2011).  
1.3.2. Aflatoxin B1 
Chemical structure 
Over a dozen different aflatoxins have
UV-light (blue or green) the four major aflatoxins are called aflatoxin B1, B2, G1 and G2, of 
which AFB1 is the most toxic 
Asao et al. (1965), and it consists of a difuro
Other aflatoxins have different substitutions but they all share the basic coumarine 
structure. 
 
Figure 7. Chemical structure of aflatoxin B1
Mode of action 
Aflatoxins are converted by cytochrome P450 enzymes (phase I metabolisation) to the 
reactive 8,9-epoxide form, which is essential for the toxicity. The responsible converting 
enzymes in mammals are mainly CYP1A2 and CYP3A4 
and turkeys, the corresponding enzymes are CYP2A6 and to a lesser extent CYP1A1 
orthologs (Diaz et al., 2010a, 
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genotoxicity) and proteins (causing cytotoxicity). More specifically it binds to guanine 
residues of nucleic acids (Doi et al., 2002). Moreover, aflatoxin B1-DNA adducts can result in 
guanine-cytosine (GC) to thymine-adenine (TA) transversions (Bennett and Klich, 2003). This 
both leads to irreversible DNA damage and causes hepatocellular carcinomas (Eaton and 
Gallagher, 1994). 
The toxic epoxide metabolite can be detoxified by gluthatione conjugation (phase II 
metabolisation) or hydrolysis by an epoxide hydrolase to AFB1-8,9-dihydrodiol (AFB1-dhd) or 
by metabolisation to less toxic compounds such as aflatoxin M1 (AFM1) or Q1 (AFQ1) (Diaz 
et al., 2010b; Gallagher et al., 1996). This AFM1 for example is the main metabolite formed 
in cattle and is excreted in the milk. As this metabolite still possesses carcinogenic properties 
(10 times lower than AFB1), maximum limits in milk intended for human consumption have 
been established (0.05 µg/kg) (European Commission, 2010). 
Toxicity in pigs and poultry 
The main biological effects of aflatoxins are carcinogenicity, immunosuppression, 
mutagenicity and teratogenicity (Ramos and Hernandez, 1997). Because of its pronounced 
carcinogenic effects, even in humans, the IARC has classified AFB1 as a group 1 compound 
(IARC, 1993). 
Acute aflatoxicosis in pigs has been long described (Coppock et al., 1989). Intake of 
contaminated feed (0.2 mg/kg) leads to reduced feed intake and body weight gain, impaired 
liver and immune functions and altered serum biochemical parameters (Harvey et al., 1990; 
Lindemann et al., 1993; Rustemeyer et al., 2010 and 2011). 
Poultry species are the most susceptible production animals to AFB1. Feed contaminated 
with even small amounts of AFB1 results in significant adverse health effects, including 
death. On autopsy, generally a firm and pale liver is found, the target organ of aflatoxins. 
When chickens are chronically exposed to lower doses, growth retardation occurs, as well as 
immunological alterations and histological changes in the liver (‘fatty liver’) (Newberne and 
Butler, 1969). Turkeys are even more susceptible to aflatoxin intoxication than chickens, 
attributed to a combination of efficient AFB1 activation and deficient detoxification by phase 
II enzymes such as glutathione-S-transferase (Klein et al., 2000). Feeding a diet contaminated 
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with 1 mg/kg AFB1 to turkeys resulted in 88% mortality rate (Kubena et al., 1991). Lower 
concentrations induced poor performance, decreased organ weights, liver damage and 
changes in biochemical serum values (Coulombe, 1993; Kubena et al., 1991).   
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2. Methods to counteract mycotoxins 
 
Because of the detrimental effects of mycotoxins, a number of strategies have been 
developed to reduce the growth of mycotoxigenic fungi and mycotoxin production, to 
detoxify contaminated feed and to lower the systemic availability once mycotoxins are 
ingested by the animal. 
 
2.1. Pre- and post-harvesting strategies 
 
Mycotoxin contamination may occur in the field, pre-harvesting, or during storage and 
processing, post-harvesting. Methods for preventing mycotoxicosis in animals may therefore 
be divided into pre- or post-harvesting strategies. Certain methods have been found to 
significantly reduce specific mycotoxin contamination although the complete elimination of 
mycotoxins is currently not achievable (Kabak et al., 2006). 
The most important strategy to bear in mind for pre-harvesting is the application of Good 
Agricultural Practices (GAP). Appropriate GAP includes crop rotation, soil cultivation, 
irrigation and proper use of chemicals. Crop rotation is important and focuses on breaking 
the chain of infectious material, for example by wheat/legume rotations. Including maize in 
the rotation should be avoided, as it is very susceptible to Fusarium spp. infestations. Any 
crop husbandry that includes destruction, removal or burial of the infected crop is seen as 
good soil cultivation. The deeper the soil is inverted (ploughing), the less plausible fungi 
growth will be on the following crop (Edwards, 2004). Reducing plant stress by irrigation is 
also valuable to prevent fungi infestation. All plants in the field need an adequate water 
supply, however excess irrigation during flowering (anthesis) makes conditions favorable for 
Fusarium infection (Codex Alimentarius, 2002). Another factor which is known to increase 
the susceptibility of agricultural commodities to mould invasion is damage due to birds, 
insects or rodents. Insect damage and consequent fungal infection must by controlled by 
appropriate use of insecticides and fungicides. This should be integrated with adequate pest 
management control (Codex Alimentarius, 2002). 
All these parameters can be controlled, however environmental conditions cannot. Relative 
humidity and temperature are known to have an important onset on mould infection and 
mycotoxin production. Drought damaged plants are shown to be more susceptible to 
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infection, so crop planting should be timed to avoid high temperatures and drought (Kabak 
et al., 2006). For Fusarium spp. infection on the other hand, sufficient moisture conditions at 
anthesis are critical for the onset of FHB (Aldred and Magan, 2004). 
Post-harvest storage conditions are essential in preventing mould growth and mycotoxin 
production (Schrodter, 2004). For example, grains should be stored with less than 15% 
moisture to avoid hotspots with high moisture, favorable for mould growth (Jard et al., 
2011). Before storage, visibly damaged or infected grains should be removed. This method is 
however not exhaustive or very specific (Jard et al., 2011) and multiple reduction strategies 
should be combined. 
Several chemical detoxification methods have also been described. In all cases, they should 
destroy or inactivate mycotoxins, generate non-toxic products, warrant the nutritional value 
of the food or feed and do not induce modification to the technical properties of the product 
(Jard et al., 2011). The wide variety of chemical decontamination processes include 
radiation, oxidation, reduction, ammonization, alkalization, acidification and deamination 
(Kabak et al., 2006). These chemical methods are not allowed in the European Union 
(European Commission, 2001) as chemical transformation might lead to toxic derivatives. In 
the United States, only ammonization is licensed for detoxifying aflatoxins. 
 
2.2. Mycotoxin detoxifying agents 
 
The use of many of the previously described methods for the detoxification of agricultural 
commodities is restricted due to the associated problems including incomplete 
detoxification and inapplicability in practice. An alternative approach to reduce the exposure 
to mycotoxins in feed is to decrease the bioavailability by the inclusion of mycotoxin 
detoxifying agents (mycotoxin detoxifiers) in the feed. This method is the most commonly 
used today (Jard et al., 2011; Kolosova and Stroka, 2011). These detoxifiers can be divided 
into two different classes, namely mycotoxin binders and mycotoxin modifiers. An overview 
of the different products covered by both classes is given in Table 1. These two classes have 
different modes of action; mycotoxin binders adsorb the toxin in the gut, resulting in the 
excretion of toxin-binder complex in the faeces, whereas mycotoxin modifiers transform the 
toxin into non-toxic metabolites (EFSA, 2009). The extensive use of these additives has led, 
in 2009, to the establishment of a new group of feed additives: ‘substances for reduction of 
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the contamination of feed by mycotoxins: substances that can suppress or reduce the 
absorption, promote the excretion of mycotoxins or modify their mode of action’ (European 
Commission, 2009). It should be pointed out that the use of such products does not mean 
that animal feed exceeding maximal regulatory limits may be used. Their use should rather 
improve the quality of the feed which is lawfully on the market, providing additional 
guarantees for animal health safety (Kolosova and Stroka, 2011).   
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Table 1. Overview of different classes and subclasses of mycotoxin detoxifiers (adapted from EFSA (2009)) 
 
Mycotoxin binders Inorganic Aluminosilicates Phylosilicates Bentonites 
    Montmorillonites 
    Hydrated sodium 
calcium aluminosilicate 
    Smectites 
    Kaolinites 
    Illites 
   Tectosilicates Zeolites 
  Activated charcoal   
  Polymers Dietary fibre  
   Polyvinylpyrrolidone  
   Cholestyramine  
 Organic Saccharomyces cerevisiae Live yeast  
   Yeast cell wall 
components 
Glucomannans 
  Lactic acid bacteria Lactococcus  
   Lactobacillus  
   Leuconostoc  
   Pediococcus  
     
Mycotoxin modifiers Bacteria Eubacterium BBSH 797   
  Nocardia asteroides   
  Corynebacterium rubrum   
  Mycobacterium 
fluoranthenivorans 
  
  Rhodococcus erythropolis   
  Flavobacterium aurantiacum   
  Pseudomonas fluorescens   
  …   
 Yeasts Trichosporon 
mycotoxinivorans 
  
  Phaffia rhodozyma   
  Xanthophyllomyces 
dendrorhous 
  
  Saccharomyces cerevisiae   
  …   
 Fungi Aspergillus sp. A. flavus  
   A. niger  
  Rhizopus sp. R. stolonifer  
   R. oryzae  
   R. microsporus  
  Penicillium raistrickii   
  Exophalia spinifera   
  Rhinocladiella atrovirens   
  …   
 Enzymes Epoxidase   
  Lactonohydrolase or 
Lactonase 
  
  Carboxypeptidase A   
  α-Chymotrypsin   
  Carboxylesterase   
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2.2.1. Mycotoxin binders 
 
Mycotoxin binders (adsorbing or sequestering agents) are large molecular weight 
compounds that should be able to bind the mycotoxins in the gastrointestinal tract of the 
animal. In this way the toxin-binder complex passes through the animal and is eliminated via 
the faeces. This prevents or minimizes exposure of animals to mycotoxins. Mycotoxin 
binders are divided in mainly silica-based inorganic compounds or carbon-based organic 
polymers (EFSA, 2009).  
 
Inorganic binders 
The efficacy of inorganic binders depends on the chemical structure of both the adsorbent 
and the mycotoxin. The most important feature is the physical structure of the adsorbent, 
i.e. the total charge and charge distribution, the size of the pores, and the accessible surface 
area. On the other hand, the properties of the adsorbed mycotoxins, such as polarity, 
solubility, shape and charge distribution, also play a significant role. Generally speaking, the 
binding capacity increases with surface area and chemical affinities between both 
(Avantaggiato et al., 2005; Huwig et al., 2001; Kabak et al., 2006). 
Aluminosilicate minerals (clays) are the largest class of mycotoxin binders and most studies 
on the alleviation of mycotoxicosis by the use of adsorbents have focused on these clays. 
Within this group, there are two different subclasses: the phyllosilicate subclass and the 
tectosilicate subclass. Phyllosilicates include bentonites, montmorillonites, smectites, 
kaolinites and illites. The tectosilicates include zeolites (EFSA, 2009). Montmorillonite is 
primarily a layered phyllosilicate composed of layers of octahedral aluminium and 
tetrahedral silicon coordinated with oxygen atoms. Bentonite is generally an impure clay 
consisting mostly of montmorillonite. Zeolites are composed of tetrahedrons of SiO4 and 
AlO4 possessing an infinite three-dimensional cage-like structure. In these minerals, some of 
the tetravalent silicon are replaced by trivalent aluminium giving rise to a deficiency of 
positive charge, which is balanced by inorganic cations, such as sodium, calcium and 
potassium ions.  Hydrated sodium calcium aluminosilicate (HSCAS) contains calcium ions and 
protons which are exchanged against the naturally occurring sodium ions (Huwig et al., 
2001). This HSCAS is a heat processed and purified montmorillonite clay. It was developed by 
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Phillips et al. (1988) and commercialized as NovaSil®. Clay products, including bentonites, 
zeolites and HSCAS, are the most common feed additives effective in binding polar 
mycotoxins, such as aflatoxins (Kabak et al., 2006). Fusarium mycotoxins, such as fumonisins, 
ZON and trichothecenes, as well as OTA, are not bound to these clays because of the fairly 
non-polar properties of the toxins (Avantaggiato et al., 2005; Kabak et al., 2006; Phillips et 
al., 2008). HSCAS has a lamellar interlayer structure in which the planar AFB1 can be bound. 
The interaction is based on the negative charge of the clay with the partly positive charged 
dicarbonyls of AFB1 (Phillips et al., 2008). Although the mentioned clays have proven to be 
effective in preventing aflatoxicosis in various animal species, several disadvantages should 
be considered. They do not exert any binding potential towards other mycotoxins, they can 
adsorb vitamins and minerals and the risk of natural clays to be contaminated with dioxins 
should surely also be considered (Huwig et al., 2001; Jouany, 2007). 
Another inorganic sorbent of interest is activated charcoal, also called active carbon (AC). AC 
is a non-soluble powder formed by pyrolysis of several organic compounds. It is 
manufactured by an activation proces to develop a highly porous structure (Galvano et al., 
2001). The sequestrant properties of AC depend on many factors including pore size, surface 
area, structure of the mycotoxin and dose. The surface-to-mass ratio of AC varies from 500 
to 3500 m
2
/g. AC has been shown to be an effective binder of a wide variety of drugs and 
toxic agents. It has been commonly used as a medical treatment for severe intoxications 
since the 19
th
 century (Huwig et al., 2001). AC has been proven an effective adsorbent of 
DON, ZON, AFB1, FB1 and OTA (Avantaggiato et al., 2004; Devreese et al., 2012; Huwig et al., 
2001). Nevertheless, its unspecific binding is the major drawback in the practical use of AC as 
a feed additive. It diminishes nutrient absorption and impairs the nutritional value of feed 
(Avantaggiato et al., 2004; Ramos et al., 1996). 
Synthetic or natural polymers are another group of inorganic mycotoxin binders. Several 
agents belong to this group, such as dietary fibre and polyvinylpyrrolidone (highly polar 
amphoteric polymer), but the most well-known is cholestyramine. Cholestyramine is an 
insoluble, quaternary ammonium anion exchange resin which strongly binds anionic 
compounds (Underhill et al., 1995). It has been used as drug in humans for absorbing bile 
acids in the gastrointestinal tract in order to reduce free cholesterol. This compound was 
proven to be an effective binder for FB1, OTA and ZON in vitro (Avantaggiato et al., 2003; 
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Avantaggiato et al., 2005; Döll et al., 2004; Ramos et al., 1996). The cost of polymers is high, 
limiting their practical use in animal feed (Kolosova and Stroka, 2011). 
 
Organic binders 
Organic mycotoxin binders which are commonly used are cell wall components from 
Saccharomyces cerevisiae yeasts. By using only yeast cell walls instead of the whole cell, 
mycotoxin binding can be enhanced. The fact that dead cells do not lose their binding ability 
shows that interaction of such products with mycotoxins is by adhesion to cell wall 
components rather than by covalent binding or metabolism (Shetty and Jesperson, 2006). It 
has been demonstrated that the β-D-glucan fraction of yeast cell wall is directly involved in 
the binding process with ZON, and that the structural organisation of β-D-glucans modulates 
the binding strength. Hydrogen and van-der-Waals bonds have been evidenced in the 
glucan-mycotoxin complexes (Jouany, 2007; Shetty and Jespersen, 2006; Yiannikouris et al., 
2004; Yiannikouris et al., 2006). Based on in vitro assays, this glucomannan (GMA) binder has 
shown to effectively adsorb DON, T-2, ZON, OTA and AFB1 (Bejaoui et al., 2004; Freimund et 
al., 2003; Yiannikouris et al., 2004; Yiannikouris et al., 2006). Protective effects of GMA 
against the detrimental consequences of mycotoxins on animal production parameters have 
been demonstrated in several studies. Raju and Devegowda (2000) demonstrated that GMA 
has beneficial effects in broilers when included in feed contaminated with AFB1 (0.3 mg/kg), 
OTA (2 mg/kg) and T-2 (3 mg/kg). Individual and combined effects of these mycotoxins were 
examined. Significant interactions were observed between any two mycotoxins, such as 
additive effects on body weight or feed intake, or antagonistic effects on serum protein and 
cholesterol content. The GMA incorporation increased body weight and feed intake, 
decreased weight of liver, and improved some serum biochemical and hematological 
parameters which were negatively influenced by the mycotoxins in the feed (Raju and 
Devegowda, 2000). These binders also alleviate the adverse effects of AFB1 (1 mg/kg) on 
performance, liver weight and mortality in broiler chickens (Kamalzadeh et al., 2009). GMA 
counteracts most of the plasma parameter alterations caused by a DON contaminated diet 
(3 mg/kg) in chickens (Faixova et al., 2006). Aravind et al. (2003) showed a protective effect 
of GMA against anti-oxidant depletion in chicken livers caused by intake of a T-2 
contaminated (8 mg/kg) diet. Some positive effects of these products have also been 
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demonstrated in pigs. In a study by Diaz-Llano and Smith (2007), GMA was able to 
counteract the alterations of serum biochemical parameters induced by DON (5.5 mg/kg) in 
sows, however no positive effect on feed intake and body weight gain was seen. 
Furthermore, Dänicke et al. (2007a) did not observe improved productive parameters in pigs 
due to GMA addition in a DON contaminated feed (4.4 mg/kg). On the other hand, Nesic et 
al. (2008) did observe improved performance of pigs when GMA was included in the diet 
compared to a diet only contaminated with ZON at 3.8 and 5.2 mg/kg. 
Another group of organic mycotoxin binders, which have recently become of interest are 
lactic acid bacteria (LAB). LAB are Gram-positive, catalase-negative, non-sporulating, usually 
non-motile rods and cocci that utilize carbohydrates fermentatively and form lactic acid as 
major end product (Gerbaldo et al., 2012). These bacteria are mainly divided into four 
genera: Lactococcus, Lactobacillus, Leuconostoc and Pediococcus. They have been used in 
the food processing industry for decades because of their fermentative and food preserving 
abilities. They have also displayed mycotoxin binding abilities (Dalie et al., 2010). The 
interaction mechanism between LAB and mycotoxins is thought to be similar as the 
interactions involved in adsorption by GMA. It appears that the polysaccharide components 
(glucans and mannans) are common sites for binding, with different toxins having different 
binding sites. Several authors have concluded that the strength of the mycotoxin-LAB 
interaction was influenced by the peptidoglycan structure and, more precisely, by its amino 
acid composition (Dalie et al., 2010). The most extensively investigated mycotoxin binding 
LAB are strains of Lactobacillus rhamnosus. L. rhamnosus strains have an in vitro binding 
capability of DON, T-2, ZON, FB1, AFB1 and OTA (El-Nezami et al., 1998; El-Nezami et al., 
2002a; El-Nezami et al., 2002b; Niderkorn et al., 2006; Piotrowska and Zakowska, 2005). The 
in vitro adsorption capacity is however, strain and dose dependent and it is a reversible 
process showing as well adsorption as desorption (Kankaanpaa et al., 2000; Lee et al., 2003). 
All the available literature on LAB-mycotoxin interactions are based on in vitro results. To 
date, no in vivo trials have been conducted to effectively demonstrate their mycotoxin 
binding potential and therefore prudency regarding their effectiveness is, in the mean time, 
recommended. 
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2.2.2. Mycotoxin modifiers 
 
Another strategy to control mycotoxicoses in animals is the application of microorganisms 
and their enzymes, called mycotoxin modifiers or mycotoxin biotransforming agents. These 
products biodegrade or biotransform mycotoxins into less toxic metabolites. They can be 
divided into four classes: bacteria, yeasts, fungi and enzymes. They act in the intestinal tract 
of animals prior to the absorption of mycotoxins. It has to be pointed out that for effective 
use of mycotoxin modifiers as feed additives, certain prerequisites should be fulfilled. Those 
include rapid degradation, degradation into non-toxic (or far less toxic) metabolites under 
different oxygen conditions and in a complex environment, preserve the organoleptic and 
nutritive properties of the feed, safety of use and stability along the intestinal tract at 
different pH levels. In addition, the choice of the biodegradation approach depends on its 
practical and economical feasibility (Awad et al., 2010; Kolosova and Stroka, 2011). 
Anaerobic microorganisms isolated from animal gut contents are generally suitable for 
developing feed additives, which will act in the animals’ intestines. Survival and adaptation 
of the microorganisms in the animal gut are key factors for successful detoxification (Zhou et 
al., 2008). 
 
Bacteria 
Mycotoxin degrading bacteria have been isolated from very different matrices such as 
rumen and intestinal flora, soil and even water. The most extensively investigated mycotoxin 
degrading microorganism is the Eubacterium BBSH 797 strain, originally isolated from bovine 
rumen fluid. This bacterial strain produces enzymes (de-epoxidases) that degrade 
trichothecenes by selective cleavage of their 12,13-epoxy group which is important for the 
toxicity of these mycotoxins. This detoxification was investigated for several trichothecenes 
(Fuchs et al., 2002) and the mode of action was proven in vitro and in vivo (Schatzmayr et al., 
2006). During its manufacture, BBSH 797 is stabilized by freeze-drying and embedding into 
protective substances (mainly organic polymers) to guarantee stability when passing through 
the acidic gastric tract of animals. Eubacterium BBSH 797 is currently the only microorganism 
which has been developed into a commercial product for detoxifying trichothecenes (He et 
al., 2010). 
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A variety of other bacterial strains have shown mycotoxin degrading abilities in vitro. For 
example, Nocardia asteroides, Corynebacterium rubrum, Mycobacterium fluoranthenivorans, 
Rhodococcus erythropolis, Flavobacterium aurantiacum and Pseudomonas fluorescens (EFSA, 
2009). However, none of them have been investigated already in vivo.  
 
Yeast 
Only one yeast, Trichosporon mycotoxinivorans, has been thoroughly investigated regarding 
its mycotoxin degrading abilities, which could result in commercial use. This yeast, derived 
from the hindgut of the termite Mastotermes darwiniensis, was isolated and characterized 
previously by Molnar et al. (2004). This yeast is able to modify ZON and OTA into non-toxic 
metabolites. ZON is detoxified by opening the macrocyclic ring of the ketogroup at C-6. The 
metabolite did not show any estrogenic effect in a yeast bioassay and did not interact with 
the β-estrogen receptor in an in vitro assay. Detoxification of OTA occurs by cleavage of the 
phenylalanine moiety from the isocoumarin derivate, producing OTα (Schatzmayr et al., 
2006). The detoxification of OTA occurs fast, after 2.5 h a conversion of almost 100% was 
observed in vitro. For ZON on the other hand, the metabolisation requires a lot more time. 
Only after 24 h of incubation ZON was completely metabolized. This questions its practical 
use as detoxification should occur fast after ingestion (<8 h). The use of T. mycotoxinivorans 
as a mycotoxin modifier against OTA is promising. A study by Politis et al. (2005) 
demonstrated that inclusion of this yeast (10
5
 CFU/g) in the diet alleviates the immunotoxic 
effects of OTA (0.5 mg/kg) in broiler chickens. 
Other potential OTA degrading yeast are Phaffia rhodozyma and Xanthophyllomyces 
dendrorhous (Peteri et al., 2007) but the responsible enzymes have not well been 
characterized and their practical application up to day is limited. Styriak and Conkova (2002) 
reported that two out of several tested Saccharomyces cerevisiae strains were able to 
degrade FB1, but only for 25 or 50% after 5 days of incubation, which is therefore unusable 
in practice. 
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Fungi 
Fungi cannot only produce mycotoxins, but some of them are also able to degrade them. 
The fungal strains Aspergillus niger, A. flavus, Eurotium herbariorum and Rhizopus sp. are 
able to convert AFB1 to aflatoxicol (AFL) by reducing the cyclopentenone carbonyl of AFB1 
(Wu et al., 2009). AFL has been reported to be 18 times less active than the parent 
compound, but it still has carcinogenic properties (Pawlowski et al., 1977), raising the 
question if this is an appropriate detoxification strategy. Other fungal strains showed AFB1 
metabolizing properties as well, such as Penicillium raistrickii, although their metabolisation 
products have almost similar toxicity (AFB2) or were not all yet identified (Wu et al., 2009). 
Next to their AFB1 degrading potential, Rhizopus isolates also showed ZON detoxifying 
abilities. The selected isolates include strains of R. stolonifer, R. oryzae and R. microsporus 
(Varga et al., 2005). Further studies are needed to identify the ZON degrading enzymes in 
the isolates. A preliminary study was performed to screen twelve black Aspergillus strains for 
their ZON transformation activity by incubation in contaminated culture medium. Analyses 
showed that ZON was removed after 48 h of incubation by two A. niger strains (EFSA, 2009). 
Aspergillus niger was also able to degrade OTA to the less toxic compound OTα. It was then 
further degraded into an unknown compound (Varga et al., 2000). 
Fumonisin degrading fungi have been identified in vitro as well. Exophalia spinifera and 
Rhinocladiella atrovirens extensively metabolize fumonisin B1 to HFB1 and free tricarballylic 
acid via esterases (Blackwell et al., 1999).  
Enzymes 
An attractive alternative to the use of live microbes to counteract mycotoxins in animal feed 
is application of enzymes responsible for degradation of mycotoxins. Enzymatic reactions 
offer a specific, often irreversible, efficient and environmentally friendly way of 
detoxification that leave neither toxic residues nor any undesired by-products (Kolosova and 
Stroka, 2011). These mycotoxin degrading enzymes are primarily produced by 
microorganisms. 
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Epoxidases are enzymes which are able to detoxify trichothecenes by transforming their 
expoxy group into diene groups (Schatzmayr et al., 2006). For example, DON can be 
detoxified to its de-epoxy form, DOM-1. 
Takahashi-Ando et al. (2002) reported that ZON was converted into a less estrogenic product 
by cleavage of the lactone structure. The responsible enzyme is a lactonohydrolase, 
originating from the fungus Clonostachys rosea IFO 7063. 
Pitout (1969) presented the first in vitro hydrolysis of OTA by carboxypeptidase A and, in 
lower amounts, by α-chymotrypsin. Abrunhosa et al. (2006) reported the ability of several 
commercial proteases to hydrolyze OTA into OTα. After a long incubation period of 25 h, a 
significant hydrolytic activity was detected for protease A (87.3%) and for pancreatin 
(43.4%). 
Recently, two genes of Sphingopyxis sp. MTA 144 responsible for detoxification of FB1 were 
identified and recombinant enzymes were produced (Heinl et al., 2010). The degradation of 
FB1 consisted of two consecutive pathways. FB1 is first metabolized to HFB1 by a 
carboxylesterase, followed by an aminotransferase which deaminates HFB1, leading to an 
even less toxic compound.  
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3. EC regulations on maximum levels of mycotoxins in animal feed 
The growing awareness that mycotoxins are a great concern to animal health, has led to 
regulations of maximum allowed contamination levels in feed in many countries (van 
Egmond et al., 2007). In Europe, these levels have been defined by European Commission 
(EC) Regulations and Recommendations. The maximum levels set are influenced by several 
factors. One of the most important factors is species susceptibility. As mentioned, pigs are 
the most susceptible species for several major mycotoxins, including DON, ZON and OTA. 
Therefore the maximum levels in feed intended for pigs will be lower compared to less 
susceptible species, such as poultry. Maximum levels can also differ within one species. 
Piglets and gilts are more susceptible to the estrogenic effects of ZON, compared to sows 
and fattening pigs, resulting in lower maximum ZON contamination levels for those 
subcategories. Of course, the toxicity of the mycotoxin itself is a key determining factor. 
AFB1 has long been known to be acutely toxic and even carcinogenic upon chronic exposure, 
resulting in very low guidance values. Next to the toxicodynamic properties, the kinetic 
properties of mycotoxins play a role as well. Fumonisins for example have a very low oral 
bioavailability, ± 3.5% in pigs (Martinez-Larranaga et al., 1999), and consequently, only low 
concentrations reach the target tissues. Hence this allows higher contamination levels in 
feed. Maximum limits have been established for complete feed as well as for main feed 
materials (i.e. maize and cereals). In general, maximum set levels are higher for feed 
materials than for complete feedingstuffs. Nevertheless, it should be taken into account that 
when a component’s composition in the daily ration of animals is higher than common 
practice, this should not lead to the animal being exposed to a higher level of these 
mycotoxins than normal. 
EC Regulations for AFB1 in feed were established by Directive 2002/32/EC of the European 
Parliament and of the Council of 7 May 2002 on undesirable substances in animal feed 
(European Commission, 2002). The guidance values for the presence of DON, ZON, OTA and 
fumonisins in products intended for animal feeding were determined in the Commission 
Recommendation of 17 August 2006 (European Commission, 2006). These limits are 
presented in Table 2.  
In 2011, the European Food Safety Authority (EFSA) has determined a tolerable daily intake 
(TDI) for the sum of T-2 and its major metabolite, HT-2, of 100 ng/kg BW (EFSA, 2011a). Just 
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recently, the EC has made a proposition regarding these toxins in grains and complete 
feedingstuffs (European Commission, 2013) (Table 3). For the Fusarium mycotoxins, BEA and 
ENNs, which have recently become of interest, no maximum levels nor TDIs has been put 
forward. The EFSA is currently establishing its opinion on the risks to human and animal 
health related to the presence of BEA and ENNs in food and feed. The results are expected at 
the latest in September 2014. 
A correct evaluation of mycotoxin contamination in food and feed is of utmost importance in 
determining the compliance with the acceptable safety standards. Because of the often 
highly heterogeneous distribution of mycotoxins in so-called ‘hot-spots’ in feed, the most 
critical stage is taking a representative sample. Appropriate sampling is essential to ensure 
that the analytically derived mean concentration of a sample is representative to the true 
mean concentration of a lot (Chaytor et al., 2011). 
Table 2. The guidance values on the presence of deoxynivalenol, zearalenone, ochratoxin A and fumonisins in 
products intended for animal feeding as determined in the Commission Recommendation of 17 August 2006 
(2006/576/EC), maximally allowed values on the presence of aflatoxin B1 in products intended for animal 
feeding as determined by EC Directive 2002/32/EC of the European Parliament and of the Council of 7 May 
2002 (2002/32/EC).  
Mycotoxin Products intended for animal feed Guidance value in 
mg/kg (ppm) relative 
to a feedingstuff 
with a moisture 
content of 12% 
Deoxynivalenol Feed materials (*) 
- Cereals and cereal products (**) with the 
exception of maize by-products 
- Maize by-products 
Complementary and complete feedingstuffs with 
the exception of: 
- Complementary and complete feedingstuffs for 
pigs 
- Complementary and complete feedingstuffs for 
calves (<4 months), lambs and kids 
 
8 
 
12 
5 
 
0.9 
 
2 
 
Zearalenone Feed materials (*) 
- Cereals and cereal products (**) with the 
exception of maize by-products 
 
2 
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- Maize by-products 
Complementary and complete feedingstuffs 
- Complementary and complete feedingstuffs for 
piglets and gilts (young sows) 
- Complementary and complete feedingstuffs for 
sows and fattening pigs 
- Complementary and complete feedingstuffs for 
calves, dairy cattle, sheep (including lambs) and 
goat (including kids) 
3 
 
0.1 
 
0.25 
 
0.5 
Ochratoxin A Feed materials (*) 
- Cereals and cereal products (**) 
Complementary and complete feedingstuffs 
- Complementary and complete feedingstuffs for 
pigs 
- Complementary and complete feedingstuffs for 
poultry 
 
0.25 
 
0.05 
 
0.1 
Fumonisin B1+B2 Feed materials (*) 
- Maize and maize products (***) 
Complementary and complete feedingstuffs for: 
- Pigs, horses (Equidae), rabbits and pet animals 
- Fish 
- Poultry, calves (<4 months), lambs and kids 
- Adult ruminants (>4 months) and mink 
 
60 
 
5 
10 
20 
50 
Aflatoxin B1 All feed materials (*) 
Complete feedingstuffs for cattle, sheep and goat 
with the exception of: 
- Complete feedingstuffs for dairy animals 
- Complete feedingstuffs for calves and lambs 
Complete feedingstuffs for pigs and poultry 
(except young animals) 
Other complete feedingstuffs 
Complementary feedingstuffs for cattle, sheep and 
goats (except complementary feedingstuffs for 
dairy animals, calves and lambs) 
Complementary feedingstuffs for pigs and poultry 
(except young animals) 
Other complementary feedingstuffs  
0.02 
0.02 
 
0.005 
0.01 
0.02 
 
0.01 
0.02 
 
 
0.02 
 
0.005 
(*) Particular attention has to be paid to cereals and cereal products fed directly to the animals that their use 
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in a daily ration should not lead to the animal being exposed to a higher level of these mycotoxins than the 
corresponding levels of exposure where only the complete feedingstuffs are used in a daily ration. 
(**) The term ‘Cereals and cereal products’ includes not only the feed materials listed under heading 1 
‘Cereal grains, their products and by-products’ of the non-exclusive list of main feed materials referred to in 
part B of the Annex to Council Directive 96/25/EC of 29 April 1996 on the circulation and use of feed 
materials (OJ L125, 23.5.1996, p. 35) but also under feed materials derived from cereals in particular cereal 
forages and roughages. 
(***) The term ‘Maize and maize products’ includes not only the feed materials derived from maize listed 
under heading 1 ‘Cereal grains, their products and by-products’ of the non-exclusive list of main feed 
materials referred to in the Annex, part B of Directive 96/25/EC but also other feed materials derived from 
maize in particular maize forages and roughages. 
 
Table 3. Indicative levels for the sum of T-2 and HT-2 toxin in cereals and cereal products, as determined in the 
Commission Recommendation of 27 March 2013 (2013/165/EC). 
 Indicative levels for the sum of T-2 and HT-2 (µg/kg) 
from which onwards/above which investigations 
should be performed, certainly in case of repetitive 
findings (*) 
1. Unprocessed cereals (**)  
1.1. barley (including malting barley) and maize 200 
1.2. oats (with husk) 1000 
1.3. wheat, rye and other cereals 100 
  
2. Cereal products for feed and compound feed (***)  
2.1. oat milling products (husks) 2000 
2.2. other cereal products 500 
2.3. compound feed, with the exception of feed for 
cats 
250 
 
(*) The levels referred to in this Annex are indicative levels above which, certainly in the case of repetitive 
findings, investigations should be performed on the factors leading to the presence of T-2 and HT-2 toxin or on 
the effects of feed and food processing. The indicative levels are based on the occurrence data available in the 
EFSA database as presented in the EFSA opinion. The indicative levels are not feed and food safety levels. 
(**) Unprocessed cereals are cereals which have not undergone any physical or thermal treatment other than 
drying, cleaning and sorting. 
(***) The indicative levels for cereals and cereal products intended for feed and compound feed are relative 
to a feed with a moisture content of 12%. 
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4. Efficacy and safety testing of mycotoxin detoxifiers 
In 2010, the EFSA panel on additives and products or substances used in animal feed 
(FEEDAP) released a scientific opinion on the establishment of guidelines for the assessment 
of additives from the functional group ‘substances for reduction of the contamination of 
feed by mycotoxins’ (EFSA, 2010). The main terms of reference were how to evaluate the 
efficacy of the additive at the existing maximum levels of mycotoxins (efficacy testing) and 
presence and characterization of possible interactions with nutrients, coccidiostats or 
veterinary medicinal products (safety testing).  
At the time, several in vitro and in vivo models were already available to evaluate the 
efficacy and safety of mycotoxin detoxifiers. In this section, an overview of the different 
methods and models is given, in relation to EFSA’s point of view. 
4.1. Efficacy testing of mycotoxin detoxifiers 
Methods used to evaluate the efficacy of mycotoxin detoxifiers range from simple in vitro 
tests to extensive in vivo investigations. 
In vitro analysis is a powerful tool for screening potential mycotoxin detoxifiers. If a 
sequestering agent does not adsorb a mycotoxin in vitro, it has little or no chance to act in 
vivo. These laboratory techniques can be very useful in identifying and ranking potential 
mycotoxin detoxifiers and determining the mechanisms and conditions favorable for 
adsorption to occur (Lemke et al., 2001b). The experimental in vitro studies range from 
single-concentration studies to classical isotherm studies (binder concentration fixed, toxin 
concentration increasing) and beyond to more elaborate set-ups (gastro-intestinal tract 
models). 
The single-concentration method is the simplest to perform and therefore most widely used. 
It measures adsorption of purified toxin preparations in aqueous medium, where a known 
amount of mycotoxin is added to a known amount of test product. The results are usually 
reported as ‘%ads’, the fraction of toxin bound to the adsorbent.  
When using adsorption isotherms, the amount of mycotoxin adsorbed per unit of weight is 
plotted against the concentration of mycotoxin in solution at a constant temperature and 
under stable conditions (Figure 8). This system takes into account that sequestering of 
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mycotoxins is a reversible process that can be characterized as a chemical equilibrium. The 
results from isotherm studies are usually interpreted by empirical models (such as 
Freundlich) based on the available dataset.  
 
Figure 8. Ideal isotherm adsorption curve, showing the two regions of the curve mainly dominated by affinity 
and capacity (EFSA, 2009) 
 
Next to these simple in vitro adsorption studies, more sophisticated models have been 
developed simulating the gastrointestinal tract. A ‘dynamic gastrointestinal model’ was 
developed by Minekus et al. (1995) and optimized by Avantaggiato et al. (2003, 2004). This 
so called TIM system (TNO Intestinal Model), compromises four compartments connected by 
peristaltic valves, simulating the kinetic digestive processes in respectively the stomach, 
duodenum, jejunum and ileum of humans and monogastric animals. Parameters include the 
secretion of saliva, gastric juice, pancreatic juice and bile for the simulation of realistic pH 
values, electrolyte concentrations, and digestive enzyme activities as well as body 
temperature and peristaltic movements for mixing and gastrointestinal transit. Hollow-fiber 
semi-permeable membranes are connected to the jejunum and ileum compartments for 
continuous dialysis of the digested and released compounds and absorption of water 
(Avantaggiato et al., 2007). Some other simulating models have been developed before, 
although they have not been applied to evaluate the binding or modifying capacity of 
mycotoxin detoxifiers. The Simulator of Human Intestinal Microbial Ecosystem (SHIME) is a 
validated dynamic model to study physicochemical, enzymatic and microbial parameters in 
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the gastrointestinal tract (Molly et al., 1993, 1994). The model consists of five reactors which 
sequentially simulate the stomach (acid conditions and pepsin digestion), small intestine 
(digestive processes) and the 3 regions of the large intestine, i.e. the ascending, transverse 
and descending colon (microbial processes). Control of the environmental parameters in 
these reactors allows to obtain complex and stable microbial communities which are highly 
similar in both structure and function to the microbial community in the different regions of 
the human colon. Recent evolutions of the SHIME involve TWINSHIME and SPIME. The 
TWINSHIME consists of two SHIME systems run in parallel, allowing direct comparison 
between two different conditions. The SPIME is similar to SHIME except for the microbiota, 
which is derived from pigs. 
Although these dynamic systems resemble the in vivo situation far more than other available 
in vitro tests, they are costly and labor intensive which are compromising factors. Simple 
adsorption studies on the other hand, are too rudimentary to represent the actual in vivo 
situation. Therefore, there is a need for in vitro models which resemble the in vivo situation, 
but are still high-throughput in order to allow screening for potential mycotoxin detoxifiers 
in a timely manner. 
In vitro studies can be used to select the most potent detoxifiers, however in vivo trials are 
still mandatory to fully proof the efficacy of the product (EFSA, 2009). Mycotoxin adsorption 
in vivo is complicated by physiological variables and the composition of feed, factors which 
are rarely accounted for in vitro (Lemke et al., 2001b). 
Most of the in vivo studies on the efficacy of mycotoxin detoxifiers assess the effects of the 
products on recording so-called ‘unspecific parameters’ of the animals. These include: 
- production parameters (growth rate, feed consumption, feed conversion ratio); 
- organ weight, e.g. liver, kidney, intestine; 
- serum biochemistry, e.g. total protein, albumin, globulins, glucose, uric acid, 
cholesterol, billirubin, phosphate, magnesium, calcium, iron, glutamate 
dehydrogenase, γ-glutamyl transferase, aspartate aminotransferase, alanine 
aminotransferase, lactate dehydrogenase, creatine kinase; 
- hematology measurements, e.g. hematocrit, hemoglobin, red blood cell count; 
- analysis of immunoglobulin (IgG, IgM and IgA) in serum and bile; 
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- determination of antibody titers for an infectious disease after vaccinal challenge; 
- histological evaluation of liver, intestine or other target tissues; 
When performing such experiments consisting of different animal groups fed different diets, 
a proper validated experimental design is mandatory. As unspecific parameters are not only 
influenced by the specific effect of the detoxifying agent, four different groups should be 
included in the trial. Namely, contaminated, contaminated with detoxifier, uncontaminated 
and uncontaminated with detoxifier. The latter is necessary to distinguish between specific 
and unspecific effects of the detoxifier (Figure 9) (Dänicke et al., 2007b; Döll and Dänicke, 
2004). 
   
Figure 9. Investigation of the efficacy of mycotoxin detoxifiers using mycotoxin unspecific parameters (Döll and 
Dänicke, 2004) 
In their scientific opinion, the EFSA states that unspecific parameters may be recorded 
although they are not sufficient to prove the efficacy of a detoxifier. The EFSA proposes 
other end-points, mainly based on specific toxicokinetic parameters (Table 3). These 
toxicokinetic parameters are derived from the ADME (absorption, distribution, 
metabolisation and excretion) approach. After oral intake, the target compound reaches the 
blood stream via uptake through the intestinal mucosa and submucosa (absorption). Next, it 
is distributed to different organs where it can take effect and/or be metabolized in other 
compounds, metabolites. These metabolites are generally more polar, facilitating their 
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excretion through bile or urine, and less toxic compared to the parent compound (some 
exceptions exist, such as AFB1). In general, mycotoxin/metabolites excretion in faeces/urine, 
concentration in blood/plasma/serum, tissues or products (milk or eggs) or other relevant 
biomarkers should be taken as end-points for demonstration the efficacy of mycotoxin 
detoxifiers. In order to do so, sensitive and specific bioanalytical techniques allowing the 
detection and quantification of mycotoxins in animal tissues are mandatory. 
 
Table 3. Most relevant end-points for substances reducing the contamination of feed by mycotoxins (EFSA, 
2010) 
Mycotoxin(s) against which the additive is intended to act Most relevant end-points 
Aflatoxin B1 Aflatoxin M1 in milk/egg yolk 
Deoxynivalenol (DON) DON/metabolites in blood serum 
Zearalenone (ZON) ZON + α- and β-zearalenol in plasma 
Excretion of ZON/metabolites 
Ochratoxin A (OTA) OTA in kidney or blood serum 
Fumonisin B1 + B2 Sphinganine/sphingosine ratio in 
blood, plasma or tissues 
 
Regarding the in vivo efficacy trials, the EFSA proposed several other guidelines. A minimum 
of three in vivo studies showing significant effects should be provided to demonstrate 
efficacy at the lowest recommended dose. Those should be carried out at least at two 
different locations. Any extrapolation of data obtained with one animal species to other 
species is limited because of differences in intestinal mycotoxin absorption and potential 
mycotoxin degradation by the gastro-intestinal microbiota and different maximum 
mycotoxin contamination levels in feed. For additives intended to be used in all animal 
species except fish, studies should be performed in at least three major species, a poultry, a 
monogastric mammal and a ruminant. The mycotoxin content in feed used in studies should 
not exceed the values given in Commission Directive 2002/32/EC for AFB1 (European 
Commission, 2002) and in Commission Recommendation 2006/576/EC for DON, ZON, OTA 
and FB1+B2 for complete feedingstuffs for the respective animal species/category (European 
Commission, 2006). For mycotoxins without a maximum content established at EU level (e.g. 
BEA and ENNs), the dietary levels chosen should not exert adverse effects in the target 
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animals. As a source of mycotoxins, naturally contaminated feed materials are preferred. 
Alternatively, feed supplemented with mycotoxins could be used, if properly justified. 
However, because some mycotoxins regularly occur in nature associated with others, diets 
with more than one added mycotoxin may be used in the relevant studies. In any case, 
detailed analysis of mycotoxins present in feed should be provided for each trial. All these in 
vivo efficacy studies are considered short-term. Any measurement of end-points should not 
be started before metabolic steady-state of mycotoxin(s) in tissues/products is reached. In 
any case, the pre-sampling period should not be shorter than seven days. If long-term 
studies are performed, the sampling period (faeces and urine) should be at least five days. 
Blood samples should also be collected over a five-day period. Finally, tissues should be 
sampled without withdrawal of the mycotoxin from the diet. 
4.2. Safety testing of mycotoxin detoxifiers 
Not only requirements regarding the efficacy testing of mycotoxin detoxifiers have been put 
forward by the EFSA, but also in relation to possible negative effects of these additives. 
For mycotoxin modifiers, the main concern is the toxicity of the mycotoxins’ metabolites. As 
the mode of action of these products is modifying the chemical structure of mycotoxins, all 
degradation products should be identified. Next, analytical methods should be developed to 
determine these metabolites in the appropriate tissues. This would allow to characterize all 
metabolites formed, with special emphasis on the possible toxicity of the metabolites. 
For mycotoxin binders, unspecific binding is the major consideration. Due to lack of 
specificity, mycotoxin binders may also adsorb nutrients, micronutrients and/or veterinary 
medicinal products. Very limited data are available on the interaction between mycotoxin 
binders and veterinary drugs. Aluminosilicates for example, have shown binding potential 
towards feed minerals, decreasing their utilization by the animal (EFSA, 2009). In 2011, 
EFSA’s FEEDAP published a scientific opinion on the safety and efficacy of bentonite 
(dioctahedral montmorillonite) as feed additive for all species (EFSA, 2011b). In this report it 
was stated that bentonite should not be mixed in feed concurrently with additives from the 
‘antibiotics', ‘growth promoters', ‘coccidiostats and other medical substances' groups, 
except in the case of monensin-sodium, narasin, lasalocid-sodium, flavophospholipol, 
salinomycin sodium and robenidine. Literature available on this topic is mainly based on 
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clinical symptoms, which are unspecific. For macrolide antibiotics for example, the Canadian 
Bureau of Veterinary Drugs reported that lack of efficiency was observed when tylosin was 
fed concurrently with bentonite clay to bovines (Canadian Bureau Of Veterinary Drugs, 
1992). Shryock et al. (1994) reported that tilmicosin added to the diet in broiler chickens 
prevented development of airsacculitis after inoculation with Mycoplasma gallisepticum, 
whereas a combined use of tilmicosin and bentonite did not prevent air-sac lesions or clinical 
symptoms, indicating a possible negative interaction between the binder and the antibiotic.  
 
Few studies used pharmacokinetic parameters to study the interaction between mycotoxin 
binders and the oral bioavailability of veterinary drugs. For instance, lowered plasma 
concentrations of lincomycin have been described when a clay-based mycotoxin binder was 
added to broiler feed (Amer, 2005). Recently, experiments were conducted to investigate 
possible interactions between mycotoxin detoxifiers and oral bioavailability of 
oxytetracycline and amoxicillin in broiler chickens and doxycycline in pigs.  
After 28 days of feeding broiler chickens either uncontaminated feed or uncontaminated 
feed supplemented with one out of two evaluated mycotoxin detoxifiers, an oral bolus of 
either oxytetracycline (100 mg/kg BW) or amoxicillin (20 mg/kg BW) was administered 
(Osselaere et al., 2012). Remarkably, birds receiving feed supplemented with one of the 
mycotoxin detoxifiers showed higher area under the plasma concentration-time profile 
(AUC0-t) and maximal plasma concentration (Cmax) of oxytetracycline compared to the 
controls. Kidney tissue concentrations of oxytetracycline were also significantly increased 
related to addition of the mycotoxin detoxifier to the feed. These higher plasma and tissue 
concentrations could be due to the observed increase of villus height and villi absorption 
area caused by the detoxifier (Osselaere et al., 2013). Addition of the detoxifier also resulted 
in higher DON levels in the distal intestinal tract, causing damage to the intestinal tissues and 
consequently to an increased oral absorption of the antibiotic (Osselaere et al., 2013). 
A more complex interaction between mycotoxins, mycotoxin binder and antibiotics was 
observed in pigs  by Goossens et al. (2012). Animals were administered one of the following 
diets: control (uncontaminated), control + GMA, contaminated (0.1 mg T-2/kg) or 
contaminated + GMA. After one-week feeding, animals were administered a single oral bolus 
of either doxycycline (10 mg/kg BW) or paromomycin (100 mg/kg BW), both frequently used 
as mass medication practices in pig and poultry industry. 
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The group which received feed supplemented with T-2 and GMA showed a significantly 
higher AUC0-t compared to the control group, but not to the other experimental groups. No 
significant differences in oral absorption of paromomycin were observed. A consecutive 
experiment was performed with the same experimental design but with DON contaminated 
feed (0.8 mg/kg, fed for 2 weeks). Again, higher plasma concentrations of doxycycline were 
observed in the contaminated + GMA group compared to the control, but not to the other 
groups. As stated above, addition of the binder could result in prolonged persistence of the 
toxins in the gastro-intestinal tract and consequently lead to promoted drug absorption. 
Similar to the previous experiment, no differences in oral absorption of paromomycin were 
demonstrated. These findings might be important for the withdrawal time of veterinary drug 
formulations containing doxycycline, and the occurrence of undesirable residues (above the 
Maximum Residue Limit, MRL) of the antibiotic in edible tissues. On the other hand, if the 
mycotoxin binder leads to increased plasma concentrations, this could, from a theoretical 
point of view, be compensated by reducing the dosage of the antibiotic. 
There is an urgent need for in vitro and in vivo models for interaction testing of mycotoxin 
detoxifiers with veterinary medicinal products based on pharmacokinetic parameters, 
especially since some interactions between mycotoxin detoxifiers and oral bioavailability of 
veterinary drugs has been described.   
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Mycotoxins are considered a major issue worldwide because of their harmful effects on 
animals. This leads to great economic losses, especially in pig and poultry industry. The most 
commonly used method to counteract the negative impact of mycotoxins on animals is 
adding mycotoxin detoxifying agents (mycotoxin detoxifiers) to feed. These products, so-
called mycotoxin binders or mycotoxin modifiers, either bind or biotransform mycotoxins in 
the gastrointestinal tract, respectively. 
These products should be tested on their ability to bind or modify mycotoxins (efficacy) in 
vitro as well as in vivo. Also the possible interaction with oral absorption of veterinary drugs 
(safety) should be evaluated. 
At the start of the research described in this thesis, no reliable in vitro models were available 
which are both high-throughput and capable of mimicking the gastrointestinal tract. The first 
goal was therefore to develop such an in vitro model able to evaluate the efficacy and safety 
of mycotoxin detoxifiers. 
In vivo efficacy testing of mycotoxin detoxifiers is generally based on unspecific parameters, 
such as animal performance, blood biochemistry and/or histological changes in organs. As 
these parameters are unspecific and only indirectly proof the adsorbing or biotransforming 
effect of mycotoxin detoxifiers, a more direct approach should be followed, based on 
specific toxicokinetic parameters. At the time being, no in vivo models for efficacy testing of 
mycotoxin detoxifiers were available based on toxicokinetic parameters. In addition, to allow 
evaluating the effect of mycotoxin detoxifiers on oral bioavailability of mycotoxins, sensitive 
methods quantifying mycotoxins in animal tissues and body fluids were needed. 
As mentioned, the possible interaction of mycotoxin binders with oral absorption of 
veterinary drugs is of great concern. Interactions between mycotoxin detoxifiers and several 
veterinary drugs (including lincomycin, tilmicosin, tylosin, doxycycline, oxytetracycline and 
amoxicillin) have already been described. However, no in vitro or in vivo models based on 
specific pharmacokinetic parameters were available to evaluate possible interactions.  
The general objective of this research was to develop in vitro and in vivo models for testing 
the efficacy of mycotoxin detoxifiers and their possible interactions with oral absorption of 
veterinary drugs. 
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The specific aims of this research were as follows: 
• To develop an in vitro model evaluating the efficacy and safety of mycotoxin 
detoxifiers. This model should be high-throughput and mimic the gastrointestinal 
tract (Chapter I). 
• To develop sensitive and specific methods for the quantification of mycotoxins in 
plasma of pigs and poultry (Chapter II & III). 
•  To develop in vivo bolus models for efficacy and safety testing of mycotoxin 
detoxifiers based on specific toxico- and pharmacokinetic parameters, respectively 
(Chapter IV & V). 
• Determine a possible correlation between specific and unspecific parameters for 
efficacy testing in vivo (Chapter VI). 
 71 
 
 
 
 
 
 
EXPERIMENTAL STUDIES 
 
 72 
 
 
Chapter I 
73 
 
 
CHAPTER I 
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Abstract - An in vitro model simulating the intestinal barrier for efficacy and drug interaction 
testing of mycotoxin detoxifying agents was developed using Transwell® cell culture inserts. 
Intestinal porcine epithelial cells derived from the jejunum of piglets were exposed to 
deoxynivalenol and a mycotoxin binder (efficacy testing) or exposed to tylosin and a 
mycotoxin binder (drug interaction testing). Active carbon and bentonite were used in the 
efficacy and drug interaction trials, respectively, to validate the developed model. The 
evaluated parameters were passage of deoxynivalenol and tylosin through the epithelial 
monolayer, the integrity of the monolayer by measurements of the trans-epithelial electrical 
resistance and the viability of the monolayer using the neutral red assay. In the efficacy 
model it was shown that active carbon effectively bound deoxynivalenol at both non-
cytotoxic and cytotoxic concentrations of deoxynivalenol, respectively 0.5 and 1 µg/mL. 
Moreover, the negative effects of deoxynivalenol at cytotoxic concentrations on cellular 
viability and integrity were completely offset. A commercially available modified 
glucomannan binder was also tested and it was able to partly reduce the negative effects on 
these latter parameter. Moreover, it reduced the transepithelial passage of deoxynivalenol 
with 37 to 57% compared to active carbon, at both cytotoxic and non-cytotoxic 
concentrations of deoxynivalenol. In our drug interaction model, the interaction between 
tylosin and mycotoxin binders was investigated as some authors suggest binding of 
macrolide antibiotics to bentonite clays. Indeed, a bentonite clay showed decreased passage 
of tylosin through the epithelial monolayer, indicating binding of tylosin by bentonite. This 
indicates that the combined use of bentonite and tylosin in the feed could lead to therapy 
failure. The modified glucomannan binder did not alter the passage of tylosin significantly, 
indicating safe combined use. 
Keywords – in vitro model - IPEC-J2 - mycotoxin binders - deoxynivalenol - tylosin  
Chapter I 
75 
 
1. Introduction 
The contamination of feed with mycotoxins is a continuing feed safety issue leading to 
economic losses in animal production (Wu, 2007). Consequently, a variety of methods for 
the decontamination of feed have been developed, but mycotoxin detoxifying agents 
(mycotoxin detoxifiers) supplemented as feed additive seem to be the most promising and 
are therefore most commonly used (Kolosova and Stroka, 2011). The extensive use of these 
feed additives has led, in 2009, to the establishment of a new group of additives: ‘substances 
for reduction of the contamination of feed by mycotoxins: substances that can suppress or 
reduce the absorption of mycotoxins (mycotoxin binders) or modify their mode of action 
(mycotoxin modifiers)’ (European Commission, 2009).  
Obviously, the binding or biotransforming ability of these feed additives should be 
examined. In addition, the binding products could affect the oral bioavailability of essential 
nutrients or interact with oral absorption of veterinary drugs. In vivo feeding trials are close 
to the situation in practice but they are cost and labor intensive. Therefore, in vitro analysis 
is a powerful tool as screening method to select the most potent mycotoxin detoxifiers. 
Basic models are single-concentration studies, where a known amount of test product is 
mixed in buffer solution with a known amount of mycotoxin, and adsorption isotherms, 
where the amount of mycotoxin adsorbed per unit of weight is plotted against the 
concentration of the mycotoxin (EFSA, 2009). These set-ups are very rudimentary and do not 
mimic the in vivo situation by far. The most complex set-up is the ‘dynamic gastro-intestinal 
model’ developed by Minekus et al. (1995) and optimized by Avantaggiato et al. (2004). 
Although it closely mimics the in vivo situation, it is labor intensive and cannot be used as a 
high-throughput screening method. 
The European Food Safety Authority (EFSA) stipulates that the efficacy and safety of 
mycotoxin detoxifiers should be investigated (EFSA, 2010). At first their efficacy, i.e. whether 
they actually bind or biotransform mycotoxins, should be evaluated, but also their safety 
aspect. Mycotoxin binders could affect the oral bioavailability of essential nutrients or 
interact with oral drug absorption. However, the aim of this study was only to investigate the 
possible interactions with veterinary drugs. In veterinary medicine, and especially in mass 
medication applied in the pig and poultry industry, drugs are often administered through the 
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feed or drinking water. If a mycotoxin detoxifier decreases or enhances the oral absorption 
of drugs, this might have significant consequences for animal health. In the drug interaction 
model, the interaction between the macrolide antibiotic tylosin and a bentonite binder was 
investigated. The Canadian Bureau of Veterinary Drugs (1992) reported that there was 
insufficient efficacy of tylosin when fed concurrently with bentonite to bovines. Moreover, 
Schryock et al. (1994) showed that a diet supplemented with tilmicosin, structurally closely 
related to tylosin, reduced the symptoms caused by Mycoplasma gallisepticum in broilers. 
However, a diet containing tilmicosin together with bentonite could not prevent airsacculitis 
and clinical symptoms caused by M. gallisepticum. These interactions have recently been 
documented by the EFSA (EFSA, 2011), and led to a negative advise for concurrent 
administration of macrolide antibiotics and bentonite to animals.  
2. Materials and methods 
2.1. Cell culture conditions 
The porcine jejunal intestinal epithelial cell line IPEC-J2 is a non-transformed cell line 
continuously maintained in cell culture. IPEC-J2 cells were cultured in 1:1 Dulbecco’s 
Modified Eagle Medium (DMEM)/Ham’s F-12 mixture (Invitrogen Life Technologies, 
Carlsbad, CA, USA), supplemented with 5% (v/v) Fetal Calf Serum (FCS) (Hyclone, 
Cramlington, England, UK), 1% (v/v) insulin-transferrin-Na selenite mixture (Gibco, Life 
Technologies, Paisley, Scotland, UK), 1% (v/v) penicillin-streptomycin (Gibco) and 1% (v/v) 
kanamycin (Gibco), further called cell medium. Cells were incubated at 37°C in ambient 
atmosphere with 5% CO2. 
2.2. Chemicals, veterinary drugs and mycotoxin binders 
Deoxynivalenol (DON) (Fermentek, Jerusalem, Israel) used for the cell culture experiments 
was prepared in anhydrous methanol as a stock solution of 1 mg/mL and stored at -20°C. 
Serial dilutions were made in cell medium. The maximal final concentration of 0.1 % 
methanol was not found to be cytotoxic based on the neutral red assay. 
The standard of DON, used for the analytical experiments, was purchased from Sigma-
Aldrich (Bornem, Belgium) and dissolved in acetonitrile (ACN) to obtain a stock solution of 1 
mg/mL. Working solutions were used to prepare matrix-matched calibrators and quality 
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control samples in cell medium. These working solutions were prepared by mixing 
appropriate volumes of the stock solution with ACN and water (50/50, v/v), both of HPLC 
grade. The internal standard (IS) (
13
C15-DON, 25 µg/mL ACN) was obtained from Biopure 
(Tulln, Austria). A working solution of 1 µg/mL IS was prepared in ACN and water (50/50, 
v/v). 
A stock solution of 1 mg/mL of tylosin (Tylan® Soluble, Elanco Animal Health, Beerse, 
Belgium) was used for the cell culture and analytical experiments and was prepared in water 
of HPLC quality (high performance liquid chromatography). Serial dilutions were made in cell 
medium. IPEC-J2 cells were exposed to 20 µg/mL tylosin which resembles the exposure of 
intestinal mucosa when used according to the leaflet. Gamithromycin, the IS for the 
analytical experiments was obtained from Merial (Brussels, Belgium) and was dissolved in 
ACN (1 µg/mL). 
Active carbon (AC) (NORIT Carbomix®, KELA Pharma, Sint-Niklaas, Belgium), a modified 
glucomannan (GMA) (Mycosorb®, Alltech Inc., Lexington, KY, USA) and a bentonite clay 
(Toxisorb Classic®, Süd-Chemie, Moosburg, Germany) were suspended in cell medium at a 
concentration of 1 mg/mL.  
2.3. Transepithelial passage assay in 24-well plate with Transwell® cell culture inserts 
Cells were seeded in Transwell® inserts, with a collagen-coated membrane, a pore size of 0.4 
µm and membrane diameter of 6.5 mm (Corning, NY, USA), at a density of 5.10
5
/mL and 
cultured for 21 days until reaching confluence. Every three days, cell medium was refreshed.  
In the efficacy trials, inserts were exposed to DON (0.5 µg/mL or 1 µg/mL) and/or AC or GMA 
(1 mg/mL). In the drug interaction trials, inserts were exposed to tylosin (20 µg/mL) and/or 
bentonite or GMA (1 mg/mL). Control inserts were only exposed to cell medium. Before 
adding DON, tylosin and/or mycotoxin binder to the wells, mixtures were first incubated 
during 90 min on a roller mixer (Stuart Scientific® 2, IMLAB, Boutersem, Belgium), in order to 
mimic the gastric passage. Next, 1 mL of the mixture was added to the basolateral chamber 
of the insert, whereas in the apical chamber 200 µL fresh cell medium was added. During the 
48 h during trial, the 24-well plates were incubated on a shaker at 200 rpm (IKA® MTS 2/4 
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digital, Staufen, Germany) in order to prevent the binder to sediment. All experiments were 
conducted in triplicate with three repeats per experiment. 
2.4. Measurement of Transepithelial Electrical Resistance (TEER) 
To evaluate the integrity of the monolayer, TEER measurements were performed. During the 
21-day grow-up, TEER was measured weekly to evaluate the confluence and viability of the 
monolayer. The measurement was performed using an epithelial volthommeter (EVOM) 
with Endohm chambers (World Precision Instruments, Sarasota, FL, USA) and expressed as 
kOhm/well. Only inserts with a TEER value > 1 kOhm/well, indicating confluence, were used. 
During the efficacy and drug interaction trials, TEER was measured just before (0 h) and 12, 
24, 36 and 48 h after exposure. 
2.5. Neutral Red assay (NR) 
To assay the cytotoxicity after 48 h of exposure, cell viability was measured using the neutral 
red assay. Two hundred µL of freshly prepared neutral red medium (33 mg/L in DMEM 
without phenolred) was added to each insert, and incubated for 2 h in the dark at 37°C. 
Next, cells were washed three times with Hanks Buffered Saline Solution (HBSS) (Invitrogen 
Life Technologies). Afterwards, 200 µL of extraction solution (ethanol/water/acetic acid, 
50/49/1, v/v/v) were added to the apical compartment of each insert. The plate was shaken 
for 10 min at 350 rpm, and 150 µL of the medium of each insert was transferred into a 96-
well IWAKI microplate (Asashi Corp., Tokyo, Japan). The absorbance was measured at 540 
nm using a microplate ELISA reader (Multiscan MS, Thermo Labsystems, Helsinki, Finland). 
Viability was calculated according to the following formula: 
% viability = (a-b) / (c-b) x 100 
In this formula a: OD540 nm derived from the inserts incubated with DON, tylosin and/or 
mycotoxin binder, b: OD540 nm derived from blank inserts without cells, c: OD540 nm derived 
from untreated control inserts. 
2.6. LC-MS/MS analysis to determine transepithelial passage of DON and tylosin 
To determine the passage of DON through the IPEC-J2 monolayer in the efficacy trials, 25 µL 
of the apical cell medium of each insert was taken at 12, 24, 36 and 48 h after the start of 
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the experiment, and replaced by fresh medium. Samples were stored at ≤ -15°C until 
analysis. The concentration of DON in these samples was determined using a validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) method. The samples (25 µL) were 
spiked with 25 µL working solution (1 µg/mL) of internal standard (
13
C15-DON) and 50 µL of 
ACN was added. Next, the samples were vortexed (15 sec) and centrifugated (10 min, 8517 x 
g, 4°C). The supernatant was then evaporated using a gentle nitrogen stream (40 ± 5°C). The 
dry residue was reconstituted in 100 µL water of HPLC grade. After vortex mixing, the 
samples were transferred into an autosampler vial and an aliquot (10 µL) was injected onto 
the LC-MS/MS instrument. 
To determine the passage of tylosin through the IPEC-J2 monolayer in the drug interaction 
trials, 25 µL of the apical cell medium of each insert was taken at 12, 24, 36 and 48 h after 
the start of the experiment, and replaced by fresh medium. Samples were stored at ≤ -15°C 
until analysis. The concentration of tylosin in these samples was determined using a 
validated LC-MS/MS method. The samples (25 µL) were diluted in 200 µL water/ACN of HPLC 
grade (50/50, v/v) after spiking with 25 µL of a working solution of the internal standard 
(gamithromycin, 1 µg/mL). Next, samples were vortexed (15 sec) and centrifugated (8517 x 
g, 10 min, 4°C) and an aliquot was transferred to an autosampler vial and injected (5 µL) 
onto the LC-MS/MS instrument. 
The LC system consisted of a quaternary, low-pressure mixing pump with vacuum degassing, 
type Surveyor MS pump Plus and an autosampler, type Autosampler Plus, both from Thermo 
Fisher Scientific (Breda, The Netherlands). Chromatographic separation was achieved on a 
Hypersil-Gold column (50 mm x 2.1 mm i.d., dp: 1.9 µm) in combination with a guard column 
of the same type, both from Thermo Fisher Scientific (Louvain-la-Neuve, Belgium). For DON 
analysis, the mobile phase A consisted of 0.1 % glacial acetic acid in water of UHPLC quality 
(ultra-high performance liquid chromatography). Mobile phase B consisted of methanol of 
UHPLC quality. A gradient elution was performed: 0-1 min (95% A/5% B), 4 min (linear 
gradient to 80% B), 4-5.1 min (20% A/80% B), 5.6 min (linear gradient to 95% A), 5.6-8 min 
(95% A/5% B). For tylosin, the mobile phase A consisted of 10 mM ammonium acetate in 
water of UHPLC quality, acidified to pH 3.5 with glacial acetic acid. Mobile phase B was ACN 
of UHPLC quality. A gradient elution was performed: 0-0.5 min (80% A/20% B), 0.5-1 min 
Chapter I 
80 
 
(linear gradient to 90% B), 1-4.5 min (10% A/90% B), 4.5-5 min (linear gradient to 80% A), 5-8 
min (80% A/20% B).  
For both analytical experiments, the flow rate was 300 µL/min. The LC column effluent was 
interfaced to a TSQ® Quantum Ultra triple quadrupole mass spectrometer, equipped with a 
heated electrospray ionization (h-ESI) probe (Thermo Fisher Scientific), operating in the 
negative ionization mode for DON and in the positive ionization mode for tylosin. Following 
selected reaction monitoring (SRM) transitions were monitored and used for identification 
and quantification (*): for DON m/z 355.1 > 265.1* and 355.1 > 295.1, for 
13
C15-DON m/z 
370.1 > 279.1* and 370.1 > 310.1, for gamithromycin m/z 777.5 > 157.8 and 777.5 > 619.3* 
and for tylosin m/z 916.5 > 173.8* and 916.5 > 772.4.  
The method was validated according to an in-house protocol compliant with the 
recommendations and guidelines of the European Community and FDA (European 
Commission, 2002; Heitzman, 1994; VICH GL 49, 2009). Calibration curve samples (range 5-
1000 ng/mL for DON and 10-20000 ng/mL for tylosin) were prepared by applying standard 
working solutions directly into IPEC-J2 cell medium, followed by a vortex mixing step. After 5 
min equilibration, the calibration curve samples were treated in a similar way as the 
unknown samples. The correlation coefficients (r) and goodness-of-fit coefficients (g) had to 
be ≥ 0.99 and ≤ 20%, respectively. The values of r and g for DON were 0.9999 and 4.22%, 
respectively. For tylosin values of r and g were 0.9983 and 9.58%, respectively. Within-day 
precision and accuracy were determined by analyzing six blank samples spiked at low (10  
ng/mL for DON and 200 ng/mL for tylosin) and high (500 ng/mL for DON and 2000 ng/mL for 
tylosin) concentration levels on the same day. The between-day precision and accuracy was 
determined by analyzing quality control samples (10 and 500 ng/mL for DON and 200 and 
2000 ng/mL for tylosin) together with each analytical batch of samples, run on three 
different days (n=12). The acceptance criteria for accuracy were -20% to +10%. Within-run 
precision (relative standard deviation, RSD) and accuracy for samples spiked with DON at 10 
ng/mL were 5.8% and 0.4%, respectively, and for samples spiked at 500 ng/mL were 0.4% 
and 0.1%, respectively. Between-run precision and accuracy was 9.6% and -3.2% and 0.4% 
and 0.2%, respectively. Within-run precision and accuracy for samples spiked with tylosin at 
200 and 2000 ng/mL were 3.5% and -5.0% and 7.5% and -1.3%, respectively. Between-run 
precision and accuracy for samples spiked with tylosin at 200 and 2000 ng/mL were 7.4% 
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and -1.5%, 8.2% and -0.3%, respectively. The limit of quantification (LOQ) was the lowest 
concentration of the analytes for which the method was validated with an accuracy and 
precision that fell within the recommended ranges. The LOQ was also established as the 
lowest point of the calibration curve. The LOQ was determined by analyzing six spiked 
samples and was for DON and tylosin 5 and 10 ng/mL, respectively. The limit of detection 
(LOD) was defined as the lowest concentration of the respective analytes that could be 
recognized by the detector with a signal-to-noise (S/N) ratio of ≥3. The LOD values were 
calculated using samples spiked at the LOQ level. The LOD of DON and tylosin was 0.3 and 
0.9 ng/mL, respectively. The specificity of the method was evaluated with respect to 
interferences from endogenous compounds. Therefore, one blank sample was analyzed 
using the above mentioned procedure. The S/N ratio of a possible interfering peak in the 
blank sample had to be below the S/N ratio of the analyt in the same elution zone at the LOD 
level. No interfering peak was found in the blank sample. The carry-over was evaluated by 
analyzing a water sample just after the highest calibrator sample. The eventual analyte 
concentration in the sample had to be below the LOD. No peak was found in the water 
sample above the LOD. Recovery experiments were performed according to Matuszewski et 
al. (2003). In summary, two types of matrix-matched calibration curves were prepared for 
each analyte in IPEC-J2 medium, namely by spiking the blank calibrator samples before 
(spiked) and after extraction (spiked extract). One calibration curve was prepared using 
standard solutions. The slopes of the resulting linear, 1/x weighted spiked calibration curves 
(spiked and spiked extracts) were compared with the related slope of the calibration curve 
with standard solutions in order to calculate the recovery of the extraction step (RE) and the 
signal suppression/enhancement (SSE) due to matrix effects. RE and SSE for DON in IPEC-J2 
medium were 90.5 ± 11.6% and 108.4 ± 12.9%, respectively. For tylosin, RE and SSE were 
87.2 ± 9.8% and 111.7 ± 16.3%, respectively. 
2.7. Statistical analysis 
All experiments were conducted in triplicate (independent replicates) with three repeats per 
experiment (technical replicates). For each experiment, means of the technical replicates 
were calculated. These means (independent replicates) were analyzed using one-way 
ANOVA after determination of normality and homogeneity of variances (SPSS 19.0, IBM, 
Chicago, IL, USA). All data are expressed as mean (+ or ± SEM) of the three independent 
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replicates. Significant differences between treated inserts and controls are indicated by a 
different superscript. 
3. Results 
3.1. Efficacy testing 
3.1.1. IPEC-J2 cellular viability 
The viability of IPEC-J2 cells after 48 h exposure to DON at 0.5 and 1 µg/mL and with or 
without mycotoxin binder (GMA or AC) is shown in Table 1. A concentration of 0.5 µg/mL 
DON was not cytotoxic for IPEC-J2 cells, whereas 1 µg/mL induced cell death. AC completely 
counteracted the cytotoxic effect of 1 µg/mL DON. GMA partially (57%) alleviated the 
cytotoxic effect of DON. 
Table 1. Cellular viability of IPEC-J2 cells after 48 h of exposure to 0.5 or 1 µg/mL DON with or without 
mycotoxin binder (1 mg/mL; glucomannan or GMA, active carbon or AC).  
Cellular Viability (%) 
DON concentration (µg/mL) 
0 0.5 1 
 / 100.0 ± 1.44a 99.8 ± 1.12a 31.4 ± 0.94b 
Mycotoxin binder AC 106.3 ± 2.63a 98.5 ± 2.04a 102.0 ± 3.12a 
 GMA 114.4 ± 1.97a 107.3 ± 1.43a 69.4 ± 1.87c 
Results represent the means of three independent experiments conducted in triplicate and their SEM. Values 
with a different superscript are statistically different at p < 0.001 
 
3.1.2. Transepithelial passage of DON  
The concentration of DON in the apical compartment after addition of DON  at a non-
cytotoxic, 0.5 µg/mL, or cytotoxic concentration, 1 µg/mL, to the basolateral compartment 
with or without mycotoxin binder (AC or GMA) is shown in Figure 1. AC diminished the 
transepithelial passage of DON almost completely (>99%) at 0.5 and 1 µg/mL DON. GMA was 
able to lower the passage at both DON concentrations, but to a lesser extent than AC (37-
57%). 
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Figure 1. DON passage in the apical compartment after basolateral exposure of IPEC-J2 cells to 0.5 or 1 µg/mL 
DON ((A) and (B) respectively) with or without mycotoxin binder (1 mg/mL; glucomannan or GMA, active 
carbon or AC). For each data point, the mean and SEM are shown for three independent replicates, each 
independent replicate consisting of the mean of three technical replicates. Values with a different superscript 
within one time point are statistically different at p < 0.001 
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3.1.3. IPEC-J2 monolayer integrity 
TEER measurements of the monolayer were performed before (0 h) and after 12, 24, 36 and 
48 h addition of DON (1 µg/mL or 0.5 µg/mL) and/or mycotoxin binder (AC or GMA). The 
results of TEER measurements after exposure of IPEC-J2 cells to 0.5 and 1 µg/mL DON are 
shown in Figure 2. A concentration of 1 µg/mL DON decreased the TEER of IPEC-J2 cells. 
When AC was added, no decrease of TEER was observed, even at cytotoxic concentrations. 
GMA could partially (65%) prevent the decrease in TEER at 1 µg/mL DON. 
 Figure 2. TEER of IPEC-J2 cells on different time points after exposure to 0.5 or 1 µg/mL DON ((a) and (b) 
respectively) with or without mycotoxin binder (1 mg/mL; 
data point, the mean and SEM are shown for three independent replicates, each independent replicate 
consisting of the mean of three technical replicates. Values with a different superscript within one time point 
are statistically different at p < 0.001. * indicates a significant difference of 0.01 < p < 0.05 compared to control 
inserts 
 
 
glucomannan or GMA, active carbo
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3.2. Drug interaction testing 
3.2.1. IPEC-J2 cellular viability 
Viability of IPEC-J2 cells after 48 h exposure to 20 µg/mL tylosin with or without mycotoxin 
binder (GMA or bentonite) was evaluated. No significant differences on cellular viability 
between different conditions was observed.   
     3.2.2. Transepithelial passage of tylosin 
The concentration of tylosin in the apical compartment after addition of tylosin (20 µg/mL) 
to the basolateral compartment with or without mycotoxin binder (GMA or bentonite) is 
shown in Figure 3. Bentonite significantly reduced the transepithelial passage of tylosin 
(92%), whereas GMA did not. 
 
Figure 3. Tylosin passage in the apical compartment after basolateral exposure of IPEC-J2 cells  to 20 µg/mL 
tylosin with or without mycotoxin binder (1 mg/mL; glucomannan or GMA, bentonite). For each data point, the 
mean and SEM are shown for three independent replicates, each independent replicate consisting of the mean 
of three technical replicates. Values with a different superscript within one time point are statistically different 
at p < 0.001  
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3.2.3. IPEC-J2 monolayer integrity 
TEER measurements of the IPEC-J2 monolayer were performed before (0 h) and after 12, 24, 
36 and 48 h addition of 20 µg/mL tylosin and/or mycotoxin binder (GMA or bentonite). No 
significant differences in TEER between the conditions was observed.   
4. Discussion 
The goal of this study was to develop an in vitro model for efficacy and drug interaction 
testing of mycotoxin detoxifiers. The model had to be high-throughput, in order to be useful 
as a screening method, but still reliable and more representative for the in vivo situation 
compared with single-concentration studies and adsorption isotherms. 
Transwell® cell culture inserts with an intestinal epithelial cell monolayer allow the 
evaluation of the passage of mycotoxins and veterinary drugs through the monolayer and 
the effects on cellular viability and integrity (Dänicke et al., 2010; Diesing et al., 2011a; 
Diesing et al., 2011b). The collagen coated inserts are deemed to be most suited for in vitro 
research with IPEC-J2 (Geens and Niewold, 2011).  At first, an efficacy model was developed 
using these inserts. Deoxynivalenol (DON) was used as it is the most common mycotoxin 
found in European commodities (Monbaliu et al., 2010). Pigs are the most susceptible to 
DON and therefore an intestinal porcine epithelial cell line derived from the jejunum of 
piglets (IPEC-J2 cell line) was used. Enterocytes are especially exposed to the effects of DON 
as this mycotoxin is almost completely absorbed in the proximal intestine in pigs (Dänicke et 
al., 2010; Eriksen et al., 2003). The intestinal epithelium is characterized by adherent and 
tight junctions, which restrict paracellular transport to small hydrophilic molecules. It was 
shown that DON disturbs epithelial cell layer integrity of IPEC-J2 cells (Diesing et al., 2011a; 
Sergent et al., 2006), leading to an increased paracellular passage of DON. Using this model, 
the absorption of mycotoxins through the monolayer, in the presence or absence of 
mycotoxin detoxifiers, can be evaluated. Two mycotoxin binders were tested, namely 
activated charcoal (AC) as positive control and modified glucomannan (GMA) as a 
commercially available binder. Suspensions of toxin and/or mycotoxin binder were first 
incubated on a roller mixer for 90 min to mimic the passage through the stomach. 
Moreover, pre-incubating the mycotoxin with the binder enhances the binding potency 
(Cavret et al., 2010). In contrast with Cavret et al. (2010), the mycotoxin binders were added 
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to the basolateral chamber of the Transwell® because addition to the apical chamber leads 
to damage of the epithelial cells due to friction and sinking of the particles (data not shown). 
This can be avoided by adding the binder to the basolateral chamber. However, this is not 
the physiological in vivo situation, where absorption through gut epithelia occurs from apical 
to basolateral. On the other hand, the DON absorption rate through the intestinal epithelial 
monolayer is independent of the route of application (Sergent et al., 2006). The same DON 
absorption rate from apical to basolateral as from basolateral to apical was observed in an 
intestinal epithelial model, because DON is absorbed through simple passive diffusion 
(paracellular transport) (Awad et al., 2007; Sergent et al., 2006). Therefore this route of 
application does not alter the realisticness of the model. What does depend of the route of 
application is the resistance of IPEC-J2 towards DON cytotoxicity (Diesing et al., 2011a). 
When added to the apical chamber, IPEC-J2 cells are more resistant than exposed from the 
basolateral side. Diesing et al. (2011a) demonstrated that 2 µg/mL of DON, added to the 
basolateral compartment, is cytotoxic for IPEC-J2 cells, whereas 0.5 µg/mL is not. We were 
able to reproduce these findings and refined them, as 1 µg/mL was also found to be 
cytotoxic. Both concentrations were used to evaluate the binding ability of mycotoxin 
binders at non-cytotoxic and cytotoxic concentrations. The passage was evaluated by 
measuring the concentrations of DON in the apical chamber (Figure 1). All inserts showed a 
passage increasing with time, suggesting adsorption mechanisms dependent on a 
thermodynamic equilibrium function of DON concentration in medium. The trend shown at 
the four different time points were the same (Figure 1). To even increase the high-
throughput character of the model, time-points at 36 and 48 h can be excluded. AC was able 
to completely inhibit the passage through the monolayer at both DON concentrations, 
indicating complete adsorption of DON by AC. A lower binding capacity of GMA compared 
with AC was expected as AC was used as positive control and is preferably avoided in 
practice due to its non-specific binding (Avantaggiato et al., 2004; Ramos et al., 1996). The 
GMA added was able to decrease passage through the monolayer due to binding. This 
interaction is based on hydrogen bonds and Van der Waals forces between hydroxyl, ketone 
and lactone groups and β-1,3 and β-1,6 glucans (Yiannikouris et al., 2006). Other evaluated 
parameters in our model were cellular viability, using a NR assay, and cellular integrity, 
based on TEER measurements. DON can induce apoptotic and necrotic cell death of IPEC-J2 
cells (Goossens et al., 2012), lowering the neutral red uptake by the lysosomes which is an 
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indicator for cell viability (Diesing et al., 2011b). As a part of cellular integrity, the loss of 
barrier function induced by DON is evoked by the decreased expression of claudin-4 protein, 
based on a MAPK-dependent mechanism (Pinton et al., 2010). No decrease in cellular 
viability and integrity was observed when AC was added, even at cytotoxic DON 
concentrations, confirming the complete adsorption of DON by AC. The cytotoxic effect of 1 
µg/mL DON on IPEC-J2 cells is also important regarding the basolateral to apical passage of 
DON with and without binder. When no binder is present, the passage from basolateral to 
apical depends not only on absorption but mainly on diffusion due to tight junction damage 
and loss of viable cells. When DON is added with a mycotoxin binder two effects are 
involved. The direct effect is that the mycotoxin binder binds DON, leaving less free DON 
available for passage to the apical compartment. The indirect effect is that the cellular 
viability and integrity of the IPEC-J2 monolayer is less affected (Table 1 and Figure 2b), and 
an intact monolayer will also lower the passage to the apical compartment compared to a 
disrupted monolayer. When we look at the passage of DON in combination with GMA, Figure 
1b, the concentration of DON in the apical compartment is around 50% or less compared to 
inserts treated with DON only. Based on the cytotoxicity and TEER measurements a passage 
of  ≥ 50% would be expected. In essence, the fact that GMA only partly decreases the 
negative effects of cytotoxic DON concentrations, indicates that the bounded amount of 
DON is lower than but close to 50%, because 1 µg/mL DON severely affects cellular viability 
and monolayer integrity, whereas 0.5 µg/mL does not. As stated, the lower (≤ 50%) DON 
passage is due to the fact that GMA partly protects monolayer integrity and cellular viability, 
so the indirect binding effects play a role. 
The interaction of mycotoxin binders with drugs, as a part of safety testing, was determined 
similarly as the efficacy model by using tylosin instead of DON. Tylosin was added to the 
basolateral chamber at a concentration of 20 µg/mL, corresponding with the exposure of 
epithelial gut cells when tylosin is used according to the leaflet. None of the conditions 
altered the cellular viability or integrity (data not shown), which was expected as in practice 
tylosin should not evoke cytotoxic effects on intestinal cells. To evaluate the tylosin binding 
of a bentonite clay and GMA, the passage through the epithelial monolayer was evaluated. 
Again, a similar trend was shown at all time points, therefore it is sufficient to evaluate the 
passage up to 24 h. Bentonite significantly reduced the tylosin passage and therefore binds 
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tylosin. These data now proof the suggestions made by other authors (Canadian Bureau of 
Veterinary Drugs, 1992; Shryock et al., 1994). Therefore, a combined use of bentonite in the 
feed with tylosin in the feed or drinking water, should be avoided as this could lead to 
therapy failure and eventually enhanced antibiotic resistance towards tylosin due to 
subtherapeutic plasma concentrations. With the proposed in vitro model, no interaction of 
tylosin with GMA was observed, indicating the safe combined use of tylosin and GMA. 
In vitro models for efficacy and drug interaction testing should be used as a screening 
method in order to select the most potent mycotoxin detoxifiers and to determine 
significant interactions between detoxifiers and veterinary drugs. However, the EFSA 
stipulates that next to these in vitro trials, in vivo trials should be performed to fully prove 
the efficacy or potential interactions with veterinary drugs of mycotoxin detoxifiers 
(Devreese et al., 2012; EFSA, 2010). Nevertheless, in vivo trials are labor and cost intensive 
which emphasizes the need for high-throughput in vitro methods. 
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Abstract - A sensitive and reliable multi-mycotoxin method was developed for the 
identification and quantification of several toxicological important mycotoxins such as 
deoxynivalenol (DON), deepoxy-deoxynivalenol (DOM-1), T-2 toxin (T-2), HT-2 toxin (HT-2), 
zearalenone (ZON), zearalanone (ZAN), α-zearalenol (α-ZOL), β-zearalenol (β-ZOL), α-
zearalanol (α-ZAL), β-zearalanol (β-ZAL), ochratoxin A (OTA), fumonisin B1 (FB1) and 
aflatoxin B1 (AFB1) in pig plasma using liquid chromatography combined with heated 
electrospray ionization triple quadrupole tandem mass spectrometry (LC-h-ESI-MS/MS). 
Sample clean-up consisted of a deproteinization step using acetonitrile, followed by 
evaporation of the supernatant and resuspension of the dry residue in water/methanol 
(85/15, v/v). Each plasma sample was analyzed twice, i.e. once in the ESI + and ESI - mode, 
respectively.  This method can be used for the assessment of animal exposure to mycotoxins 
and in the diagnosis of mycotoxicosis. For the performance of toxicokinetic studies with 
individual mycotoxins, highly sensitive analyte-specific LC-MS/MS methods were developed.  
The multi-mycotoxin and analyte-specific methods were in-house validated: matrix-matched 
calibration graphs were prepared for all compounds and correlation and goodness-of-fit 
coefficients ranged between 0.9974 - 0.9999 and 2.4% - 15.5%, respectively. The within- and 
between-run precision and accuracy were evaluated and the results fell within the ranges 
specified. The limits of quantification for the multi-mycotoxin and analyte-specific methods 
ranged from 2 - 10 ng/mL and 0.5 - 5 ng/mL, respectively, whereas limits of detection fell 
between 0.01 - 0.52 ng/mL and <0.01 - 0.15  ng/mL, respectively.  
Keywords - multi-mycotoxin analysis – LC-ESI-MS/MS – pig plasma – validation – 
toxicokinetics  
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1. Introduction 
Mycotoxins are secondary metabolites produced by different fungal species. Over 400 
mycotoxins have been identified, although only a few of them present a significant toxic 
effect and are of major concern. These include deoxynivalenol (DON), T-2 toxin (T-2), 
zearalenone (ZON), ochratoxin A (OTA), aflatoxin B1 (AFB1) and fumonisin B1 (FB1) 
(Lattanzio et al., 2011). The contamination of feed with mycotoxins is a continuing feed 
safety issue leading to economic losses in animal production (Wu, 2007), especially for pigs 
as they are known to be one of the most susceptible species for the stated mycotoxins. 
Diagnosing mycotoxicosis in animals and assessing animal exposure to mycotoxins is usually 
performed by analysis of commodities and feed. However, several disadvantages are present 
when estimating mycotoxin intake as such. In particular, no measurement of exposure at the 
individual level is possible, the variability of feed contamination is high and it does not 
provide a good dose response and specificity for the target mycotoxin. This can be overcome 
by measuring specific biomarkers or target compounds in body fluids, e.g. plasma or urine. 
Measuring the target compound in blood is also the most appropriate way for other 
purposes, including toxicokinetic studies with mycotoxins and evaluation of the efficacy of 
mycotoxin reduction strategies. Adding mycotoxin detoxifying agents (mycotoxin detoxifiers) 
to feed contaminated with mycotoxins is commonly used and seems to be the most 
promising way of counteracting the harmful effects of mycotoxins in animals (Kolosova and 
Stroka, 2011). Manufacturers have to prove the efficacy of these products, which is generally 
based on in vitro adsorption studies. However, the European Food Safety Authority (EFSA) 
has recently proposed guidelines for efficacy testing of mycotoxin detoxifiers (EFSA, 2010). In 
their guidelines, it is stated that in vivo efficacy trials should be performed based on 
absorption, distribution, metabolisation and excretion (ADME) studies. Devreese et al. 
(2012) has recently developed in vivo models for efficacy testing of mycotoxin detoxifiers 
based on these guidelines. 
It is obvious that for assessing animal exposure to mycotoxins (screening) on the one hand 
and the investigation of mycotoxin toxicokinetics on the other hand, the availability of 
sensitive and specific validated analytical methods is mandatory. In the last decades, high-
performance liquid chromatography (HPLC) has become the most important method for the 
analysis of mycotoxins in food, feed and other matrices. The mass spectrometer is a reliable 
detector for HPLC and it is an important analytical tool for routine analysis of mycotoxins in 
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complex matrices because of unambiguous identification and accurate quantification 
(Lattanzio et al., 2011). A huge amount of literature on high-performance liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis of several mycotoxins in 
food and feed is available (Malik et al., 2010; Songsermsakul and Razzazi-Fazeli, 2008), 
however, analytical methods for detection of mycotoxins in biological matrices, such as 
blood, are scarce. In addition, most methods are analyte-specific, which means that they 
allow the detection and/or quantification of only a limited number of mycotoxins at the 
same time. Until now, no multi-mycotoxin method for the analysis of plasma has been 
reported. 
Therefore, the goal of this study was to develop such methods for the simultaneous 
determination and quantification of several toxicological important mycotoxins in animal 
plasma.  The final methods should be applicable in two areas of expertise, i.e. screening for 
animal mycotoxin exposure and evaluation of the toxicokinetics of individual mycotoxins for 
the efficacy testing of mycotoxin detoxifiers. Since a large amount of samples had to be 
analyzed, special attention has been paid to the development of a high-throughput sample 
preparation procedure and LC-MS/MS analysis, but not at the expense of reliability and 
sensitivity.  
2. Materials and Methods 
2.1. Chemicals, products and reagents 
The analytical standards of ZON, ZAN, α-ZOL, β-ZOL, α-ZAL, β-ZAL, HT-2 and DOM-1 were 
obtained from Sigma-Aldrich (Bornem, Belgium). Standards of DON, T-2, OTA, FB1 and AFB1 
were obtained from Fermentek (Jerusalem, Israel). Internal standards (IS) (
13
C15-DON, 
13
C24-
T-2, 
13
C18-ZON, 
13
C20-OTA, 
13
C34-FB1, 
13
C17-AFB1) were purchased from Biopure (Tulln, 
Austria). All standards were stored at ≤ -15°C. Water, methanol and acetonitrile (ACN) were 
of LC-MS grade and were obtained from Biosolve (Valkenswaard, The Netherlands). 
Ammonium acetate, ethyl acetate and glacial acetic acid were of analytical grade and were 
obtained from VWR (Leuven, Belgium). Millex®-GV-PVDF filter units (0.22 µm) were obtained 
from Millipore (Brussels, Belgium). 
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2.2. Preparation of standard solutions 
Standard stock solutions of DON, T-2, HT-2, ZON, ZAN, α-ZOL, β-ZOL, α-ZAL, β-ZAL, T-2, OTA, 
FB1 and AFB1 were prepared in acetonitrile (analyte concentration: 1 mg/mL). Following 
standards were purchased as solutions: DOM-1 (50 µg/mL ACN), 
13
C17-AFB1 (10 µg/mL ACN), 
13
C15-DON, 
13
C24-T-2, 
13
C18-ZON, 
13
C20-OTA and 
13
C34-FB1 (all 25 µg/mL ACN). The stock 
solutions were stored at ≤ -15°C. 
Working solutions of 100 µg/mL were prepared in ACN/water (50/50, v/v). Serial dilutions of 
separate working solutions were prepared to achieve analyte concentrations of 10, 1, 0.1 
and 0.01 µg/mL. A combined working solution of 10 µg/mL of all analytes (except IS) was 
prepared by transferring 10 µL of each stock solution of 1 mg/mL and 200 µL of the stock 
solution of DOM-1 (50 µg/ml) to an eppendorf cup, followed by further dilution with 
ACN/water (50/50, v/v) up to a final volume of 1 mL. By appropriate dilution of this solution 
with ACN/water (50/50, v/v), combined working solutions of 1, 0.1 and 0.01 µg/ml were 
obtained. For the internal standards, individual and  combined working solutions of 1 µg/mL 
were prepared in ACN/water (50/50, v/v). All working solutions were stored at 2-8°C. 
2.3. Biological samples 
Blank plasma samples were obtained from pigs (19.4 ± 1.8 kg BW) that received blank feed 
for a one week acclimatization period. The blank plasma samples were used for the 
preparation of matrix-matched calibrator and quality control (QC) samples. 
After the acclimatization period, a bolus toxicokinetic study was performed. Six pigs received 
a single oral bolus of the following mycotoxins (Fermentek, Jerusalem, Israel): DON, T-2, 
ZON, OTA and AFB1 (all 0.05 mg/kg BW). Blood samples were drawn before (0 min) and at 
15, 30 and 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h post-administration. Blood samples 
were taken in heparinized tubes and centrifugated (2851 x g, 10 min, 4°C). Aliquots (250 µL) 
of plasma samples were stored at ≤ -15°C until analysis. 
This animal experiment was approved by the Ethical Committee of Ghent University (case 
number EC 2012_08). 
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2.4. Sample pretreatment 
To 250 µL of plasma were added 12.5 µL of the combined IS working solution and 750 µL of 
ACN, followed by a vortex mixing (15 sec) and centrifugation step (8517 x g, 10 min, 4°C). 
Next, the supernatant was transferred to another tube and evaporated using a gentle 
nitrogen (N2) stream (45 ± 5°C). The dry residue was reconstituted in 200 µL of 
water/methanol (85/15, v/v). After vortex mixing (15 sec), the sample was passed through a 
Millex® GV-PVDF filter (0.22 µm) and transferred into an autosampler vial. An aliquot (2.5 - 
10 µL) was injected onto the LC-MS/MS instrument. 
2.5. Liquid chromatography 
The LC system consisted of a quaternary, low-pressure mixing pump with vacuum degassing, 
type Surveyor MS pump Plus and an autosampler with temperature controlled tray and 
column oven, type Autosampler Plus, from Thermo Fisher Scientific (Breda, The 
Netherlands). Chromatographic separation was achieved on a Hypersil Gold column (50 mm 
x 2.1 mm i.d., dp: 1.9 µm) in combination with a guard column of the same type (10 mm x 
2.1 mm i.d., dp: 3 µm), both from Thermo Fisher Scientific. The temperatures of the column 
oven and autosampler tray were set a 45 and 5°C respectively.   
For multi-mycotoxin screening analysis, two gradient elution programs were performed 
depending on the MS/MS detection mode, i.e. positive or negative electrospray ionization 
(ESI). The flow rate was set at 300 µL/min. An overview of the gradient programs is given in 
Table 1.  
For the toxicokinetic studies, separate LC-MS/MS methods were run for each type of 
mycotoxin and its metabolites, i.e. DON and DOM-1, T-2 and HT-2, ZON and metabolites, 
FB1, OTA and AFB1. Instrument parameters (mobile phase, gradient programs and MS/MS 
conditions) were optimized in such a way that optimal chromatographic separation and 
sensitivity could be reached for all analytes of interest. An overview of the HPLC conditions 
for the analysis of the individual mycotoxins (and their metabolites) is shown in Table 1. 
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Table 1. Overview of the LC gradient programs that were used for the multi-mycotoxin and the analyte-specific 
LC-MS/MS methods. 
Method Analyte(s) 
Mobile phase 
Time 
(min) 
MF A:B ratio (%) 
A B 
Multi-
mycotoxin 
DON, DOM-1, 
ZON, α/β-ZOL, 
α/β-ZAL, ZAN, 
OTA (ESI -) 
0.1 % acetic acid in water methanol 
0.0 - 1.0 95:5 
1.0 - 4.0 Linear to 20 % A 
4.0 - 5.1 20:80 
5.1 - 5.6 Linear to 95 % A 
5.6 - 8.0 95:5 
T-2, HT-2, FB1, 
AFB1 (ESI +) 
0.1 % acetic acid in water methanol 
0.0 - 0.5 70:30 
0.5 - 5.0 Linear to 30 % A 
5.0 - 6.4 30:70 
6.4 - 6.5 Linear to 70 % A 
6.5 - 10.0 70:30 
Analyte-
specific 
DON, DOM-1 0.1% acetic acid in water methanol 
0.0 - 1.0 95:5 
1.0 - 4.0 Linear to 20 % A 
4.0 - 5.1 20:80 
5.1 - 5.6 Linear to 95 % A 
5.6 - 8.0 95:5 
T-2, HT-2 
5 mM ammonium acetate 
in water/methanol/acetic 
acid (94/5/1, v/v/v) 
methanol/5 mM 
ammonium 
acetate in 
water/acetic acid 
(97/2/1, v/v/v) 
0.0 - 0.1 60:40 
0.1 - 1.0 Linear to 10 % A 
1.0 - 4.0 10:90 
4.0 - 4.1 Linear to 60 % A 
4.1 - 8.0 60:40 
ZON, α/β-ZOL, 
α/β-ZAL, ZAN 
0.01% acetic acid in water ACN 
0.0 - 0.5 70:30 
0.5 - 5.0 Linear to 30 % A 
5.0 - 6.4 30:70 
6.4 - 6.5 Linear to 70 % A 
6.5 - 10.0 70:30 
OTA 
5 mM ammonium acetate 
in water/methanol/acetic 
acid (94/5/1, v/v/v) 
ACN 
0.0 - 1.0 65:35 
1.0 - 1.5 Linear to 10 % A 
1.5 - 3.5 10:90 
3.5 - 3.7 Linear to 65 % A 
3.7 - 6.0 65:35 
FB1 0.1% acetic acid in water methanol 
0.0 - 1.5 65:35 
1.5 - 2.0 Linear to 10 % A 
2.0 - 3.5 10:90 
3.5 - 3.7 Linear to 65 % A 
3.7 - 6.0 65:35 
AFB1 0.01% formic acid methanol 
0.0 - 0.5 90:10 
0.5 - 1.5 Linear to 20 % A 
1.5 - 5.1 20:80 
5.1 - 5.6 Linear to 90 % A 
5.6 - 8.0 90:10 
 
 
Chapter II 
102 
 
2.6. Mass spectrometry 
The LC column effluent was interfaced to a TSQ® Quantum Ultra triple quadrupole mass 
spectrometer, equipped with a heated electrospray ionization (h-ESI) probe operating in 
both the positive and negative ionization mode (all from Thermo Fisher Scientific). 
Instrument parameters were optimized by syringe infusion of working solutions of 1 µg/mL 
of each compound (flow rate 10 µL/min) in combination with its corresponding mobile 
phases (50% A, 50% B, flow rate: 200 µL/min).  
The following general MS/MS parameters were used for the multi-mycotoxin screening 
method: ESI(+): spray voltage: 4000 V, vaporizer temperature: 300°C, sheath gas pressure: 
40 au (arbitrary units), ion sweep gas pressure: 2.0 au, auxiliary gas pressure: 15 au, capillary 
temperature: 300 °C, tube lens offset: 100 V, source CID collision energy: 5 V, collision 
pressure: -1.5 mTorr and quad MS/MS bias: 3.0. The parameters for ESI(-) analysis were set 
at:  spray voltage: -3500 V, vaporizer temperature: 300 °C, sheath gas pressure: 40 au, ion 
sweep gas pressure: 2.0 au, auxiliary gas pressure: 15 au, capillary temperature: 300°C, tube 
lens offset: -60 V, source CID collision energy: 5 V, collision pressure: -1.5 mTorr and quad 
MS/MS bias: 3.0. The resolution for Q1 and Q3 were set at 0.7 peak width half-height. 
Acquisition was performed in the selected reaction monitoring (SRM) mode. For each 
compound, the two most intense product ions of the precursor ion were monitored in the 
SRM mode for quantification and identification, respectively. For the analyte-specific 
methods, MS/MS parameters were optimized for each individual mycotoxin (and its 
metabolites) so that an optimal sensitivity could be obtained and the results are shown in 
Table 2.  
2.7. In-house method validation 
Both the multi-mycotoxin and analyte-specific methods were validated according to a 
validation protocol previously described by De Baere et al. (2011). A set of parameters that 
were  in compliance with the recommendations and guidelines defined by the European 
Community and with criteria described in the literature, were evaluated (European 
Commission,  2002; Heitzman, 1994; VICH GL 49, 2009).  
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Linearity was evaluated by preparing matrix-matched calibration curves. Calibration curve 
samples (range 1-200 ng/mL for ZON and metabolites and 1-1000 ng/mL for all other 
compounds) were prepared by applying standard working solutions directly onto the blank 
plasma samples, followed by a vortex mixing step. After 5 min of equilibration, the 
calibration curve samples were treated in a similar way as the unknown samples. The 
correlation coefficients (r) and goodness-of-fit coefficients (g) were calculated and had to be 
≥ 0.99 and ≤ 20%, respectively. 
Within-run precision (repeatability) and accuracy were determined by analyzing six blank 
samples spiked at low (1 and/or 10 ng/mL) and high (50, 100, 200 and/or 500 ng/mL) 
concentration levels in the same run. The between-run precision (reproducibility) and 
accuracy were determined by analyzing quality control samples (1, 10 and/or 100 ng/mL) 
together with each analytical batch of samples, run on three different days. The acceptance 
criteria for accuracy were: -30% to +10% and -20% to +10% for concentrations between 1 
and 10 ng/mL and > 10 ng/mL, respectively. For the precision, the relative standard 
deviation (RSD) had to be below the RSDmax value with RSDmax = 2
(1-0.5logConc) 
x 2/3 for within-
run precision (RSDr) and 2
(1-0.5logConc) 
for between-run precision (RSDR) (European 
Commission, 2002; Heitzman, 1994). RSDmax values for the RSDr were as follows: 1 ng/mL: 
30.2%, 2 ng/mL: 27.2%, 5 ng/mL: 23.7%, 10 ng/mL: 21.3%, 50 ng/mL: 16.7%, 100 ng/mL: 
15.1%, 200 ng/mL: 13.6% and 500 ng/mL: 11.8%. For the RSDR the RSDmax values were: 10 
ng/mL: 32.0%, 50 ng/mL: 25.1%, 100 ng/mL: 22.6% and 200 ng/mL: 20.4%. 
The limit of quantification (LOQ) was the lowest concentration of the analytes for which the 
method was validated with an accuracy and precision that fell within the recommended 
ranges (see section accuracy and precision). The LOQ was also established as the lowest 
point of the calibration curve. The LOQ was determined by analyzing six spiked samples. 
The limit of detection (LOD) was defined as the lowest concentration of the respective 
analytes that could be recognized by the detector with a signal-to-noise (S/N) ratio of ≥3. 
The LOD values were calculated using samples spiked at the LOQ level. 
The specificity of the method was evaluated with respect to interferences from endogenous 
compounds. Therefore, one blank sample was analyzed using the above mentioned 
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procedure. The S/N ratio of a possible interfering peak in the blank sample had to be below 
the S/N ratio of the analyt(es) in the same elution zone at the LOD level. 
The carry-over on the LC-MS/MS instrument was evaluated by analyzing an ACN/water 
sample (50/50, v/v) just after the highest calibrator sample. The eventual analyt 
concentration in the sample had to be below the LOD.  
Recovery experiments were performed according to Matuszewski et al. (2003). In summary, 
two types of matrix-matched calibration curves were prepared for each analyte, namely by 
spiking the blank calibrator samples before (spiked) and after extraction (spiked extract). 
One calibration curve was prepared using standard solutions. The slopes of the resulting 
linear, 1/x weighted, spiked calibration curves with spiked and spiked extracts samples were 
compared with the related slopes of the calibration curves with spiked extracts and standard 
solution, in order to calculate the recovery of the extraction step (RE) and the signal 
suppression/enhancement (SSE) due to matrix effects, respectively. 
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Table 2. Overview of the different MS/MS parameters that were used for the analyte-specific LC-MS/MS method. 
 
Analyt 
MM Precursor ion Product ions RT CE DT SV VT SG ISG AG CT TLO CGP Quad 
MS/MS bias (g/mol) (m/z) (m/z) (min) (V) (ms) (V) (°C) (au) (au) (au) (°C) (V) (mTorr) 
DON 296 
355.20   
[M+CH3COO]
-
 
265.10 
295.10 
* 
3.49 
15 
200 -3500 300 40 2.0 15 300 
-75 
-1.5 3.0 
 10 
DOM-1 280 
339.10 
[M+CH3COO]
-
 
59.10 
249.10 
 
4.26 
35 
-85 
* 15 
13
C15-DON 311 
370.20   
[M+CH3COO]
-
 
279.10 
310.10 
* 
3.45 
15 
-75 
 10 
ZON 318 
317.3 
[M-H]
-
 
131.00 
175.00 
* 
4.55 
41 
100 -3500 300 40 2.0 25 300 
-80 
-1.5 2.8 
 37 
ZAN 320 
319.2 
[M-H]
-
 
205.00 
275.10 
* 
4.55 
32 
-67 
 28 
α/β -ZOL 320 
319.2 
[M-H]
-
 
275.10 
301.11 
 
3.77/2.93 
28 
-67 
* 25 
α/β -ZAL 322 
321.2 
[M-H]
-
 
277.13 
303.11 
* 
3.59/2.80 
30 
-74 
 32 
13
C18-ZON 336 
335.3 
[M-H]
-
 
169.10 
185.06 
 
4.50 
38 
-76 
* 30 
OTA 403 
402.20 
[M-H]
-
 
166.96 
358.04 
* 
6.53 
36 
200 -3500 300 39 2.0 20 300 
-86 
-0.5 3.7 
 28 
13
C20-OTA 423 
422.25 
[M-H]
-
 
175.03 
377.10 
* 
6.54 
46 
-90 
 32 
T-2 466 
484.08 
[M+NH4]
+
 
185.05 
215.07 
* 
5.82 
25 
200 4000 300 43 2.0 12 300 
100 
-0.5 2.6 
 24 
HT-2 424 
442.02 
[M+NH4]
+
 
263.10 
215.07 
* 
5.21 
15 
100 
 14 
13
C24-T-2 490 
508.18 
[M+NH4]
+
 
198.10 
229.14 
 
5.83 
25 
100 
* 23 
FB1 721 
722.3 
[M+H]
+
 
333.90 
352.37 
 
3.96 
44 
250 4000 300 23 4.0 18 300 
136 
-0.5 2.1 * 35 
13
C34-FB1 755 756.4                 356.17 * 3.97 34 125 
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[M+H]
+
 374.19  
31 
AFB1 
312 
312.90              
[M+H]
+
 
240.92 
284.89 
* 
3.65 
46 
300 4000 300 41 2.0 20 300 
100 
-0.5 2.6  35 
13
C17-AFB1 329 
330.04              
[M+H]
+
 
255.04 
300.88 
* 
3.59 
34 
100 
 35 
 
MM : molecular mass; RT: retention time; CE: collision energy; ; DT: dwell time ; SV: spray voltage; VT: vaporizer temperature; SG: sheath gas; ISG: ion sweep gas; AG: auxiliary gas; CT: 
capillary temperature; TLO: tube lens offset; CGP: collision gas pressure; the asterix (*) indicates the quantifier ion. 
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3. Results and discussion 
3.1. Method development 
3.1.1. Sample preparation and extraction 
The goal of this study was to develop a sensitive LC-MS/MS method for screening and 
quantitation of toxicological important mycotoxins in plasma. These plasma samples can be 
taken during assessment experiments to evaluate animal exposure to mycotoxins 
(screening) or as a part of toxicokinetic studies with mycotoxins (quantitation). Since these 
surveys or trials generate a large number of samples, the use of a simple and practical 
sample preparation procedure is advisable in order to reduce the time and cost of analysis. 
When using a sensitive and specific analytical technique such as LC-MS/MS, cleanup of raw 
extracts can be kept to a minimum (Van Pamel et al., 2011). However, the most simple 
procedure - dilute-and-shoot - was not found suitable for plasma analysis, as this could lead 
to clogging and serious contamination of the MS instrument. On the other hand, more 
sophisticated extraction procedures using solid phase extraction (SPE) and immuno-affinity 
columns (IAC) are not recommended, as they are generally time-consuming and expensive, 
which is a disadvantage if a large amount of samples have to be analyzed (i.e. for screening 
or toxicokinetical analysis). To achieve a good compromise between simplicity of extraction 
and acceptable sample clean-up, a generic extraction procedure was developed which 
consisted of a combination of protein precipitation with liquid extraction.  
Organic solvents, such as methanol and acetonitrile, are commonly used for deproteinization 
of plasma samples (Corcuera et al., 2011). In our method, 750 µL acetonitrile was used for 
combined precipitation of plasma proteins and extraction of mycotoxins, as it showed high 
extraction recoveries (RE, %) for all compounds (ranging from ± 73 to 110 %), as can be seen 
in Table 3. Acetonitrile gave more clear supernatants after centrifugation compared to 
methanol, indicating improved deproteinization efficiency compared to methanol. In order 
to concentrate the samples as much as possible, the supernatants were evaporated under 
nitrogen and reconstituted in 200 µL water/methanol (85/15, v/v).  
Matrix effects (SSE, %) were evaluated and varied between ± 76 and 113 % for all 
compounds, as can be seen in Table 3. These results are acceptable taking into account that 
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a generic extraction procedure was used and correlate well with those reported by other 
authors (Corcuera et al., 2011; De Baere et al., 2011; Munoz et al., 2010). Hence, it can be 
stated that for the first time a generic extraction procedure was developed for the 
simultaneous extraction of mycotoxins (and their metabolites) belonging to different groups, 
from animal plasma.  
3.1.2. Optimization of LC-MS/MS conditions 
During preliminary experiments, three different reversed-phase C18 columns were tested 
(Nucleosil, Varian/Agilent; Alltima HP, Alltech; Hypersil Gold, ThermoScientific). The Hypersil 
Gold column was retained since the best results were obtained with respect to separation of 
analytes within a short analysis time (i.e. less than 10 min).  
For the simultaneous detection of several mycotoxins, the mobile phases reported in the 
literature consist generally of a combination of water with the addition of a volatile organic 
acid (formic or acetic acid or ammonium acetate) and an organic solvent (methanol or 
acetonitrile) (De Baere et al., 2011; Monbaliu et al., 2010; Razzazi-Fazeli et al., 2003). In case 
of the multi-mycotoxin method, it was decided to perform two analytical runs, i.e. in the ESI 
+ and ESI - mode, respectively. In both ionization modes, the best sensitivity for all 
investigated compounds was achieved using 0.1 % acetic acid in water (MF A) and methanol 
(MF B) as mobile phase. In addition, nearly all compounds could be separated, except ZAN 
and the α- and β-isomers of ZOL and the α- and β-isomers of ZAL, which eluted at the same 
retention time (Supplementary Material: Figure 1). 
For quantitative purposes, it was necessary to achieve a baseline-separation between all 
analytes of interest, especially between ZAN and the isomers of ZOL and between the 
isomers of ZAL, and to reach a sensitivity that was as high as possible. Therefore, it was 
decided to optimize the chromatographic and MS/MS parameters for each individual 
mycotoxin and its metabolites (analyte-specific methods). For DON, T-2 and ZON analysis, 
the LC-MS/MS conditions were based on methods previously developed by our group (De 
Baere et al., 2011; De Baere et al., 2012). As can be seen from Table 1, all mobile phases 
consisted of a combination of acidified water and an organic solvent, except for T-2 and HT-
2. For these compounds, mobile phases containing 5 mM ammonium acetate in 
water/methanol/acetic acid (94/5/1, v/v/v) and 5 mM ammonium acetate in 
methanol/water/acetic acid (97/2/1, v/v/v) were used. The inclusion of ammonium salts in 
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the mobile phase induced the formation of ammonium adducts ([M+NH4]
+
), which are easier 
to fragment compared to protonized ([M+H]
+
) ions and sodium adducts ([M+Na]
+
) 
(Heitzman, 1994). Fragmentation of the [M+NH4]
+ 
ions enhanced the sensitivity of the LC-
MS/MS method, shown by lower LOQ and LOD values obtained when using these mobile 
phases compared with those of the multi-mycotoxin method. 
In case of ZON analysis, the organic modifier has been changed from methanol to 
acetonitrile, resulting in a baseline-separation of ZAN, α- and β-ZOL on the one hand and α- 
and β-ZAL on the other hand (Supplementary Material: Figure 2). 
Each compound was analyzed in its most sensitive ESI mode: T-2, HT-2, FB1 and AFB1 were 
acquired in the positive ionization mode, whereas DON, DOM-1, OTA, ZON, ZAN, α/β-ZOL 
and α/β-ZAL were acquired in the negative mode. These data are compliant with other 
papers (Lattanzio et al., 2011; Soleimany et al., 2012). 
Acquisition was performed in the SRM mode, which means that for each analyte the two 
most intense precursor ion > product ion transitions were monitored. The product ion with 
the highest  intensity was selected as quantifier, while the other ion was used as qualifier. In 
Table 2 the MS/MS conditions for all target analytes are shown.  
3.1.3. Internal standard 
The use of an isotopically labeled internal standard for every single mycotoxin is preferable 
(Spanjer et al., 2008), as this leads to maximal compensation for losses during extraction, 
matrix effects during LC-MS/MS analysis, and general analysis errors. Moreover, isotopically 
labeled internal standards have similar physical and chemical properties as the target 
compound (European Commission, 2002). Disadvantages of the use of isotopically labeled 
internal standards are the high costs and the dependence on commercial availability. As an 
alternative only one isotopically labeled internal standard could be used per ionization 
mode. However, due to the diversity in chemical and physical properties of the different 
toxin classes, we preferred to use a 
13
C labeled internal standard for all parent compounds in 
the presented methods (i.e. 
13
C15-DON, 
13
C24-T-2, 
13
C18-ZON, 
13
C20-OTA, 
13
C34-FB1 and 
13
C17-
AFB1). Prior to use, all internal standards were analyzed using the described LC-MS/MS 
method in order to determine if any non-labeled mycotoxins were present in the solution, 
which was negative. 
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3.2. Method validation 
Both the multi-mycotoxin and the analyte-specific methods were in-house validated. The 
following parameters were evaluated for each mycotoxin and its respective metabolite(s): 
linearity, within- and between-run precision and accuracy, LOQ, LOD and specificity. The 
results are shown in Table 3 and as Supplementary Material: Table 4 and 5.  
Matrix-matched calibration graphs were linear over the working concentration range for all 
tested mycotoxins, with r values between 0.9974 and 0.9999 and g values between 2.4 and 
15.5 %. The within- and between-run accuracy and precision were tested at two different 
concentration levels and fell within the acceptability ranges. The limits of quantification 
(LOQ) ranged from 2-10 ng/mL for the multi-mycotoxin method and from 0.5-5 ng/mL for 
the analyte-specific methods. These lower LOQ levels for the analyte-specific methods can 
be explained by the fact that optimal LC and MS/MS conditions were used for each 
individual mycotoxin, whereas the conditions for the multi-mycotoxin were the best 
compromise for all analytes combined. The limits of detection (LOD) were calculated taking 
into account a S/N ratio of 3 and ranged from 0.01 to 0.52 ng/mL for the multi-mycotoxin 
method and from <0.01 to 0.15 ng/mL for the analyte-specific methods. Several studies 
reported by other authors showed that the concentrations of the investigated mycotoxins in 
human and animal plasma fell within the lower ppb (ng/mL) range (De Baere et al., 2011; 
Munoz et al., 2009; Santini et al., 2010). When developing a method for assessing mycotoxin 
exposure in animals by analyzing plasma, it is therefore a prerequisite to reach these low 
LOQ and LOD levels. Moreover, for toxicokinetic studies, dosing high mycotoxin 
concentrations to animals is no longer ethically acceptable as it compromises animal 
welfare. The developed methods succeeded in the detection and quantitation of the various 
mycotoxins at these low levels. For the evaluation of the specificity of the method, a blank 
plasma sample was analyzed. No endogenous interferences were detected in the elution 
zone of the target analytes. 
Carry-over of one sample to another on the LC-MS/MS instrument was evaluated by the 
analysis of a solvent sample after the highest calibrator sample. No carry-over was present, 
as there were no peaks detected in the same retention time zone of the compounds of 
interest.
Chapter II 
111 
 
Table 3. Results of the evaluation of linearity (goodness-of-fit coefficient (g), correlation coefficient (r)), extraction recovery (RE), matrix effect (SSE), limit of 
quantification (LOQ), limit of detection (LOD) for all analytes using the multi-mycotoxin and the analyte-specific methods, respectively. 
         
Method Analyte 
Calibration 
Range (ng/mL) 
g 
(%) 
r 
RE 
(%) 
SSE 
(%) 
LOQ 
(ng/mL) 
LOD 
(ng/mL) 
Multi-mycotoxin DON 10-1000 2.95 0.9999 99.27 85.49 10 0.40 
 DOM-1 5-1000 5.07 0.9990 101.58 95.39 5 0.22 
 ZON 5-1000 5.15 0.9999 94.38 90.73 5 0.52 
 ZAN 5-1000 5.83 0.9985 109.80 90.58 5 0.05 
 α/β-ZOL 5-1000 6.63 0.9990 108.49 83.73 5 0.02 
 α/β-ZAL 5-1000 6.73 0.9984 108.58 87.73 5 0.02 
 OTA 2-1000 4.90 0.9995 77.57 87.89 2 0.02 
 T-2 2-1000 2.39 0.9999 96.37 108.67 2 0.05 
 HT-2 5-1000 6.79 0.9990 77.62 80.15 5 0.15 
 FB1 2-1000 3.11 0.9997 102.85 98.77 2 0.01 
 AFB1 5-1000 4.11 0.9996 99.36 98.74 2 0.05 
Analyte-specific DON 1-1000 7.37 0.9993 99.85 101.40 1 0.05 
 DOM-1 2-1000 5.09 0.9992 93.86 86.49 2 0.04 
 ZON 1-200 12.58 0.9993 83.46 100.60 1 0.03 
 ZAN 1-200 8.28 0.9994 84.65 97.36 1 0.04 
 α-ZOL 5-200 7.41 0.9989 85.14 112.86 5 0.05 
 
β-ZOL 1-200 15.52 0.9979 84.48 102.24 1 0.02 
 α-ZAL 1-200 3.87 0.9996 85.97 105.06 1 0.02 
 
β-ZAL 1-200 6.32 0.9991 84.60 102.52 1 <0.01 
 OTA 0.5-1000 4.88 0.9979 99.89 97.43 0.5 <0.01 
 T-2 1-200 5.51 0.9981 86.52 80.03 1 0.05 
 HT-2 1-200 6.70 0.9974 72.95 76.35 1 0.03 
 FB1 1-1000 5.39 0.9995 96.10 89.31 1 0.08 
 AFB1 1-1000 4.15 0.9993 96.68 96.93 0.5 0.15 
 
Note: acceptance criteria: g ≤ 20 %, r ≥ 0.99 
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3.3. Biological samples 
To demonstrate the applicability of the developed multi-mycotoxin and analyte-specific 
methods, six piglets were administered an intra-gastric bolus of DON, ZON, OTA, T-2 and 
AFB1. Fumonisin B1 was not included in the bolus, as the maximum allowed concentration in 
pig feed is high, up to 60 mg/kg feed (European Commission, 2006), which would have led to 
a serious increase of the mycotoxin purchase costs. Lowering the administered dose was not 
an option as FB1 has a low oral bioavailability in pigs (± 3.5%) (Martinez-Larranaga et al., 
1999). Blood samples were drawn at different time points post-administration. All plasma 
samples were extracted once using the described sample preparation procedure. Thereafter, 
the extracted samples were injected several times, i.e. once for each ionization mode for the 
multi-mycotoxin method and once for each analyte-specific method. Following analysis, the 
correlation between the plasma concentrations obtained for both methods were set-up for 
each analyte and the correlation coefficients (R²) were calculated. 
Using the multi-mycotoxin method, DON and OTA could be detected and quantified, 
whereas AFB1 and ZON could be detected but not quantified as the concentrations were 
below the LOQ (2 and 5 ng/mL, respectively). No metabolites of these compounds, nor T-2 
toxin could be detected. T-2 toxin is very rapidly metabolized, as demonstrated by a very 
short elimination half-life (T1/2el), < 5 min in broiler chickens (Osselaere et al., 2013). This 
explains why this toxin was not detected in our biological samples. 
The mean concentrations detected for DON, ranging from 0 – 30 ng/mL, and ZON, up to 2.1 
ng/mL, correlate well with previous results from our group (De Baere et al., 2013; Devreese 
et al., 2012). Plasma concentrations for OTA, up to 135 ng/mL, and AFB1, ranging from LOD 
to 2.2 ng/mL, are in accordance with other literature (Corcuera et al., 2011). 
The same analytes were detected and quantified using the analyte-specific methods, but 
AFB1 could also be quantified as the plasma concentrations were above the LOQ (0.5 
ng/mL). The plasma concentrations for DON and OTA correlate very well between the multi-
mycotoxin and analyte specific methods (R² = 0.98 and 0.97, respectively). The correlation 
between the two methods for AFB1 is lower, however still acceptable (R² = 0.90), because 
the concentrations fell below the LOQ in the multi-mycotoxin method. For ZON, no R² was 
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calculated as the plasma concentrations were below the LOQ for both methods. Results are 
presented in Supplementary Material: Table 6. 
 4. Conclusions 
This paper describes a highly sensitive and specific LC-MS/MS method for the analysis of 
several toxicological important mycotoxins in pig plasma. All analytes were isolated from 
plasma by performing a generic, fast and low-cost sample preparation procedure. The 
extracted samples could be analyzed by two types of LC-MS/MS methods: a multi-mycotoxin 
method was used for the simultaneous analysis of all mycotoxins and can be applied in the 
field of animal exposure assessment to mycotoxins (screening). Analyte-specific methods 
were developed for the analysis of every mycotoxin (and its relevant metabolites) 
separately. These methods can be used for toxicokinetic studies, in vivo efficacy testing of 
mycotoxin detoxifiers based on toxicokinetic parameters and diagnosing mycotoxicosis in 
animals. Both the multi-mycotoxin and analyte-specific methods were successfully validated. 
In addition, the applicability of the method was shown by the analysis of real plasma 
samples that were taken from pigs that received an oral bolus of the investigated 
mycotoxins.   
5. Acknowledgments 
The authors would like to thank the Agency for Innovation by Science and Technology (IWT, 
Brussels, Belgium) for its financial support (SB grant 2010 N
o
 101301). 
  
Chapter II 
114 
 
6. References 
 
Corcuera, L.A., Ibanez-Vea, M., Vettorazzi, A., Gonzalez-Penas, E., Cerain, A.L., 2011. 
Validation of a UHPLC-FLD analytical method for the simultaneous quantification of 
aflatoxin B1 and ochratoxin a in rat plasma, liver and kidney. Journal of Chromatography 
B 879, 2733-2740. 
De Baere, S., Goossens, J., Osselaere, A., Devreese, M., Vandenbroucke, V., De Backer, P., 
Croubels, S., 2011. Quantitative determination of T-2 toxin, HT-2 toxin, deoxynivalenol 
and deepoxy-deoxynivalenol in animal body fluids using LC-MS/MS detection. Journal of 
Chromatography B 879, 2403-2415. 
De Baere, S., Osselaere, A., Devreese, M., Vanhaecke, L., De Backer, P., Croubels, S., 2012. 
Quantitative determination of zearalenone and its major metabolites in animal plasma 
using LC-MS/MS and (U)HPLC-HR-MS detection. Analytica Chimica Acta 756, 37-48. 
Devreese, M., Osselaere, A., Goossens, J., Vandenbroucke, V., De Baere, S., Eeckhout, M., De 
Backer, P., Croubels, S., 2012. New bolus models for in vivo efficacy testing of mycotoxin-
detoxifying agents in relation to EFSA guidelines, assessed using deoxynivalenol in broiler 
chickens. Food Additives & Contaminants Part A 29, 1101-1107. 
EFSA, 2010. Statement on the establishment of guidelines for the assessment of additives 
from the functional group ‘substances for reduction of the contamination of feed by 
mycotoxins’. EFSA Journal 8, 1693. 
European Commission, 2002. Commission Decision 2002/657/EC implementing Council 
Directive 96/23/EC concerning the performances of analytical methods and the 
interpretation of results. Official Journal of the European Commission, L 221. 
European Commission, 2006. Commission Recommendation 576/2006/EC of 17 August 2006 
on the presence of deoxynivalenol, zearalenone, ochratoxin A, T-2 and HT-2 and 
fumonisins in products intended for animal feeding. Official Journal of the European 
Union L 229, 7. 
Heitzman, R.J. (Ed.), 1994. Veterinary Drug Residues. Residues in food producing animals and 
their products: Reference materials and methods Report Eur. 14126-EN, Brussels. 
Kolosova, A., Stroka, J., 2011. Substances for reduction of the contamination of feed by 
mycotoxins: a review. World Mycotoxin Journal 4, 225-256. 
Lattanzio, V.M.T., Della Gatta, S., Suman, M., Visconti, A., 2011. Development and in-house 
validation of a robust and sensitive solid-phase extraction liquid chromatography/tandem 
mass spectrometry method for the quantitative determination of aflatoxins B(1), B(2), 
G(1), G(2), ochratoxin A, deoxynivalenol, zearalenone, T-2 and HT-2 toxins in cereal-based 
foods. Rapid Communications in Mass Spectrometry 25, 1869-1880. 
Malik, A.K., Blasco, C., Pico, Y., 2010. Liquid chromatography-mass spectrometry in food 
safety. Journal of Chromatography A 1217, 4018-4040. 
Martinez-Larranaga, M.R., Anadon, A., Diaz, M.J., Fernandez-Cruz, M.L., Martinez, M.A., 
Frejo, M.T., Martinez, M., Fernandez, R., Anton, R.M., Morales, M.E., Tafur, M., 1999. 
Chapter II 
115 
 
Toxicokinetics and oral bioavailability of fumonisin B-1. Veterinary and Human Toxicology 
41, 357-362. 
Matuszewski, B.K., Constanzer, M.L., Chavez-Eng, C.M., 2003. Strategies for the assessment 
of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical 
Chemistry 75, 3019-3030. 
Monbaliu, S., Van Poucke, C., Detavernier, C., Dumoulin, F., Van De Velde, M., Schoeters, E., 
Van Dyck, S., Averkieva, O., Van Peteghem, C., De Saeger, S., 2010. Occurrence of 
Mycotoxins in Feed as Analyzed by a Multi-Mycotoxin LC-MS/MS Method. Journal of 
Agricultural and Food Chemistry 58, 66-71. 
Munoz, K., Blaszkewicz, M., Degen, G.H., 2010. Simultaneous analysis of ochratoxin A and its 
major metabolite ochratoxin alpha in plasma and urine for an advanced biomonitoring of 
the mycotoxin. Journal of Chromatography B 878, 2623-2629. 
Munoz, K., Degen, G., Blaszkewicz, M., Campos, V., Neira, J., Vega, M., 2009. Biomonitoring 
of Ochratoxin A and its metabolite Ochratoxin alpha in urine, plasma and human milk. 
Toxicology Letters 189, S151-S151. 
Osselaere, A., Devreese, M., Goossens, J., Vandenbroucke, V., De Baere, S., De Backer, P., 
Croubels, S., 2013. Toxicokinetic study and absolute oral bioavailability of deoxynivalenol, 
T-2 toxin and zearalenone in broiler chickens. Food and Chemical Toxicology 51, 350-355. 
Razzazi-Fazeli, E., Bohm, J., Jarukamjorn, K., Zentek, J., 2003. Simultaneous determination of 
major B-trichothecenes and the de-epoxy-metabolite of deoxynivalenol in pig urine and 
maize using high-performance liquid chromatography-mass spectrometry. Journal of 
Chromatography B 796, 21-33. 
Santini, A., Ferracane, R., Meca, G., Ritieni, A., 2010. Comparison and improvement of the 
existing methods for the determination of aflatoxins in human serum by LC-MS/MS. 
Analytical Methods 2, 884-889. 
Soleimany, F., Jinap, S., Abas, F., 2012. Determination of mycotoxins in cereals by liquid 
chromatography tandem mass spectrometry. Food Chemistry 130, 1055-1060. 
Songsermsakul, P., Razzazi-Fazeli, E., 2008. A review of recent trends in applications of liquid 
chromatography-mass spectrometry for determination of mycotoxins. Journal of Liquid 
Chromatography & Related Technologies 31, 1641-1686. 
Spanjer, M.C., Rensen, P.M., Scholten, J.M., 2008. LC-MS/MS multi-method for mycotoxins 
after single extraction, with validation data for peanut, pistachio, wheat, maize, 
cornflakes, raisins and figs. Food Additives & Contaminants Part A 25, 472-489. 
Van Pamel, E., Verbeken, A., Vlaemynck, G., De Boever, J., Daeseleire, E., 2011. Ultrahigh-
Performance Liquid Chromatographic-Tandem Mass Spectrometric Multimycotoxin 
Method for Quantitating 26 Mycotoxins in Maize Silage. Journal of Agricultural and Food 
Chemistry 59, 9747-9755. 
VICH GL 49 (MRK), 2009. Studies to evaluate the metabolism and residue kinetics of 
veterinary drugs in food producing animals: validation of analytical methods used in 
residue depletion studies. November 2009, Brussels, Belgium. 
Chapter II 
116 
 
Wu, F., 2007. Measuring the economic impacts of Fusarium toxins in animal feeds. Animal 
Feed Science and Technology 137, 363-374. 
 
7. Supplementary material 
Chapter II 
117 
 
Table 4. Results of the within-run and between-run precision and accuracy evaluation for the analysis of 
toxicological important mycotoxins in pig plasma determined by a multi-mycotoxin LC-MS/MS method. 
 
Analyt 
Theoretical 
concentration (ng/mL) 
Mean concentration ± SD 
(ng/mL) 
Precision, RSD (%) Accuracy (%) 
DON 10 10.5 ± 0.69
 a
 6.6
 a
 4.7
 a
 
 50 50.3 ± 4.73
 a
 9.4
a
 0.5
a
 
 50 50.8 ± 2.74 
b
 5.4
b 
1.6
b 
 200 205.4 ± 8.28
 a
 4.0
a
 2.7
a
 
 200 204.8 ± 5.95 
b
 5.4
b
 2.9
b
 
DOM-1 10 10.7 ± 1.02
 a
 9.5
 a
 7.2
 a
 
 50 49.8 ± 3.47
 a
 7.0
 a
 -0.2
 a
 
 50 48.8 ± 4.49 
b
 9.2
 b
 -2.5
 b
 
 200 194.0 ± 14.51
 a
 7.5
 a
 -3.0
 a
 
 200 192.4 ± 11.59 
b
 6.0
 b
 -3.8
 b
 
ZON 10 9.7 ± 1.70
 a
 17.4
 a
 -2.7
 a
 
 50  54.2 ± 3.09 
 a
 5.7
 a
 8.5
 a
 
 50 53.7 ± 4.74 
b
 8.8
 b
 7.3
 b
 
 200 210.3 ± 12.39
 a
 5.9
 a
 5.2
 a
 
 200 209.1 ± 12.85 
b
 6.1
 b
 4.5
 b
 
ZAN 10 9.8 ± 1.09
 a
 11.1
 a
 -2.1
a
 
 50 52.5 ± 3.53
 a
 6.7
 a
 4.9
 a
 
 50 53.8 ± 3.42 
b
 6.4
 b
 7.5
 b
 
 200 204.6 ± 9.02
 a
 4.4
 a
 2.3
 a
 
 200 206.9 ± 6.54 
b
 3.2
 b
 3.5
 b
 
α/β-ZOL 10 10.8 ± 0.65
 a
 6.1
 a
 7.7
 a
 
 50 54.1 ± 3.93
 a
 7.3
 a
 8.3
 a
 
 50 54.7 ± 3.64 
b
 6.7
 b
 9.3
 b
 
 200 205.1 ± 14.22
 a
 6.9
 a
 2.5
 a
 
 200 206.4 ± 14.69 
b
 7.1
 b
 3.2
 b
 
α/β-ZAL 10 9.9 ± 0.87
 a
 8.8
 a
 -1.2
 a
 
 50 52.6 ± 3.74
 a
 7.1
 a
 5.1
 a
 
 50 54.5 ± 5.41 
b
 9.9
 b
 9.0
 b
 
 200 203.3 ± 10.54
 a
 5.2
 a
 1.7
 a
 
 200 208.3 ± 12.10 
b
 5.8
 b
 4.1
 b
 
OTA 10 10.5 ± 0.38
 a
 3.6
 a
 4.7
 a
 
 50 53.3 ± 3.95
 a
 7.4
 a
 6.5
 a
 
 50 53.1 ± 3.16 
b
 6.0
 b
 6.2
 b
 
 200 204.5 ± 6.82
 a
 3.3
 a
 2.3
 a
 
 200 206.5 ± 6.37 
b
 3.1
 b
 3.3
 b
 
T-2 10 10.2 ± 0.18
 a
 1.8
 a
 1.6
 a
 
 50 51.7 ± 1.67
 a
 3.2
 a
 3.5
 a
 
 50 51.3 ± 2.95 
b
 5.8
 b
 2.6
 b
 
 200 205.3 ± 2.84
 a
 1.4
 a
 2.6
 a
 
 200 200.2 ± 7.89 
b
 3.9
 b
 0.1
 b
 
HT-2 10 9.6 ± 1.04
 a
 10.9
 a
 -4.1
 a
 
 50 49.4 ± 5.58
 a
 11.3
 a
 -1.1
 a
 
 50 50.2 ± 5.34 
b
 10.6
 b
 0.3
 b
 
 200 193.6 ± 11.76
 a
 6.1
 a
 -3.2
 a
 
 200 197.0 ± 11.56 
b
 5.9
 b
 -1.5
 b
 
FB1 10 9.6 ± 0.77
 a
 8.0
 a
 -3.7
 a
 
 50 51.4 ± 2.06
 a
 4.0
 a
 2.9
 a
 
 50 50.5 ± 3.29 
b
 6.5
 b
 1.0
 b
 
 200 204.5 ± 6.14
 a
 3.0
 a
 2.2
 a
 
 200 200.7 ± 6.97 
b
 3.5
 b
 0.4
 b
 
AFB1 10 9.8 ± 0.50
 a
 5.1
 a
 -2.2
 a
 
 50 48.4 ± 2.45
 a
 5.1
 a
 -3.3
 a
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 50 48.1 ± 2.49 
b
 5.2
 b
 -3.8
 b
 
 200 195.4 + 8.02
 a
 4.1
 a
 -2.3
 a
 
 200 199.9 ± 10.40 
b
 5.2
 b
 0.0
b
 
     
a 
Results of within-run accuracy and precision (n=6); 
b 
Results of between-run accuracy and precision (n=12); 
SD: standard deviation; RSD: relative standard deviation 
Table 5. Results of the within-run and between-run precision and accuracy evaluation for the analysis of 
toxicological important mycotoxins in pig plasma determined by analyte-specific LC-MS/MS methods. 
     
Analyte 
Theoretical 
concentration (ng/mL) 
Mean concentration ± SD 
(ng/mL) 
Precision, RSD (%) Accuracy (%) 
DON 1 1.1 ± 0.25
 a
 21.5
 a
 14.6
 a
 
 1 1.1 ± 0.18 
b
 14.5 
b
 12.2 
b
 
 10 9.4 ± 0.55
 a
 5.8
 a
 -5.7
 a
 
 10 9.5 ± 0.47 
b
 4.9 
b
 -4.6 
b
 
 100 100.1 ± 1.83
 a
 1.8
 a
 0.1
 a
 
 100 100.7 ± 1.71 
b
 1.7 
b
 0.7 
b
 
DOM-1 1 0.9 ± 0.10
 a
 11.4
 a
 -8.6
 a
 
 1 1.0 ± 0.15 
b
 14.9 
b
 -0.6 
b
 
 10 9.8 ± 0.56
 a
 5.8
 a
 -2.0
 a
 
 10 10.4 ± 0.83 
b
 8.0 
b
 4.4 
b
 
 100 107.5 ± 2.62
 a
 2.4
 a
 7.5
 a
 
 100 100.7 ± 5.44 
b
 5.4 
b
 0.7 
b
 
ZON 1 1.2 ± 0.08 
a
 6.5
 a
 16.3
 a
 
 10 10.8 ± 0.54
 a
 5.0
 a
 7.9
 a
 
 10 10.4 ± 0.97 
b
 9.3 
b
 4.0 
b
 
 100 100.9 ± 4.93
 a
 4.9
 a
 0.9
 a
 
 100 104.2 ± 4.57 
b
 4.4 
b
 4.2 
b
 
ZAN 1 1.0 ± 0.16
 a
 16.9
 a
 -3.2
 a
 
 10 11.0 ± 0.77
 a
 7.0
 a
 2.9
 a
 
 10 10.5 ± 0.84 
b
 7.9 
b
 5.3 
b
 
 100 105.7 ± 3.06
 a
 2.9
 a
 5.7
 a
 
 100 105.4 ± 3.07 
b
 2.9 
b
 5.4 
b
 
α-ZOL 5 5.3 ± 0.33
 a
 6.1
 a
 6.9
 a
 
 10 10.3 ± 0.93
 a
 9.0
 a
 3.0
 a
 
 10 10.5 ± 0.42 
b
 4.0 
b
 5.0 
b
 
 100 101.9 ± 3.19
 a
 3.1
 a
 1.9
 a
 
 100 102.9 ± 7.87 
b
 7.6 
b
 2.9 
b
 
β-ZOL 1 0.9 ± 0.15
 a
 16.0
 a
 -8.4
 a
 
 10 9.6 ± 1.22
 a
 11.4
 a
 -4.1
 a
 
 10 10.8 ± 0.84 
b
 7.8 
b
 -7.5 
b
 
 100 102.3 ± 4.68
 a
 4.6
 a
 2.3
 a
 
 100 105.8 ± 6.28 
b
 5.9 
b
 5.8 
b
 
α-ZAL 1 1.2 ± 0.14
 a
 11.6
 a
 17.1
 a
 
 10 10.1 ± 0.80
 a
 7.9
 a
 1.4
 a
 
 10 10.5 ± 0.84 
b
 7.9 
b
 5.3 
b
 
 100 103.0 ± 5.94
 a
 5.8
 a
 3.0
 a 
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Table 6. Slopes a and intercepts b of equation y = ax + b, their standard deviations and the correlation 
coefficient R² of deoxynivalenol (DON), ochratoxin A (OTA) and aflatoxin B1 (AFB1) of the comparison between 
analysis by the multi-mycotoxin method and analyte specific methods (n = 84) 
 
Analyte a b R² 
DON 1.030 ± 0.045 0.539 ± 0.082 0.9806 
OTA 0.989 ± 0.049 -2.082 ± 0.389 0.9705 
AFB1 1.033 ± 0.082 -0.156 ± 0.009 0.9058 
 
  
 100 107.4 ± 7.00 
b
 6.5 
b
 7.4 
b
 
β-ZAL 1 0.8 ± 0.16
 a
 19.5
 a
 -20.3
 a
 
 10 10.6 ± 0.64
 a
 6.0
 a
 6.2
 a
 
 10 10.6 ± 0.39 
b
 3.6 
b
 5.8 
b
 
 100 103.4 ± 3.09
 a
 3.0
 a
 3.4
 a
 
 100 107.5 ± 5.47 
b
 5.1 
b
 7.5 
b
 
OTA 10 10.5 ± 0.26
 a
 2.4
 a
 5.1
 a
 
 10 11.0 ± 0.83 
b
 7.3 
b
 8.4 
b
 
 100 100.4 ± 1.51
 a
 1.5
 a
 0.4
 a
 
 500 514.6 ± 13.42
 a
 2.6
 a
 2.9
 a
 
 500 512.3 ± 14.09 
b
 2.7 
b
 2.5 
b
 
T-2 1 1.0 ± 0.29
 a
 22.1
 a
 3.1
 a
 
 10 9.7 ± 1.13
 a
 11.6
 a
 -3.0
 a
 
 10 9.4 ± 1.66 
b
 17.6 
b
 -5.9 
b
 
 100 107.7 ± 4.18
 a
 3.9
 a
 7.7
 a
 
 100 99.2 ± 5.35 
b
 5.4 
b
 -0.8 
b
 
HT-2 1 0.8 ± 0.20
 a
 26.0
 a
 -22.3
 a
 
 10 10.5 ± 1.25
 a
 11.9
 a
 4.9
 a
 
 10 10.5 ± 1.18 
b
 11.2 
b
 5.1 
b
 
 100 105.1 ± 2.32
 a
 2.2
 a
 5.1
 a
 
 100 99.0 ± 10.0 
b
 10.1 
b
 -1.0 
b
 
FB1 1 1.1 ± 0.08
 a
 8.0
 a
 5.1
 a
 
 10 10.2 ± 0.84
 a
 8.3
 a
 2.1
 a
 
 10 9.7 ± 0.90 
b
 9.3 
b
 -3.4 
b
 
 100 101.9 ± 5.67
 a
 5.6
 a
 1.9
 a
 
 100 103.7 ± 5.51 
b
 5.3 
b
 3.7 
b
 
AFB1 1 1.0 ± 0.07
 a
 7.2
 a
 2.3
 a
 
 10 10.1 ± 0.37
 a
 3.7
 a
 1.3
 a
 
 10 10.0 ± 0.48 
b
 4.8 
b
 0.0 
b
 
 100 101.2 ± 2.41
 a
 2.4
 a
 1.2
 a
 
 100 100.6 ± 1.97 
b
 2.0 
b
 0.6 
b
 
 
a 
Results of within-run accuracy and precision (n=6); 
b 
Results of between-run accuracy and precision (n=12) 
 Figure 1. LC-MS/MS chromatogram of a spiked plasma sample (concentration of all analytes: 10 ng/mL) 
analyzed using the multi-mycotoxin method, showing the SRM traces of (a) DON, DOM
13
C20-OTA,  ZON, ZAN, 
13
C18-ZON,  (α and β)
T-2, FB1, 
13
C34-FB1, AFB1 and 
13
C17-AFB1 acquired in the ESI + mode
(a) 
  
-ZOL and (α and β)-ZAL  in the ESI - mode and of (b) T
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13
C15-DON, OTA, 
-2, HT-2, 
13
C24-
 
 (b) 
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 Figure 2. LC-MS/MS chromatogram of a spiked plasma sample of ZON and its major metabolites (analyte 
concentration: 10 ng/mL) using the analyte
ZON and the separated metabolites β
 
 
-specific method for ZON, showing the SRM traces of ZON,  
-ZOL, α-ZOL and ZAN and β-ZAL and α-ZAL 
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Abstract - A sensitive and reliable method was developed for the identification and 
quantification of beauvericin, enniatin A, A1, B and B1 in pig plasma using liquid 
chromatography combined with heated electrospray ionization tandem mass spectrometry. 
Sample clean-up consisted of a deproteinization step using acetonitrile, followed by 
evaporation of the supernatant and resuspension of the dry residue in acetonitrile/water 
(20/80, v/v). The method was in-house validated: matrix-matched calibration graphs were 
prepared for all compounds and correlation and goodness-of-fit coefficients ranged between 
0.9980 - 0.9995 and 5.2% - 11.3%, respectively. The within- and between-run precision and 
accuracy were evaluated and the results fell within the ranges specified. The limits of 
quantification were 0.1 ng/mL for enniatin A and A1 and 0.2 ng/mL for beauvericin, enniatin 
B and B1, whereas limits of detection were ≤ 10 pg/mL for all analytes.  
  The method has been applied for the analysis of real plasma samples from one pig that 
received an oral bolus (0.05 mg/kg BW) of the investigated mycotoxins. At the applied 
dosage, the results indicated the suitability of the method for use in toxicokinetic studies 
with enniatines.  
 
Keywords - mycotoxin analysis – LC-ESI-MS/MS – pig plasma – validation – enniatin - 
beauvericin  
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1. Introduction 
Mycotoxins are secondary metabolites produced by different fungal species contaminating 
several food and feed commodities. Over 400 mycotoxins have been identified, although 
only a few of them have been thoroughly investigated because of their distinct toxic effects. 
The most prevalent mycotoxin producing fungi in moderate climates are Fusarium species. 
Several Fusarium spp. are capable of producing well-known mycotoxins like the 
trichothecenes, fumonisins and/or zearalenone, but also other mycotoxins including 
beauvericin (BEA) and enniatins (ENNs) such as ENN A, A1, B and B1 (Logrieco et al., 2002). 
These Fusarium mycotoxins are cyclic hexadepsipeptides consisting of alternating D-α-
hydroxyisovaleric acids and N-methyl-L-amino acids (Zhukhlistova et al., 1999) (Figure 1). 
BEA is a common contaminant of grains and has been detected for example in 6 of 22 Italian 
maize samples, in concentrations ranging from <1 up to 520 mg/kg, with an average of 102 ± 
119 mg/kg. In maize samples from Poland, BEA was detected in 13 of 14 samples, with 
contamination levels ranging between 5 and 60 mg/kg with an average of 18 ± 11 mg/kg 
(Logrieco et al., 1993; Ritieni et al., 1997). ENNs have been detected for example in 
Scandinavian barley (ENN A: 21/22 positive samples, range 2-950 µg/kg and mean 
contamination level of 67 ± 90 µg/kg; ENN A1: 22/22 contaminated samples, contamination 
range: 10-2000 µg/kg and mean 282 ±300 µg/kg; ENN B: 22/22 positive samples, range: 4-
9760 µg/kg, mean: 1622 ± 1482 µg/kg and ENN B1: 22/22 positive samples, range 11-5720 
µg/kg and mean: 1514 ± 1691 µg/kg) (Jestoi, 2008). More recently, ENNs have been 
detected in rice from Maroc (35/70 samples contaminated with ENNs and for ENN A: 
maximum level 120 mg/kg, mean 23 ± 15 mg/kg; ENN A1: maximum level 449 mg/kg, mean 
258 ± 135 mg/kg; ENN B: maximum level 26 mg/kg, mean 9 ± 1 mg/kg; ENN B1: maximum 
level 24 mg/kg and mean 9 ± 2 mg/kg) (Sifou et al., 2011). 
ENNs and BEA are of interest because they can exert antibacterial, antifungal and phytotoxic 
effects (Jestoi, 2008; Meca et al., 2010; Meca et al., 2011). On the other hand, they can also 
be toxic for mammalian cells. Their main mode of action is based on their ionophoric 
properties (Ivanov et al., 1973). They are capable of transporting cations through the cell 
membrane, leading to toxic actions by an altered membrane potential (Ivanov et al., 1973; 
Jestoi et al., 2009). Next to their ionophoric properties, ENNs exhibit other effects, such as 
inhibiting acyl-coenzyme A:cholesterol acyl transferase (ACAT) and 30,50-cyclo-nucleotide 
phosphodiesterase enzymes (Tomoda et al., 1992) causing mitochondrial dysfunction 
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(Tonshin et al., 2010), and the inhibition of multidrug resistance associated protein-1 
(ABCG2) and P-glycoprotein (ABCB1) efflux pumps (Dornetshuber et al., 2009). Many in vitro 
studies have reported cytotoxic effects of ENNs and BEA on several cell types, as reviewed 
by Jestoi (2008). Data on their in vivo toxicity are however lacking (Jestoi, 2008). 
Nevertheless, their possible subclinical effects are of greater importance as these may lead 
to reduced performance parameters in food producing animals and increased susceptibility 
to infectious disease. Opinions of the European Food Safety Authority (EFSA) on BEA and 
ENNs are currently being drafted on request by the European Commission. To evaluate their 
potential in vivo toxic effects, knowledge of their toxicokinetic properties, namely 
absorption, distribution, metabolisation and excretion (ADME) in livestock is crucial. As an 
example, no information is available on their oral absorption and bioavailability in any 
animal species, including pigs. Jestoi et al. (2007, 2009) detected trace level residues of ENNs 
and BEA in Finnish eggs, poultry meat and liver samples. One other study (Frenich et al., 
2011) reported trace levels of BEA in eggs from local retailers in Spain. To date, no other 
data are available on the tissue distribution and presence of these mycotoxins in other 
animal tissues or on their toxicokinetic properties in general (Meca et al., 2012). This lack of 
data could explain why there are no maximum guidance levels set for animal feed yet, in 
contrast to other mycotoxins (European Commission, 2006). 
It is obvious that for assessing animal exposure to BEA and ENNs and to investigate their 
toxicokinetics, the availability of sensitive and specific validated analytical methods is 
mandatory. In recent decades, high-performance liquid chromatography (HPLC) has become 
the most important separation method for the analysis of mycotoxins in food, feed and 
other matrices (Zollner and Mayer-Helm, 2006). For BEA and ENNs, the most common 
detection method used to be UV-detection. Nowadays mass spectrometry (MS) is in favour 
over spectrophotometric techniques because of unambiguous identification, detection and 
accurate quantification. Furthermore, it allows quantification of multiple residues (Jestoi, 
2008; Lattanzio et al., 2011; Songsermsakul and Razzazi-Fazeli, 2008; Uhlig and Ivanova, 
2004). 
Many high-performance liquid chromatography-tandem mass spectrometric (LC-MS/MS) 
methods for the analysis of ENNs and BEA in food and feed have been described (Logrieco et 
al., 1993; Sulyok et al., 2006; Uhlig and Ivanova, 2004; Van Pamel et al., 2011), however, 
analytical methods for detection of these mycotoxins in biological matrices are scarce 
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(Frenich et al., 2011; Jestoi et al., 2009; Jestoi et al., 2007). Until now, no method for the 
analysis of these compounds in plasma has been reported. 
The goal of this study was to develop a method which quantifies the Fusarium mycotoxins  
BEA, ENN A, A1, B and B1 in animal plasma, using liquid chromatography combined with 
heated electrospray ionization tandem mass spectrometry (LC-h-ESI-MS/MS). The final 
method should be applicable for evaluation of their toxicokinetic properties and oral 
bioavailability in different animal species. Since a large amount of samples are generated in 
such experiments, special attention has been paid to the development of a high-throughput 
sample preparation procedure and LC-MS/MS analysis, but not at the expense of reliability 
and sensitivity. 
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Figure 1. Full mass spectrum (range 150-1000 m/z), chemical structure and molecular mass (MM) of beauvericin (BEA), enniatin (ENN) A, A1, B and B1 
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2. Materials and Methods 
2.1. Chemicals, products and reagents 
The analytical standards of ENN A, A1, B and B1 were obtained from Sigma-Aldrich (Bornem, 
Belgium). Standard of BEA was obtained from Fermentek (Jerusalem, Israel). The internal 
standard  (IS) maduramicin (MAD) was a kind gift from Alpharma (Wilrijk, Belgium). 
Mycotoxin standards were stored at ≤ -15°C, maduramicin standard at 2-8°C. Water, 
methanol and acetonitrile (ACN) were of LC-MS grade and obtained from Biosolve 
(Valkenswaard, The Netherlands). Glacial acetic acid was of analytical grade and obtained 
from VWR (Leuven, Belgium).  
2.2. Preparation of standard solutions 
Separate standard stock solutions of all mycotoxins were prepared in ACN (analyte 
concentration: 1 mg/mL) and were stored at ≤ -15°C (Frenich et al., 2011; Jestoi et al., 2005). 
A combined working solution of 10 µg/mL of all analytes (except IS) was prepared by 
transferring 10 µL of each stock solution of 1 mg/mL into an eppendorf tube, followed by 
further dilution with ACN/water (50/50, v/v) up to a final volume of 1.0 mL. Combined 
working solutions of 1, 0.1, 0.01 and 0.001 µg/mL were obtained by diluting 100 µL of the 10 
times higher concentrated solution with 900 µL ACN/water (50/50, v/v). This method allows 
leverage to be kept to a minimum. For the IS, a working solution of 1 µg/mL was prepared in 
ACN/water (50/50, v/v). All working solutions were stored at 2-8°C. The decrease in signal 
intensity after 4 months storage was for all compounds less than 10% and therefore 
considered as stable. 
2.3. Biological samples 
A bolus toxicokinetic study was performed in one piglet (20.2 kg BW). The pig received a 
single oral intra-gastric bolus of the investigated mycotoxins BEA, ENN A, A1, B and B1 (all 
0.05 mg/kg BW). This dose resembled a feed contamination level of 1 mg/kg, since the feed 
intake of a 20 kg weighing pig is about 1 kg/day. This theoretical feed contamination level 
was chosen arbitrarily as it lies within the wide range of Fusarium-mycotoxins concentration 
levels that have been detected in feed (∼10 µg/kg to > 100 mg/kg) (Jestoi, 2008). The bolus 
solution was prepared instantly before administration by dissolving the mycotoxin standards 
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(1 mg of each individual compound) in 1 mL of ACN and further dilution with 50 mL of water. 
Blood samples were drawn before (0 min) and at 10, 20, 30 and 40 min, 1, 1.5, 2, 3, 4, 6, 8, 
10 and 12 h post-administration in heparinized tubes and centrifugated (2851 x g, 10 min, 
4°C). Plasma samples (250 µL) were stored at ≤ -15°C until analysis. 
This animal experiment was approved by the Ethical Committee of Ghent University (case 
number EC 2012_110). 
2.4. Sample pretreatment 
To 250 µL of plasma were added 12.5 µL of the IS working solution and 750 µL of ACN, 
followed by a vortex mixing (15 sec) and centrifugation step (8517 x g, 10 min, 4°C). Next, 
the supernatant was transferred to another tube and evaporated using a gentle nitrogen 
(N2) stream (45 ± 5°C). The dry residue was reconstituted in 200 µL of ACN/water (20/80, 
v/v). After vortex mixing (15 sec), the sample was transferred into an autosampler vial. The 
injection volume was 5 µL. One extraction and LC-MS/MS analysis was performed for each 
sample. 
2.5. Liquid chromatography 
The chromatographic system consisted of a quaternary, low-pressure mixing pump with 
vacuum degassing (Surveyor MS pump Plus, ThermoFischer Scientific, Breda, The 
Netherlands) connected to an autosampler (Autosampler Plus, Thermo Fisher Scientific) with 
temperature controlled tray and column oven. Chromatographic separation was achieved on 
a Hypersil Gold column (50 mm x 2.1 mm i.d., dp: 1.9 µm) in combination with a guard 
column of the same type (10 mm x 2.1 mm i.d., dp: 3 µm), both from Thermo Fisher 
Scientific. The temperatures of the column oven and autosampler tray were set a 45°C and 
5°C, respectively.  Mobile phase A consisted of 0.1% glacial acetic acid in water whereas 
mobile phase B was ACN. Following gradient elution program was run: 0-0.5 min (70% A, 
30% B), 0.5-2.5 min (linear gradient to 20% A), 2.5-8.5 min (20% A, 80% B), 8.5-10.0 min 
(linear gradient to 70% A), 10.0-12.0 min (70% A, 30% B). Flow rate was set at 300 µL/min. 
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2.6. Mass spectrometry 
The LC column effluent was interfaced to a TSQ® Quantum Ultra triple quadrupole mass 
spectrometer, equipped with a heated electrospray ionization (h-ESI) probe operating in the 
positive ionization mode (all from Thermo Fisher Scientific). Instrument parameters were 
optimized by syringe infusion of working solutions of 1 µg/mL of each compound (flow rate 
10 µL/min) in combination with the mobile phases (50% A, 50% B, flow rate: 200 µL/min).  
The following general MS/MS parameters were used: spray voltage: 4000 V, vaporizer 
temperature: 300 °C, sheath gas pressure: 49 au (arbitrary units), ion sweep gas pressure: 
2.0 au, auxilliary gas pressure: 30 au, capillary temperature: 250 °C, source CID collision 
energy: 10 V, collision pressure: -1.5 mTorr and quad MS/MS bias: 2.9. The resolution for Q1 
and Q3 were set at 0.7 full width at half maximum (FWHM). 
Acquisition was performed in the selected reaction monitoring (SRM) mode. For each 
compound, the two most intense product ions of the precursor ion were monitored in the 
SRM mode for quantification and identification, respectively (see Table 1).  
Table 1. SRM transitions and MS/MS parameters for the target analytes 
Analyte 
Precursor ion Product ions RT CE TLO 
(m/z) (m/z) (min) (V) (V) 
BEA 
784.46 
 [M+H]
+
 
244.06 
261.99 
* 
5.12 
25 
214 
 24 
ENN A 
704.48 
[M+Na]
+
 
350.15 
231.99 
* 
5.45 
55 
180 
 45 
ENN A1 
668.50 
[M+H]
+
 
210.05 
228.18 
* 
5.26 
29 
145 
 30 
ENN B 
640.46 
[M+H]
+
 
196.15 
214.01 
* 
4.79 
28 
137 
 30 
ENN B1 
654.46 
[M+H]
+
 
196.08 
214.07 
* 
5.03 
35 
186 
 35 
MAD 
934.49 
[M+H]
+
 
629.23 
393.14 
* 
6.99 
24 
150 
 29 
   
m/z: mass to charge ratio, RT: retention time; CE: collision energy; TLO: tube lens offset; 
the asterix (*) indicates the quantifier ion; BEA: beauvericin; ENN: enniatin; MAD: 
maduramicin 
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2.7. In-house method validation 
The method was validated according to a validation protocol previously described by De 
Baere et al. (2011). A set of parameters that were in compliance with the recommendations 
and guidelines defined by the European Community and with criteria described in the 
literature, were evaluated (European Commission, 2002; Heitzman, 1994; Knecht and Stork, 
1974; VICH GL 46). This includes evaluation of linearity, within- and between-run accuracy,  
within- and between-run precision (RSDr and RSDR, respectively), limit of detection (LOD), 
limit of quantification (LOQ), specificity, carry-over, extraction recovery (RE) and signal 
suppression/enhancement (SSE).  
Linearity was evaluated by preparing matrix-matched calibration curves over a concentration 
range of 0.1 - 200 ng/ml. This concentration range was chosen based on studies with other 
mycotoxins (De Baere et al., 2011; De Baere et al., 2012; Devreese et al., 2012a). Calibration 
curve samples (calibration levels (0.1,) 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100 and 200 ng/mL) were 
prepared by applying standard working solutions directly onto the blank plasma samples, 
followed by a vortex mixing step. After 5 min of equilibration, the calibration curve samples 
were treated in a similar way as the unknown samples. The correlation coefficients (r) and 
goodness-of-fit coefficients (g) were calculated and had to be ≥ 0.99 and ≤ 20%, respectively. 
RSDr (repeatability) and accuracy were determined by analyzing six blank samples spiked at 
low (1 ng/mL) and high (10 and 100 ng/mL) concentration levels in the same run. The RSDR 
(reproducibility) and accuracy were determined by analyzing quality control samples (1, 10 
and 100 ng/mL) together with each analytical batch of samples, run on three different days. 
The acceptance criteria for accuracy were: -50% to +20%, -30% to +10% and -20% to +10% 
for concentrations <1 ng/mL, between 1 and 10 ng/mL and > 10 ng/mL, respectively. For the 
precision, the relative standard deviation (RSD, %) had to fall within 2/3 of the values 
calculated according to the Horwitz equation: RSDmax = 2
(1-0.5logConc) 
x 2/3 for within-run 
precision, and within the values calculated according to the Horwitz equation for between-
run precision RSDmax = 2
(1-0.5logConc) 
 (European Commission, 2002; Heitzman, 1994). RSDmax 
values for the RSDr were as follows: 1 ng/mL: 30.2%, 10 ng/mL: 21.3% and 100 ng/mL: 
15.1%. For the RSDR the RSDmax values were: 1 ng/mL: 45.3%, 10 ng/mL: 32.0% and 100 
ng/mL: 22.6%. 
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The limit of quantification (LOQ) was the lowest concentration of the analytes for which the 
method was validated with an accuracy and precision that fell within the recommended 
ranges (see section accuracy and precision and Table 2). The LOQ was also established as the 
lowest point of the calibration curve. The LOQ was determined by analyzing six samples 
spiked at 0.1 or 0.2 ng/mL, on the same day. 
The limit of detection (LOD) was defined as the lowest concentration of the respective 
analytes that could be recognized by the detector with a signal-to-noise (S/N) ratio of ≥3. 
The LOD values were calculated using samples spiked at the LOQ level. 
The specificity of the method was evaluated with respect to interferences from endogenous 
compounds. Therefore, one blank sample was analyzed using the above mentioned 
procedure. The S/N ratio of a possible interfering peak in the blank sample had to be below 
the S/N ratio of the analyt(es) in the same elution zone at the LOD level. 
The carry-over on the LC-MS/MS instrument was evaluated by analyzing a water/ACN 
sample (50/50, v/v) just after the highest calibrator sample. The eventual analyte 
concentration in the sample had to be below the LOD.  
Recovery experiments were performed according to Matuszewski et al. (2003). In summary, 
two types of matrix-matched calibration curves were prepared for each analyte, namely by 
spiking the blank calibrator samples before (spiked) and after extraction (spiked extract). 
One calibration curve was prepared using standard solutions. The calibration curves were 
1/x weighted in order to reduce the risk of leverage. The slopes of the resulting linear, or 
quadratic for ENN A, 1/x weighted, calibration curves with spiked and spiked extracts 
samples were compared with the related slopes of the calibration curves with spiked 
extracts and standard solution, in order to calculate the recovery of the extraction step (RE) 
and the signal suppression/enhancement (SSE) due to matrix effects, respectively. 
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Table 2. Results of the evaluation of linearity (goodness-of-fit coefficient (g), correlation coefficient (r)), extraction recovery (RE), signal suppression/ 
enhancement (SSE), limit of quantification (LOQ), limit of detection (LOD) for all analytes 
         
Analyte 
Calibration 
Range (ng/mL) 
Spike levels  
(ng/mL) 
g 
(%) 
r 
RE 
(%) 
SSE 
(%) 
LOQ 
(ng/mL) 
LOD 
(pg/mL) 
BEA 0.2-200 
0.2, 0.5, 1, 2, 5, 10, 20, 
50, 100, 200 
11.30 0.9980 81.94 90.56 0.2 10 
ENN A 0.1-200 
0.1, 0.2, 0.5, 1, 2, 5, 10, 
20, 50, 100, 200 
8.48 0.9995 91.03 111.03 0.1 1.1 
ENN A1 0.1-200 
0.1, 0.2, 0.5, 1, 2, 5, 10, 
20, 50, 100, 200 
6.19 0.9995 82.28 81.49 0.1 3.3 
ENN B 0.2-200 
0.2, 0.5, 1, 2, 5, 10, 20, 
50, 100, 200 
5.19 0.9992 94.29 91.60 0.2 4.2 
ENN B1 0.2-200 
0.2, 0.5, 1, 2, 5, 10, 20, 
50, 100, 200 
11.31 0.9992 88.31 92.26 0.2 8.1 
 
Note: acceptance criteria: g ≤ 20 % (VICH GL 49, 2009), r ≥ 0.99 (European Commission, 2002), LOD: S/N > 3 (European Commission, 2002; VICH GL 49, 2009), LOQ: accuracy -50 
% to +20 %, RSDmax < 30.2 % (European Commission, 2002; Heitzman, 1994),  RE and SSE (Matuszewski et al., 2003) 
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3. Results and discussion 
3.1. Method development 
3.1.1. Sample preparation and extraction 
The goal of this study was to develop a sensitive LC-MS/MS method for screening and 
quantitation of BEA and ENNs in pig plasma. These plasma samples can be obtained during 
assessment experiments to evaluate animal exposure to these mycotoxins (screening) or as 
a part of toxicokinetic studies (quantitation). Since these surveys or trials generate a large 
number of samples, the use of a simple and practical sample preparation procedure is 
advisable in order to reduce the time and cost of analysis. When using a sensitive and 
specific analytical technique such as LC-MS/MS, clean-up of raw extracts can be kept to a 
minimum (Van Pamel et al., 2011). However, the most simple procedure, i.e. dilute-and-
shoot, was not found suitable for plasma analysis, as this could lead to clogging and serious 
contamination of the MS instrument. On the other hand, more sophisticated extraction 
procedures using solid-phase extraction (SPE), for example, are not recommended as they 
are generally time-consuming and expensive, which is a disadvantage if a large amount of 
samples have to be analyzed (i.e. for screening or toxicokinetic analysis). Moreover, selecting 
the right column may sometimes be tricky and when using a silica based SPE column, 
selectivity is rather low (Songsermsakul and Razzazi-Fazeli, 2008). Such SPE columns have 
been used as sample preparation technique for BEA and ENNs analysis, although the 
recoveries are generally lower compared to our sample preparation method (Jestoi et al., 
2005). The sample preparation for eggs, meat and liver samples described by Jestoi et al. 
(2007, 2009) consisted of extraction with ACN followed by SPE (silica). Frenich et al. (2011) 
used a QuEChERS-based extraction procedure followed by SPE (silica or Oasis HLB) for egg 
samples. As mentioned for SPE, the disadvantage is mainly the labor when a large amount of 
samples have to be analyzed. To achieve a good compromise between simplicity of 
extraction and acceptable sample clean-up, a generic extraction procedure was developed 
which consisted of a combination of protein precipitation with liquid extraction.  
Organic solvents, such as methanol and acetonitrile, are commonly used for deproteinization 
of plasma samples (Corcuera et al., 2011; De Baere et al., 2011). In our method, 750 µL of 
ACN was used for combined precipitation of plasma proteins and extraction of mycotoxins, 
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as it showed high extraction recoveries (RE, %) for all compounds (ranging from ± 82 to 94 
%), as can be seen in Table 2. Acetonitrile gave more clear supernatants after centrifugation 
compared to methanol, indicating improved deproteinization efficiency. Deproteinization 
with ACN has also been successfully applied for extracting other mycotoxins from plasma (De 
Baere et al., 2012; Devreese et al., 2012a). In order to concentrate the samples as much as 
possible, the supernatants were evaporated under nitrogen and reconstituted in 200 µL 
acetonitrile/water (20/80, v/v). The addition of organic solvent to dissolve the residue is 
crucial due to the lipophilicity of the investigated toxins (Jestoi, 2008). 
Matrix effects (SSE, %) were evaluated and varied between 90 and 111 % for all compounds 
(Table 2). These results are excellent taking into account that a generic extraction procedure 
was used. They correlate well with other matrices such as wheat (Sulyok et al., 2006) and 
there is less ion suppression compared to egg samples (Frenich et al., 2011; Jestoi et al., 
2009). Hence, it can be stated that a generic extraction procedure was developed for the 
simultaneous extraction of several emerging Fusarium mycotoxins from animal plasma. The 
extraction procedure was straightforward, cheap and combined a high extraction recovery 
with limited matrix effects on the LC-MS/MS instrument. 
3.1.2. Optimization of LC-MS/MS conditions 
The Hypersil Gold column was used as good results were obtained with respect to 
separation of analytes by HPLC within a short analysis time, i.e. <15 min, comparable to 
other chromatographic methods used for separation of these compounds (De Baere et al., 
2012; Frenich et al., 2011; Jestoi et al., 2009).  
For the detection of ENNs, the mobile phases reported in the literature consist generally of a 
combination of water and an organic solvent (methanol or acetonitrile) (Jestoi, 2008). To 
facilitate the ionization process in mass spectrometry, often volatile acids are added (formic 
acid, acetic acid) (Jestoi, 2008). In our experiments the best sensitivity and separation for all 
investigated compounds was achieved using 0.1 % acetic acid in water (A) and ACN (B) as 
mobile phase (Supplementary Material Figure 2S). For other mycotoxins, including DON, 
ZON, T-2, OTA, FB1 and AFB1, methanol seems to be a more suitable organic solvent for the 
separation of those compounds (Jestoi et al., 2005). 
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The MS instrument was operated in the positive ion electrospray mode (ESI +) as this was 
the most sensitive mode, confirmed by previous studies (Jestoi et al., 2007; Logrieco et al., 
1993; Meca et al., 2012). Using ESI, adducts are often formed, i.e. with NH4
+
, Na
+
, K
+
 and Ca
2+
 
(Jestoi et al., 2005). This is however dependent on type of mobile phases and MS 
parameters. Uhlig and Ivanova (2004) showed that a higher capillary temperature favors 
protonation ([M+H]
+
) instead of [M+NH4]
+
 adduct formation for ENNs and BEA. Despite 
adduct formation, the majority of the molecules are protonated and consequently used for 
detection and quantification by several other authors (Jestoi et al., 2007; Jestoi et al., 2009; 
Uhlig and Ivanova, 2004). In our experiments sodium adduct formation was also present, but 
[M+H]
+
 ions gave the most intense signal except for ENN A where the [M+Na]
+
 ion was 
monitored, as did Frenich et al. (2011). The full scan MS spectra of precursor and product 
ions are shown in Figure 1 and 2, respectively. 
Acquisition was performed in the SRM mode, which means that for each analyte the two 
most intense precursor ion > product ion transitions were monitored. The two most intense 
product ions were generated both with an automated procedure and manually by 
comparing the signal intensity with applying increased collision energy. The same product 
ions were retrieved by both methods and comparable collision energies were found. The 
product ion with the highest  intensity was selected as quantifier, while the other ion was 
used as qualifier. In Table 1 the MS/MS conditions for all target analytes are shown.  
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Figure 2. Full mass spectrum (100-400 m/z) of the product ions of beauvericin (BEA), enniatin (ENN) A, A1, B and B1 
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3.1.3. Internal standard 
Other authors (Frenich et al., 2011; Jestoi et al., 2009; Jestoi et al., 2007) describing methods 
for quantification of ENNs and BEA in biological matrices did not use an internal standard 
(IS). However, it is preferable to use an IS, because this leads to maximal compensation for 
losses during extraction, signal suppression/enhancement effects during LC-MS/MS analysis, 
and general analysis errors (Songsermsakul and Razzazi-Fazeli, 2008). Isotopically labeled IS 
are seen as the ideal IS, because of their similar physico-chemical properties as the target 
compound (Spanjer et al., 2008). However, these IS are very costly or not commercially 
available for ENNs nor BEA, in contrast to other mycotoxins (Devreese et al., 2012a). Then 
compounds having similar physicochemical properties are often used as IS. Ionophoric 
coccidiostats are closely related to ENNs and BEA, especially based on their chemical 
structure and properties (Jestoi et al., 2007), therefore they can be used as an IS (Van Pamel 
et al., 2011). In our study maduramicin was used since it showed improved fragmentation 
patterns compared to others such as valinomycin. 
However, it has to be considered that coccidiostats are frequently used as feed additives in a 
practical situation for animal production. Therefore, it must be verified before the start of 
the analysis that MAD is not present in the animal feed, e.g. by analyzing the feed or an 
animal plasma sample without the addition of the IS (MAD). Otherwise contamination of 
plasma samples with MAD can occur, which should be avoided when performing 
toxicokinetical studies or assessing exposure. 
3.2. Method validation 
The following parameters were evaluated for each mycotoxin: linearity, within- and 
between-run precision and accuracy, LOQ, LOD and specificity. The results are shown in 
Table 3.  
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Matrix-matched calibration graphs were linear over the working concentration range for all 
tested mycotoxins, with r values between 0.9980 and 0.9995 and g values between 5.2 and 
11.3 %. For all compounds except ENN A, the best fitting graphs were linear and 1/x 
weighted. For ENN A, the best fitting was obtained by applying quadratic, 1/x weighted 
regression since a small deviation from linearity was observed for concentrations above 50 
Table 3. Results of the within-run and between-run precision and accuracy evaluation for the analysis of 
emerging Fusarium mycotoxins  in pig plasma determined by a multi-mycotoxin LC-MS/MS method 
     
Analyt 
Theoretical concentration 
(ng/mL) 
Mean concentration ± SD 
(ng/mL) 
Precision, RSD (%) Accuracy (%) 
BEA 0.2
 a
 0.2 ± 0.01 6.9 1.1 
 1
 a
 1.0 ± 0.13 12.1 4.4 
 1
 b
 1.0 ± 0.11 11.0 0.6 
 10
 a
 10.5 ± 0.29 2.8 4.7 
 10
 b
 10.0 ± 1.38 13.8 0.1 
 100
 a
 100.4 ± 5.03 5.0 0.4 
 100
 b
 105.5 ± 11.45 10.9 5.5 
ENN A 0.1
 a
 0.1 ± 0.01 10.8 7.6 
 1
 a
 1.0 ± 0.02 1.9 2.3 
 1
 b
 0.9 ± 0.11 12.0 -6.1 
 10
 a
 9.8 ± 0.20 2.1 9.3 
 10
 b
 9.0 ± 2.80 30.9 -9.5 
 100
 a
 103.3 ± 9.66 9.3 3.3 
 100
 b
 105.3 ± 14.4 13.7 5.3 
ENN A1 0.1
 a
 0.1 ± 0.01 10.0 13.1 
 1
 a
 1.0 ± 0.15 14.5 0.5 
 1
 b
 1.1 ± 0.10 9.4 8.9 
 10
 a
 10.8 ± 0.73 6.7 8.3 
 10
 b
 10.3 ± 0.44 4.2 2.7 
 100
 a
 109.5 ± 7.62 7.0 9.5 
 100
 b
 100.0 ± 7.49 7.5 0.0 
ENN B 0.2
 a
 0.2 ± 0.02 10.8 4.4 
 1
 a
 1.1 ± 0.07 6.7 6.9 
 1
 b
 1.0 ± 0.09 9.0 1.1 
 10
 a
 10.6 ± 0.74 7.0 5.7 
 10
 b
 10.5 ± 0.55 5.2 4.7 
 100
 a
 101.4 ± 1.69 1.7 1.4 
 100
 b
 102.9 ± 6.96 6.8 2.9 
ENN B1 0.2
 a
 0.2 ± 0.03 13.6 5.8 
 1
 a
 1.0 ± 0.04 3.4 4.7 
 1
 b
 1.1 ± 0.08 7.0 6.3 
 10
 a
 10.4 ± 0.59 5.7 3.5 
 10
 b
 10.2 ± 0.71 7.0 1.9 
 100
 a
 97.9 ± 4.12 4.2 -2.1 
 100
 b
 105.9 ± 7.83 7.4 5.9 
 
a 
Within-run accuracy and precision (n=6); 
b 
Between-run accuracy and precision (n=12); SD: standard deviation; RSD: 
relative standard deviation; Acceptance criteria: accuracy: < 1 ng/mL: -50% to +20%, 1-10 ng/mL: -30% to +10%, > 10 
ng/mL: -20% to +10%, within-run precision (RSDmax): 1 ng/mL: 30.2%, 10 ng/mL: 21.3% and 100 ng/mL: 15.1%, between-
run precision: 1 ng/mL: 45.3%, 10 ng/mL: 32.0% and 100 ng/mL: 22.6%. 
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ng/ml. As can be seen from Table 3, values for r (0.9995) and g (8.48 %) fell within the 
accepted ranges, indicating the reliability of the quadratic calibration model for quantitation 
of ENN A in real samples up to a concentration level of 200 ng/ml . 
 The within- and between-run accuracy and precision were tested at three different 
concentration levels and fell within the acceptability ranges. The limits of quantification 
(LOQ) were 0.1 ng/mL for ENN A and A1 and 0.2 ng/mL for ENN B, B1 and BEA. These limits 
are comparable (Jestoi et al., 2009; Jestoi et al., 2007) or ten-fold lower (Frenich et al., 2011) 
than other LC-MS/MS methods quantifying ENNs and BEA in other biological matrices. 
The limits of detection (LOD) were calculated taking into account a S/N ratio of 3 and were 
10 pg/mL, for BEA, or lower, for all other analytes. Several studies reported that plasma 
concentrations of mycotoxins in general fall within the lower ppb (ng/mL) range. After bolus 
administration of DON, ZON, OTA and AFB1 to pigs (all 0.05 mg/kg BW), mean plasma 
concentrations ranged between 0 and respectively 30.1, 2.1, 132.0 and 2.1 ng/mL (Devreese 
et al., 2012a). After feeding a DON contaminated diet (7.5 mg/kg feed) to broiler chickens for 
21 consecutive days, mean plasma levels were 3.87 ± 0.86 ng/mL at day 7, 2.66 ±2.02 ng/mL 
at day 14 and <LOQ (1.25 ng/mL) after 21 days (De Baere et al., 2011; Osselaere et al., 2012). 
In human plasma samples, OTA was detected at very low concentrations, 0.25 ± 0.03 ng/mL 
(Munoz et al., 2009). When developing a method for assessing mycotoxin exposure in 
animals by analyzing plasma, it is therefore a prerequisite to reach these low LOQ and LOD 
levels. Moreover, for toxicokinetic studies, dosing high mycotoxin concentrations to animals 
is no longer ethically acceptable as it compromises animal welfare. From the results shown 
in Table 3, it can be concluded that the developed method succeeded in quantifying the 
investigated ENNs in spiked matrix-matched samples at concentration levels which can be 
expected in real pig plasma samples after administration of one oral bolus of 0.05 mg/kg BW 
(range: 0.1/0.2 ng/ml – 200 ng/ml). For BEA, the results for accuracy and precision fell within 
the specified ranges for the analysis of matrix-matched samples that were spiked in the 
same concentration range (0.2 ng/ml to 200 ng/ml). However, taken into account the low 
oral bioavailability of BEA (see section 3.3), it is clear that a higher oral dosing (> 0.05 mg/kg 
BW) is needed to reach quantifiable plasma levels.  
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An analyzed blank sample did not demonstrate a possible interfering peak with a S/N ratio 
above the S/N ratio of the analyt(es) in the same elution zone at the LOD level, testifying the 
good specificity of the method. 
No carry-over was present, as there were no peaks detected in the same retention time zone 
of the compounds of interest, as can be seen in Figure 1S (Supplementary Material). 
3.3. Biological samples 
To demonstrate the applicability of the developed mycotoxin method, one piglet was 
administered an intra-gastric bolus of BEA, ENN A, A1, B and B1 (dose 0.05 mg/kg BW). 
Blood samples were drawn before and at different time points post-administration. One 
blood sample was drawn per time-point and analyzed once using the described method. In 
Figure 3, a LC-MS/MS chromatogram is demonstrated showing the SRM traces of the target 
analytes for the analysis of a pig plasma sample that was taken at 40 min after the oral 
administration of 0.05 mg/kg BW of the target analytes. Following analysis, a plasma 
concentration-time profile for ENN A, A1, B and B1 was set-up and shown in Figure 4. 
Interestingly, there is a big difference in oral absorption between the different ENNs 
although they have a similar chemical structure. ENN B seems to have the highest oral 
absorption, followed by ENN B1, A1, A and finally BEA. The maximal plasma concentrations 
(Cmax) for ENN B, B1, A1 and A were respectively 73.4, 35.2, 11.6 and 6.8 ng/mL. The time to 
maximal plasma concentration (Tmax) was 20 min after bolus administration for ENN B1, B 
and A1, whereas the Tmax for ENN A was 30 min post-administration. For BEA, no plasma 
concentration-time profile could be designed as the plasma concentration was above the 
LOQ level at only 2 time points, i.e. 0.51 ng/mL at 30 min and 0.82 ng/mL at 40 min post-
administration. The elimination rate of all ENNs is fast and comparable to DON (Devreese et 
al., 2012b; Knecht and Stork, 1974). With the dose tested, the applicability of the developed 
method for toxicokinetical analysis of ENNs has been demonstrated. As BEA has now 
demonstrated to have a lower oral bioavailability, higher dosing is needed to reach 
quantifiable plasma levels. These results should be taken into account when a 
comprehensive animal experiment would be conducted to determine the toxicokinetic 
parameters of these mycotoxins. 
Chapter III 
143 
 
 
Figure 3. LC-MS/MS chromatogram showing the SRM traces of the target analytes for the analysis of a pig 
plasma sample that was taken at 40 min after the oral administration of 0.05 mg/kg BW of the target analytes 
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Figure 4. Plasma concentration time profile of ENN A, A1, B and B1 after single oral bolus administration of the 
target analytes (dose 0.05 mg/kg BW) to a pig 
4. Conclusions 
This paper describes a sensitive and specific LC-MS/MS method for the analysis of several 
important Fusarium mycotoxins in pig plasma. All analytes were isolated from plasma by 
performing a generic, fast and low-cost sample preparation procedure. The extracted 
samples were analyzed using a multi-mycotoxin method which can be applied in the field of 
animal exposure assessment and toxicokinetic studies. The method was successfully 
validated and the applicability for toxicokinetical analysis of ENNs was shown by the analysis 
of incurred plasma samples that were taken from a pig which received an oral bolus of the 
investigated mycotoxins. 
In conclusion, this is - to our knowledge - the first paper describing the simultaneous 
detection and quantification of these emerging Fusarium mycotoxins in animal plasma. 
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7. Supplementary Material 
 
Figure 1. LC-MS/MS chromatogram showing the SRM traces of the target analytes for the analysis of a blank pig 
plasma sample  
 Figure 2. LC-MS/MS chromatogram showing the SRM traces of the target analytes for the analysis of (a pig 
plasma spiked with the analytes beauvericin (BEA), enniatin (ENN) A, A1, B, B1 and the internal standard 
maduramicin (MAD) at 10 ng/mL 
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Adapted from: Food Additives & Contaminants Part A (2012) 29, 1101-1107 
Abstract - In this study, three new models were developed for efficacy testing of mycotoxin 
detoxifiers in relation to recent European guidelines. In the first model, deoxynivalenol was 
given to broiler chickens as an intra-crop bolus together with a mycotoxin detoxifier in order 
to study the plasma concentration-time profile of deoxynivalenol. In the second model the 
same oral bolus was given, preceded by an oral bolus of mycotoxin detoxifier, to make sure 
the detoxifier was present in the whole intestinal tract when the mycotoxin was 
administered. In the third model, the mycotoxin detoxifier was mixed in the feed of broiler 
chickens, and after one week feeding, deoxynivalenol was given as an oral bolus. In order to 
evaluate the efficacy of these agents, plasma concentration-time profiles were set up and 
the main toxicokinetic parameters were compared. Two commercially available mycotoxin 
detoxifiers were tested, but they were not able to lower the oral availability of 
deoxynivalenol. As a positive control, activated carbon was used. We showed that activated 
carbon significantly reduced the absorption and oral availability of deoxynivalenol in all 
three models. Therefore, it can be concluded that these models are able to demonstrate the 
efficacy of mycotoxin detoxifiers in relation to EFSA guidelines. 
Keywords – mycotoxins – deoxynivalenol - efficacy testing - mycotoxin detoxifier – 
modeling - legal assessment 
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1. Introduction 
The contamination of feed with mycotoxins is a continuing feed safety issue leading to 
economic losses in animal production (Wu, 2007). Consequently, a variety of methods for 
the decontamination of feed have been developed, but mycotoxin detoxifying agents 
(mycotoxin detoxifiers) seem to be the most promising and are therefore most commonly 
used (Jard, et al., 2011, Kolosova and Stroka, 2011). These detoxifiers can be divided into 
two different classes, namely mycotoxin binders and mycotoxin modifiers. These two classes 
have different modes of action; mycotoxin binders adsorb the toxin in the gut, resulting in 
the excretion of toxin-binder complexes in the faeces, whereas mycotoxin modifiers 
transform the toxin into non-toxic metabolites (EFSA, 2009). The extensive use of these 
additives has led, in 2009, to the establishment of a new group of feed additives: ‘substances 
for reduction of the contamination of feed by mycotoxins: substances that can suppress or 
reduce the absorption, promote the excretion of mycotoxins or modify their mode of action’ 
(European Commission, 2009). Evidently, the efficacy of these products for their 
adsorbing or degrading ability should be tested. Many in vitro methods have been developed 
ranging from single-concentration studies to classical isotherm studies (binder concentration 
fixed, toxin concentration increasing) and beyond, to more complex set-ups such as gastro-
intestinal tract models (EFSA, 2009). Nevertheless, in recent guidelines the European Food 
Safety Authority (EFSA) has stated that in vitro tests do not fully prove the efficacy of 
mycotoxin detoxifiers (EFSA, 2010) and that in vivo trials should be performed. Although 
these in vivo trials can report non-specific parameters such as organ weight, performance 
parameters (e.g. growth rate, feed conversion rate) and blood serum parameters (e.g. total 
protein, albumin, key enzymes), they are not sufficient as proof of efficacy of mycotoxin 
detoxifiers. In addition, specific parameters should be measured based on toxicokinetic 
studies including the bioavailability and absorption/excretion of the toxin. For each 
mycotoxin the EFSA has proposed specific end-points. For deoxynivalenol (DON), the most 
relevant end-point is measuring DON and its major metabolite (deepoxy-deoxynivalenol or 
DOM-1) in plasma.   
In their guidelines, the EFSA proposes feeding trials in which the mycotoxin and detoxifier 
are mixed in the feed (steady-state design). In these experimental set-ups the pre-sampling 
period should not be shorter than seven days, and the blood samples should be collected 
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over a five-day period during feeding (EFSA, 2010). However, these trials are labor intensive 
and quite complicated to perform. Moreover, in a three week feeding trial with broiler 
chickens where the maximum allowed level of 5 mg DON/kg feed (European Commission, 
2006) was added to the feed, no plasma concentrations of DON and DOM-1 could be 
measured when sampled on a weekly basis (Osselaere, et al., 2012). This indicates that a 
model where DON and detoxifier are mixed in the feed, is not an appropriate way to prove 
the efficacy of mycotoxin detoxifiers for DON in broiler chickens using EFSA endpoints. 
Therefore, we propose oral bolus models which are easy to perform, have a straightforward 
design and can easily be adopted by the feed additive producing industry. All three proposed 
models in our study are in relation to the EFSA guidelines, stating that specific parameters 
should be evaluated, based on in vivo toxicokinetic or ADME studies (absorption, 
distribution, metabolisation and excretion) (EFSA, 2010).  
To the author’s knowledge, no studies have been published yet according to these recent 
EFSA guidelines. Broiler chickens were chosen as they are convenient to handle and blood 
collections can be easily performed. Moreover, poultry meat represents one-third of all 
meat produced globally, indicating the major importance of the broiler chicken industry 
(Scanes, 2007). As mycotoxin, deoxynivalenol was used as it is the most common mycotoxin 
found in European feed commodities. In a recent study it was found that 78% of European 
feed samples were contaminated with DON (Monbaliu, et al., 2010). Deoxynivalenol is 
produced by several fungi of the Fusarium genus and it impairs the protein synthesis by 
binding to the 60S ribosomal unit and therefore interferes with the activity of 
peptidyltransferase. Trichothecenes can also cause the ‘ribotoxic stress syndrome’ by 
activating mitogen-activated protein kinases (MAPKs) (Pestka, 2007). Poultry seem to be 
relatively resistant to DON compared to other species, especially pigs. Nevertheless, low to 
moderate levels of this toxin can cause several effects, which influence immunological and 
performance parameters (Awad, et al., 2006). 
In our models, we tested two commercially available mycotoxin detoxifiers on their ability to 
lower the oral bioavailability of DON. The first product is a mycotoxin binder, composed of 
esterified glucomannan (GMA) derived from the cell wall of Saccharomyces cerevisiae 
yeasts. Unspecific in vivo trials have shown the ability of the GMA product to counteract the 
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negative effects of DON on performance parameters and blood biochemical parameters in 
broiler chickens and pigs (Aravind, et al., 2003, Faixova, et al., 2006, Swamy, et al., 2004). 
The second product is a combination of mycotoxin binder and modifier. The bentonite 
fraction (binder) has a high affinity towards aflatoxins, but not towards DON (Avantaggiato, 
et al., 2005) as aflatoxins are hydrophilic planar structures with a high affinity for planar 
surfaces. In contrast, DON is a non-ionisable molecule with a more polar structure and a 
bulky epoxy group and therefore not easily bound by mycotoxin binders (EFSA, 2009). 
Nevertheless, this product also contains a yeast, claimed to be able to open the C-12,13 
epoxide ring, converting DON into a non-toxic metabolite DOM-1 (Awad, et al., 2010, Diaz, et 
al., 2005). This mycotoxin detoxifier showed potential in diminishing the deleterious effects 
of DON on growth performance and other non-specific parameters in pigs (Plank, et al., 
2009). However, Dänicke et al. (2003) could not show benefits of this detoxifier on 
performance and blood chemical parameters in poultry. As positive control, activated carbon 
was used as it proved to adsorb various compounds, including mycotoxins such as DON 
(Avantaggiato, et al., 2004, Cavret, et al., 2010). 
2. Materials and methods 
2.1. Animals and housing conditions 
For each bolus model, thirty-two twenty-one-day-old healthy broiler chickens (Ross 308, 
Poeke, Belgium) were randomly allotted in 4 groups of eight chickens, males and females 
equally divided. The animals were housed in pens of 4 m
2
/pen (8 animals/pen), one week 
before the start of the experiment to adapt to the environment. Blank feed was given ad 
libitum during the trial. The light schedule was 20 h light, 4 h darkness. The temperature was 
kept between 18 and 25°C. The relative humidity was between 40 and 80%. The bedding of 
the pens consisted of wood shavings, allowing the animals to perform their natural dust 
bathing and foraging behaviour. 
This experiment was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine (Ghent University, case number EC 2011_14). 
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2.2. Feed 
Commercially available broiler feed (Bromix Plus®) was obtained from Versele-Laga (Deinze, 
Belgium). This feed was analyzed for the presence of mycotoxins by a validated multi-
mycotoxin liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (Fytolab, 
Zwijnaarde, Belgium). The analyzed mycotoxins were aflatoxin B1, B2, G1 and G2, 
cytochalasin E, deoxynivalenol, 3-acetyl-deoxynivalenol, nivalenol, fumonisin B1 and B2, T-2 
and HT-2 toxin, ochratoxin A, zearalenone, α- and β-zearalenol. The concentrations of the 
mycotoxins were all below the limit of detection (LOD), which was 100 µg/kg for DON, 3-
acetyl-DON and nivalenol and between 0.5 and 50 µg/kg for the other mycotoxins. The 
animals received this blank feed during the complete trial. 
2.3. Mycotoxins and detoxifiers 
Deoxynivalenol used for the animal experiments was purchased as a powder from 
Fermentek (Jerusalem, Israel). The administered dose of 0.750 mg DON/kg BW was 
calculated based on the maximally allowed concentration in poultry feed, i.e. 5 mg/kg 
(European Commission, 2006), and the daily feed intake, i.e. 150 g/kg BW. The mycotoxin 
was dissolved in ethanol pro analysis and water of HPLC quality (1:8, v/v), in order to obtain 
a stock solution of 1 mg/mL, which was used for dosing the broiler chickens. 
The standards of DON and DOM-1, used for the analytical experiments, were purchased 
from Sigma-Aldrich (Bornem, Belgium) and were dissolved in acetonitrile (ACN) to obtain 
stock solutions of 1 mg/mL. Working solutions were used to prepare matrix-matched 
calibrators and quality control samples in plasma. These working solutions were prepared by 
mixing appropriate volumes of the stock solution with ACN and water (1:1, v/v), both of 
HPLC quality. The internal standard (
13
C15-DON, 25 µg/mL ACN) was obtained from Biopure 
(Tulln, Austria). 
Two commercially available mycotoxin detoxifiers were used. The first product was a 
mycotoxin binder, composed of glucomannan derived from the cell wall of Saccharomyces 
cerevisiae yeasts. The second product was a combination of a mycotoxin binder (i.e. 
bentonite) and a modifier (a yeast). The mycotoxin detoxifiers were administered at a dose 
of 1 g/kg BW for the intra-crop bolus. The negative control group was given blank feed (1 
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g/kg BW) instead of a detoxifier. Both detoxifier and blank feed were suspended in 5 mL of 
water in a syringe immediately before administration into the crop, and flushed afterwards 
with 1 mL of water. This administration was performed using the tubing of a catheter (14G, 
2”, Vasofix® Braunüle®) (Braun, Melsungen, Germany).  The positive control group received 
activated carbon (AC) (1 g/kg BW) (NORIT Carbomix®, KELA Pharma, Sint-Niklaas, Belgium) 
suspended in water, also by means of an intra-crop bolus. 
2.4. Study design 
2.4.1. Bolus model 1 
The animals were divided into four groups of eight animals. Each group received a different 
treatment. The animals in the Detoxifier 1, Detoxifier 2, Negative Control and Positive 
Control group received a bolus of DON and mycotoxin detoxifier 1, DON and mycotoxin 
detoxifier 2, DON and blank feed and DON and AC, respectively. Feed was withheld for 12 h 
before the bolus administration, until 4 h post-administration. 
Following the administration, blood samples were taken from the leg vein at different time 
points, at 0 (just before bolus administration), 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h 
post-administration. The samples were centrifugated (2851 x g, 10 min, 4°C), and plasma 
was stored at ≤ -15°C until further analysis. 
2.4.2. Bolus model 2 
The experiment was similar to experiment 1, except that the mycotoxin detoxifier was now 
not only given at the same time of the DON bolus, but also 1 and 2 hours before the DON 
administration as an intra-crop bolus (‘preload’ of the animals with the detoxifier). 
2.4.3. Bolus model 3 
In this experiment the mycotoxin detoxifiers were mixed in the blank feed at a dose of 2 
kg/ton feed, as recommended by the manufacturers. This feed was given from the start of 
the experiment onwards, i.e. one week before the bolus administration, until the last blood 
sampling point (8 h post-bolus administration). In this experiment there was no special feed 
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deprivation period. 
 
Table 1. Schematic representation of the different bolus model designs 
Bolus model 1 
Acclimatization period 
Diet: blank feed 
Feed 
deprivation 
 
Oral administration 
detoxifier/blank 
feed + DON 
Blood 
sampling 
Bolus model 2 
Acclimatization period 
Diet: blank feed 
Feed 
deprivation 
Oral 
administration 
detoxifier/blank 
feed 
Oral administration 
detoxifier/blank 
feed + DON 
Blood 
sampling 
Bolus model 3 
Acclimatization period 
Diet: blank feed + detoxifier 
No 
deprivation 
 
Oral administration 
detoxifier/blank 
feed + DON 
Blood 
sampling 
       
Time line -8 d to -1 d -12 h -2 h 0 h 0 h to +8 h 
2.5. Plasma analysis 
The plasma concentrations of DON and DOM-1 were determined by LC-MS/MS, based on a 
validated method with modifications in the sample preparation and chromatography set-up 
(De Baere, et al., 2011). Briefly, 250 µl of plasma was spiked with 12.5 µL working solution (1 
µg/mL) of internal standard (IS) (
13
C15-DON). This was followed by adding 750 µL of ACN. 
Next, the samples were vortexed (15 sec) and centrifugated (8517 x g, 10 min, 4°C). The 
supernatant was then evaporated using a gentle nitrogen stream (40 ± 5°C). The dry residue 
was reconstituted in 200 µL of a 95/5 (v/v) mixture of mobile phase A/B. The mobile phase A 
consisted of 0.1 % glacial acetic acid in water of UHPLC quality. Mobile phase B consisted of 
methanol of UHPLC quality. After vortex mixing and filtering through a Millex® filter (0.22 
µm), the sample was transferred to an autosampler vial, and an aliquot (10 µL) was injected 
onto the LC-MS/MS instrument. 
The LC system consisted of a quaternary, low-pressure mixing pump with vacuum degassing, 
type Surveyor MS pump Plus and an autosampler, type Autosampler Plus, from Thermo 
Fisher Scientific (Breda, The Netherlands). Chromatographic separation was achieved on a 
Hypersil-Gold column (50 mm x 2.1 mm i.d., dp: 1.9 µm) in combination with a guard column 
of the same type, both from Thermo Fisher Scientific (Louvain-la-Neuve, Belgium). A 
gradient elution was performed: 0-1 min (95% A/5% B), 4 min (linear gradient to 80% B), 4-
5.1 min (20% A/80% B), 5.6 min (linear gradient to 95% A), 5.6-8 min (95% A/5% B). The flow 
rate was 300 µL/min. The LC column effluent was interfaced to a TSQ® Quantum Ultra triple 
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quadrupole mass spectrometer, equipped with a heated electrospray ionization (h-ESI) 
probe (Thermo Fisher Scientific), operating in the negative ionization mode. Following 
selected reaction monitoring (SRM) transitions were monitored used for identification and 
quantification: for DON m/z 355.1 > 265.1* and 355.1 >295.1, for DOM-1 m/z 339.1 > 59.1 
and 339.1 > 249.1* and for 
13
C15-DON m/z 370.1 > 279.1* and 370.1 > 310.1. The asterix (*) 
indicates the ion used for quantification. The limit of quantification (LOQ) of DON and DOM-
1 was 1 ng/mL and the limit of detection (LOD) of DON 0.1 ng/mL and 0.19 ng/mL of DOM-1. 
2.6. Toxicokinetic and statistical analysis 
The following toxicokinetic parameters were calculated (WinNonlin 6.2.0, Phoenix, Pharsight 
corp., USA) using non-compartmental analysis: area under the plasma concentration-time 
curve from time 0 to infinite (AUC0-inf), maximal plasma concentration (Cmax), time to 
maximal plasma concentration (Tmax), elimination half-life (T1/2el), elimination rate constant 
(kel) and relative oral bioavailability (relative OBB). This relative OBB was calculated 
according to the formula: relative OBB =
	 ()
	  ()
 x 100. Using non-
compartmental analysis, a better estimate of Cmax could be made, which is of great 
importance for the interpretation of the data. The absorption rate constant (ka) and the 
absorption half-life (T1/2a) were calculated using one-compartmental analysis. The statistical 
analysis was performed with SPSS via one-way ANOVA (SPSS 19.0, IBM, USA). The 
significance level was set at 0.05. 
3. Results 
The plasma concentration-time profiles of DON after bolus administration with or 
without detoxifier (model 1), after bolus administration preceded by preload with 
blank feed or a detoxifier (model 2) and after a bolus administration of DON preceded 
by one week feeding of blank feed with or without mycotoxin detoxifier added, are 
shown in Figure 1. The main toxicokinetic parameters are summarized in Table 2. 
Plasma concentrations of the main metabolite of DON, DOM-1, were not detected. 
Moreover, the concentration of DON in all samples of the positive control group 
(DON+AC) were below LOQ and therefore, no toxicokinetic parameters could be 
calculated for this group.  
Chapter IV 
160 
 
 
  
Table 2. Main toxicokinetic parameters of DON after administration of DON and blank feed (negative control) or DON and a detoxifier (detoxifier 1 or 2) in broiler chickens (n=8), using 
model 1, 2 and 3. Results are given as mean values ± SD 
 
 Model 1 Model 2 Model 3 
Toxicokinetic 
parameter 
Negative 
control 
Detoxifier 1 Detoxifier 2 
Negative 
control 
Detoxifier 1 Detoxifier 2 
Negative 
control 
Detoxifier 1 Detoxifier 2 
AUC 0-inf 
(ng.h/mL) 
10.22 ± 3.15 24.71 ± 10.75* 15.60 ± 5.91 14.86 ± 2.66 20.23 ± 5.20 19.42 ± 3.50 12.13 ± 4.99 10.58 ± 1.68 12.02 ± 5.77 
Cmax (ng/mL) 8.22 ± 2.69 23.74 ± 12.00* 15.21 ± 6.11 14.13 ± 2.25 19.26 ± 7.25 22.56 ± 10.43 12.22 ± 7.42 9.83 ± 4.06 9.68 ± 6.28 
Tmax (h) 0.66 ± 0.16 0.59 ± 0.28 0.47 ± 0.22 0.50 ± 0.25 0.50 ± 0.19 0.38 ± 0.16 0.57 ± 0.22 0.53 ± 0.35 0.69 ± 0.27 
ka (h
-1
) 1.76 ± 0.29 10.48 ± 10.40* 3.90 ± 2.27* 17.20 ± 19.50 11.14 ± 10.76 24.66 ± 22.37 13.19 ± 5.98 8.72 ± 4.05 10.04 ± 3.52 
T1/2a (h) 0.41 ± 0.07 0.22 ± 0.18* 0.26 ± 0.13* 0.20 ± 0.16 0.22 ± 0.15 0.18 ± 0.16 0.29 ± 0.19 0.27 ± 0.21 0.32 ± 0.15 
kel (h
-1
) 1.29 ± 0.48 1.70 ± 0.45 1.47 ± 0.45 0.95 ± 0.48 1.04 ± 0.30 0.95 ± 0.13 1.24 ± 0.25 1.02 ± 0.28 1.01 ± 0.29 
T1/2el (h) 0.70 ± 0.27 0.44 ± 0.11 0.57 ± 0.21 0.73 ± 0.37 0.80 ± 0.29 0.75 ± 0.11 0.59 ± 0.13 0.82 ± 0.31 0.86 ± 0.38 
Relative OBB 
(%) 
 256 ± 109* 153 ± 58  136 ± 35 131 ± 24  87 ± 14 99 ± 47 
AUC 0-inf  = area under the plasma concentration-time curve from time 0 to infinite; Cmax = maximal plasma concentration; Tmax = time to maximal plasma concentration; ka = absorption rate constant; T1/2a = 
absorption half-life; kel = elimination rate constant; T1/2el = elimination half-life; OBB = oral bioavailability; the asterix (*) indicates a significant difference (p<0.05) compared to the negative control group 
 Figure 1. Plasma concentration-time profile of DON after administration of DON and blank feed (negative control) or DON and a 
broiler chickens (n=8), using model 1, 2 and 3. Results are presented as mean values + SD. 
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4. Discussion 
Up till now, no straightforward models for in vivo efficacy testing of mycotoxin detoxifiers, in 
relation to the recent EFSA guidelines, have been reported.  No studies have been published 
on the ability of mycotoxin detoxifiers to lower the oral bioavailability of mycotoxins in 
poultry. Dänicke et al. (2001) studied the excretion kinetics of zearalenone (ZON) in broiler 
chickens and the efficacy of a mycotoxin detoxifier to alter the excretion of ZON. No 
difference in toxicokinetic parameters were found after bolus administration of ZON with or 
without the mycotoxin detoxifier. The enterohepatic recirculation of ZON and the rapid 
passage of the detoxifier through the intestinal tract was put forward as a possible 
explanation. 
Previous studies (Döll, et al., 2004, Sabater-Vilar, et al., 2007) have evaluated the in vitro 
binding or biotransforming ability of different mycotoxin detoxifiers, including those used in 
this study. In those screening studies, none of the tested products were able to effectively 
bind DON, except for activated carbon. These in vitro findings correlate with our findings, 
where no significant differences in toxicokinetic parameters were found between the 
detoxifier groups and the negative control group, except in the first bolus model. 
Surprisingly, a significant higher AUC0-inf, relative oral bioavailability, Cmax and ka and a 
shorter T1/2a were found in the detoxifying group 1 compared with the negative control 
group. However, this relates with the study by Goossens et al. (2012) in which the 
interaction between a yeast derived mycotoxin detoxifier and the antibiotic doxycycline was 
investigated in pigs. It was found that the detoxifier, in combination with T-2 toxin, 
enhanced the oral absorption of the drug. A recent study showed a significant influence of a 
mycotoxin detoxifier on the oral absorption of oxytetracycline in broiler chickens (Osselaere, 
et al., 2012). Again, an increased oral bioavailability in the detoxifier group was observed. 
The mechanisms of this interaction still have to be elucidated and are currently being 
investigated. Most probably, these effects are not related to a direct interaction between 
drug and detoxifier. Possible indirect effects such as promotion of intestinal health, altered 
intestinal immunological parameters, influence on intestinal mucus production, etc. can be 
put forward. 
In the present study, activated carbon was used as a positive control. This product is a basic 
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universal antidote which adsorbs various compounds, including mycotoxins such as DON 
(Avantaggiato, et al., 2004, Cavret, et al., 2010). However, the commercial use of AC in 
practice should be avoided in order to minimize the risk of a diminished nutrient absorption 
as well as the impairment of nutritional value (Avantaggiato, et al., 2004, Ramos, et al., 
1996). In all of the three bolus models, the plasma concentration of DON was below LOQ, 
indicating the efficient adsorption of DON by AC in the intestinal tract. Therefore, we can 
conclude that the 3 models developed in this study are able to demonstrate the (in)efficacy 
of mycotoxin detoxifiers. Further research should be performed on testing these models 
with other mycotoxins and detoxifiers.  
5. Conclusions 
It can be stated that three suitable in vivo models for efficacy testing of mycotoxin 
detoxifiers were developed. The reliability of the models was demonstrated using activated 
carbon. The two mycotoxin detoxifiers used in this study were not able to lower the oral 
bioavailability of DON.  
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Abstract - In this study, the interaction between bentonite and tylosin was investigated in 
broiler chickens, based on pharmacokinetic characteristics obtained in vivo. Also a gluco-
mannan binder was evaluated for possible interactions with tylosin absorption. 
Simultaneous oral administration of bentonite and tylosin significantly lowered plasma levels 
of tylosin and reduced the area under plasma concentration-time curve (AUC0-inf), maximal 
plasma concentration (Cmax), time to maximal plasma concentration (Tmax) and relative oral 
bioavailability (OBB). These results prove unambiguously the binding of tylosin by bentonite. 
Simultaneous administration of tylosin, in the drinking water or feed, and bentonite, mixed 
in the feed as a mycotoxin binder, should therefore be avoided. No interaction with gluco-
mannan was demonstrated, therefore tylosin and this binder can be safely co-administered 
in animal feed. 
 
Keywords - Veterinary drugs - Tylosin - Mycotoxin binders – Pharmacokinetics - Safety 
testing - LC-MS/MS 
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Mycotoxin binders are commonly used in the feed additive industry to prevent 
mycotoxicosis in farm animals (Kolosova and Stroka, 2011). These products are deemed to 
adsorb mycotoxins in the gut and consequently prevent mycotoxin absorption. Recently, the 
European Food Safety Authority (EFSA, 2010) stated that too little is known about the 
interaction between mycotoxin binders and veterinary drugs. Therefore more studies are 
needed to investigate possible interactions at the level of intestinal absorption. 
Some suggestions have been made about a possible interaction between macrolide 
antibiotics and bentonite clay (EFSA, 2011), however no specific proof has been put forward 
yet. The Canadian Bureau of Veterinary Drugs (1992) reported a case of lack of efficiency of 
tylosin when fed concurrently with bentonite to bovines. Shryock et al. (1994) reported that 
tilmicosin added to the diet in broiler chickens prevented development of airsacculitis after 
inoculation with Mycoplasma gallisepticum, whereas a combined use of tilmicosin and 
bentonite did not prevent air-sac lesions or clinical symptoms, indicating a possible negative 
interaction between both. Therefore, the goal of this study was to investigate the capacity of 
bentonite to bind tylosin, based on specific pharmacokinetic characteristics instead of 
clinical symptoms which can be biased. A commercially available glucomannan (GMA) 
mycotoxin binder was also included in the study. 
Bentonite clays are inorganic mycotoxin binders, generally impure clays consisting mostly of 
montmorillonite, a layered silicate (Al2O3 • 4SiO2 • H2O). They exhibit a high affinity towards 
aflatoxins but not towards other mycotoxins (Phillips et al., 1988). Besides their aflatoxin 
binding potency, the inclusion of 2% bentonite in broiler feed improves weight gain, feed 
efficiency and feed intake (Ali et al., 1996; Katouli et al., 2010). Tylosin (Figure 1) is a 
macrolide antibiotic produced by fermentation of Streptomyces strains. It consists of a 
substituted 16-membered lactone, an amino sugar (mycaminose) and two neutral sugars, 
mycinose and mycarose. Tylosin is used extensively as a therapeutic substance in the 
treatment of mycoplasmosis in poultry and livestock (Ashenafi et al., 2011). 
 Figure 1. Chemical structure of tylosin
Twenty-four 3-week-old broiler chickens (Ross 308) were randomly allocated in two groups. 
After a one-week acclimatization period, the animals were famished for 12 h. This was 
followed by an oral intra-crop bolus. One group received a bolus of tylosin (24 mg/kg BW, 
Tylan Soluble, Elanco Animal Health). 
mg/kg BW) and bentonite (Toxisorb Classic, Süd
USA) (both 100 mg/kg BW). The dose of tylosin administered was according to the l
The dose of the mycotoxin binders
g/kg BW) and the dose recommended
taken from the leg vein just before (0 h) and at different time points 0.5
10 and 12 h after bolus administration. The samples were centrifugated (2851
4°C), and plasma was stored at 
approved by the Ethical Committee of the Faculty of 
(case number EC 2011_014). The sample preparation for tylosin analysis in plasma was 
performed as follows: samples (250 µL) were spiked with 25 µL of a working solution of the 
internal standard (gamithromycin, 1 µg/mL 
250 µL of acetonitrile (ACN) were added, samples were vortexed (15 s) and centrifugated 
(8517 x g, 10 min, 4°C). The supernatant was passed through a Millex GV
µm) and transferred into an autosampler vial. An aliquot (5 µL) was injected onto the LC
MS/MS instrument. The LC system consisted of Surveyor 
type Autosampler Plus, both from 
achieved on a Hypersil-Gold column (50 mm x 2.1 mm i.d., dp: 1.9 µm) in combination with a 
 
 
The other two groups received a bolus of tylosin (24 
-Chemie) or GMA (Alltech 
 was based on the daily feed intake of the animals (100 
 by the manufacturer (1 kg/ton). Blood samples were 
, 1, 1.5, 2, 3, 4, 6, 8, 
≤ -15°C until further analysis. The animal experiment was 
Veterinary Medicine, Ghe
in water/acetonitrile, 50/50, v/v) (Merial). Next, 
MS pump Plus and an autosampler, 
Thermo Fisher Scientific. Chromatographic separation was 
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guard column of the same type, both from Thermo Fisher Scientific. The mobile phase A 
consisted of 10 mM ammonium acetate in water of UHPLC quality, acidified to pH 3.5 with 
glacial acetic acid. Mobile phase B was ACN of UHPLC quality. A gradient elution was 
performed at a flow rate of 300 µL/min: 0-0.5 min (80% A/20% B), 0.5-1 min (linear gradient 
to 90% B), 1-4.5 min (10% A/90% B), 4.5-5 min (linear gradient to 80% A), 5-8 min (80% 
A/20% B). The LC column effluent was interfaced to a TSQ Quantum Ultra triple quadrupole 
mass spectrometer, equipped with a heated electrospray ionization (h-ESI) probe (Thermo 
Fisher Scientific), operating in the positive ionization mode. Detection was performed in the 
selected reaction monitoring (SRM) mode and following transitions were monitored and 
used for identification and quantification (*): m/z 777.5 > 157.8 and 777.5 > 619.3* for 
respectively gamithromycin and m/z 916.5 > 173.8* and 916.5 > 772.4 for tylosin. The limit 
of quantification (LOQ) was 10 ng/mL and the limit of detection (LOD) 0.09 ng/mL. 
After LC-MS/MS analysis, plasma concentration-time profiles of tylosin were compared 
(Figure 2). It was shown that bentonite significantly lowered plasma concentrations of 
tylosin. This was confirmed with pharmacokinetic analysis, using non-compartmental 
modeling (WinNonlin 6.2.0, Phoenix, Pharsight) (Table 1). No significant interaction between 
tylosin and GMA could be demonstrated. Statistical analysis was performed via one-way 
ANOVA (SPSS 19.0, IBM). Following pharmacokinetic characteristics reflecting drug 
absorption were significantly altered by addition of bentonite to the oral bolus: area under 
the plasma concentration-time curve from time 0 to infinite (AUC0-inf), maximal plasma 
concentration (Cmax), time to maximal plasma concentration (Tmax) and relative oral 
bioavailability (relative OBB). This relative OBB was calculated according to the formula: 
relative OBB = AUC0-inf (Tylosin+Bentonite) / AUC0-inf (Tylosin) x 100. No significant effect on 
elimination parameters were found, including elimination rate constant (Kel) and elimination 
half-life (T1/2el). 
Chapter V 
172 
 
 
Figure 2. Plasma concentration-time profile of tylosin after a single oral bolus administration of tylosin (24 
mg/kg BW) with or without bentonite or glucomannan (GMA) (100 mg/kg BW) to broiler chickens. Values are 
presented as mean + SD (n=8) 
Table 1. Main pharmacokinetic parameters of tylosin after a single oral bolus administration of tylosin (24 
mg/kg BW) with or without bentonite or glucomannan (GMA) (100 mg/kg BW) to broiler chickens. Values are 
presented as mean ± SD (n=8) 
 Tylosin Tylosin + Bentonite Tylosin + GMA 
AUC0-inf (µg.h/mL) 17.06 ± 5.31 2.89 ± 1.14 ** 16.37 ± 4.14 
Cmax (µg/mL) 7.08 ± 3.64 1.66 ± 0.77 ** 5.84 ± 1.67 
Tmax (h) 3.00 ± 0.33 1.92 ± 0.42 * 2.92 ± 0.38 
kel (h
-1) 0.51 ± 0.08 0.59 ± 0.23 0.52 ± 0.14 
T1/2el (h) 1.42 ± 0.21 1.67 ± 0.99 1.49 ± 0.51 
relative OBB (%) 100.00 23.30 ± 7.22 *** 98.04 
AUC0-inf : area under plasma concentration-time profile from time 0 to infinite; Cmax: maximal plasma concentration; Tmax: 
time to maximal plasma concentration; Kel: elimination rate constant; T1/2el: elimination half-life; relative OBB: relative oral 
bioavailability; * p < 0.05, ** p < 0.01 and *** p < 0.001 
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These results confirm the suggestion made by other authors (Canadian Bureau of Veterinary 
Drugs, 1992; EFSA, 2011; Shryock et al., 1994) that bentonite is able to bind macrolide 
antibiotics. The mechanism behind is the replacement of mineral cations by organic cations 
such as tylosin. The combined use of tylosin and bentonite in animal husbandry should 
therefore be avoided, as this interaction can have serious consequences. Lowered plasma 
concentrations of antibiotics may implicate therapy failure and enhanced microbial 
resistance development. In contrast, tylosin can be safely co-administered with GMA in 
poultry feed as no interaction was observed using the developed in vivo model. 
Future research should be performed on the interaction with other veterinary drugs and 
different mycotoxin binders. This research should be based on specific pharmacokinetic 
parameters instead of unspecific clinical symptoms, as only pharmacokinetic parameters can 
really prove a decreased oral bioavailability of the drug, due to adsorption. 
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Abstract - An experiment was conducted to investigate the effects of feeding grains naturally 
contaminated with Fusarium mycotoxins and a yeast derived glucomannan mycotoxin 
adsorbent (GMA) on selected unspecific and specific parameters in turkey poults. Two 
hundred and forty 1-day-old male turkey poults were fed the experimental diets for twelve 
weeks. Experimental diets were formulated with control grains, control grains + 0.2% GMA, 
contaminated grains, or contaminated grains + 0.2% GMA. Deoxynivalenol (DON) was the 
major contaminant of the contaminated grains and its concentrations varied from 4.0 to 6.5 
mg/kg in the contaminated diets. Unspecific parameters measured included: performance 
parameters, plasma biochemistry profiles, morphometry and CD8
+
 T-lymphocyte counts in 
the duodenum. Plasma concentrations of DON and de-epoxydeoxynivalenol (DOM-1) were 
used as specific parameter. Performance parameters and plasma biochemistry were altered 
by DON and GMA but this was not consistent throughout the trial. Deoxynivalenol reduced 
the villus height and apparent villus surface area in the duodenum. This effect was 
prevented by GMA supplementation to the diets. Deoxynivalenol elevated the total CD8
+
 T-
lymphocyte count in the duodenum but this effect was not prevented by GMA. No 
significant differences in plasma concentrations of DON and DOM-1 between contaminated 
and contaminated + GMA groups were observed, suggesting that GMA did not prevent DON 
absorption.  
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1. Introduction 
Mycotoxins are secondary metabolites produced by toxigenic fungal species. They are of 
great interest because of their deleterious effects on animal health and performance, which 
consequently leads to economic losses in animal production (Wu, 2007). A variety of 
methods to prevent the adverse effects of mycotoxins have been developed. Utilizing 
mycotoxin detoxifying agents (mycotoxin detoxifiers) is the most commonly used 
preventative method (Jard et al., 2011; Kolosova and Stroka, 2011). These detoxifiers can be 
divided into two different classes, namely, mycotoxin binders and mycotoxin modifiers. 
Mycotoxin binders adsorb the toxin in the gut, resulting in the excretion of toxin-binder 
complex in faeces, whereas mycotoxin modifiers transform the toxin into non-toxic 
metabolites (Kolosova and Stroka, 2011). 
Mycotoxin detoxifiers should be tested for their mycotoxin binding or degrading ability in 
vitro as well as in vivo. In vitro models are a powerful tool to screen and select a large 
number of compounds. However, only in vivo trials can fully proof the efficacy of mycotoxin 
detoxifiers as mycotoxin adsorption or biotransformation in vivo is influenced by 
physiological variables and the composition of feed (Lemke et al., 2001). Up to day, 
mycotoxin detoxifiers are commonly evaluated in vivo by so-called unspecific parameters. 
Those include animal performance (e.g. growth rate, feed intake and feed conversion rate), 
plasma biochemistry (e.g. concentration of proteins, enzymes and minerals), effect on 
immune function and histological changes in different tissues. As the criteria are unspecific, 
differences obtained between treated and untreated animals cannot be solely attributed to 
the efficacy of the detoxifier. There may be some confounding effects such as immuno-
modulating activity of β-glucans and antioxidant action of other feed components. Due to 
the lack of specificity of these parameters, the European Food Safety Authority (EFSA) 
recently proposed other end-points based on specific toxicokinetic parameters (EFSA, 2010). 
As mycotoxin binders are deemed to adsorb mycotoxins in the gut, a lowered oral 
absorption is expected. According to the EFSA, the most relevant parameter to evaluate the 
efficacy of these products against mycotoxins is the plasma concentration of these toxins or 
their main metabolites (Devreese et al., 2012). 
The goal of the present study was: (1) to determine the effects of the Fusarium mycotoxins, 
mainly deoxynivalenol (DON), on specific and unspecific parameters in turkey poults, and (2) 
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to evaluate the efficacy of a yeast derived glucomannan mycotoxin binder (GMA). The 
selection of unspecific parameters for this trial was based on previous research (Girish and 
Smith, 2008; Girish et al., 2008; Girish et al., 2010; Yunus et al., 2012a; Yunus et al., 2012b). 
These included performance parameters, plasma biochemistry profile, morphometry and 
CD8
+
 cell population in the duodenum. Specific parameters, plasma concentrations of DON 
and its main metabolite de-epoxydeoxynivalenol (DOM-1), were selected as advised by  the 
EFSA (EFSA, 2010). 
2. Materials and methods 
2.1. Experimental birds and diets 
Two hundred and forty one-day-old male Hybrid turkey poults (Hybrid Turkeys, Kitchener, 
ON, Canada) were individually weighed and randomly distributed in 12 pens at the Arkell 
Poultry Research Station of the University of Guelph (Guelph, ON, Canada). Three pens were 
randomly assigned to each of the four different diets. The temperature and lighting 
programs were followed according to standard recommendations of the supplier. Birds were 
managed as has been prescribed by the Canadian Council on Animal Care with the Animal 
Utilization Protocols approved by the Animal Care Committee of the University of Guelph 
(CCAC, 2009). 
Four different corn-, wheat- and fish meal-based diets were formulated for each rearing 
phase including starter (0-3 w), grower (4-6 w), developer (7-9 w) and finisher (10-12 w). The 
diets met the standard nutritional specifications for turkey poults. The mycotoxin 
contaminated diets were formulated to the nutrient specifications of the control diets by 
replacing control corn with corn naturally contaminated with Fusarium mycotoxins. GMA-
supplemented diets contained 0.2% GMA (Mycosorb®, Alltech Inc., Lexington, KY, USA).  
2.2. Analysis of dietary mycotoxin concentrations 
Dietary concentrations of DON, 3-acetyl-DON (3-aDON), 15-acetyl-DON (15-aDON), nivalenol 
(NIV), fusarenan-X (FUS-X), neosolaniol (NEO), diacetoxyscirpenol (DAS), T-2 toxin (T-2) and 
HT-2 toxin (HT-2) were analyzed using gas chromatography-mass spectrometry (GC-MS) 
according to Raymond et al. (2003). The limits of detection (LODs) were 0.06, 0.05, 0.05, 
0.12, 0.11, 0.07, 0.06, 0.04 and 0.06 µg/g, respectively. Ochratoxin A (OTA) and zearalenone 
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(ZON) concentrations were analyzed by high performance liquid chromatography with 
ultraviolet detection (HPLC-UV) (Wang et al., 2008). The LODs were respectively 0.2 and 20 
ng/g. The sum of aflatoxin (AF) B1, B2, G1 and G2 concentrations and the sum of fumonisin 
B1 (FB1) and B2 (FB2) concentrations were analyzed by enzyme-linked immunosorbent assay 
(ELISA) and the LODs were 1.0 and 25.0 ng/g, respectively. 
2.3. Body weight, feed intake and feed conversion ratio 
Poults were individually weighed at placement and at the end of each growth phase. Feed 
consumption was measured for each pen at the end of each growth phase. Weight gain, 
feed intake, and feed conversion ratio (FCR) were calculated. Feed intake and FCR were 
adjusted for mortalities when necessary. 
2.4. Plasma and tissue collection 
At week 1 and the end of starter phase (week 3), 4 birds per pen (12 birds/diet) were 
euthanized by cervical dislocation. Blood was sampled from the jugular vein prior to 
euthanasia. Blood was centrifugated (2851 x g, 4°C, 10 min) and plasma was collected and 
frozen (≤ -15°C) until analysis. Proximal and intermediary sections of the duodenum 
descendens were collected and flushed with 0.9% saline for immunohistochemistry and 
histology, respectively. For immunohistochemistry, tissue samples were embedded in 
Optimum Cutting Temperature (OCT) compound (Tissue-Tek, Sakura Finetek, Torrance, CA, 
USA) and snap frozen in liquid nitrogen. Frozen tissue samples were sectioned at 5 µm 
thickness, placed on Superfrost® Excell® glass slides (Fisher Scientific, Ottawa, ON, Canada) 
and stored at -20°C until further staining. For histology, tissues were fixed in 10% neutral-
buffered formalin for 48 hr, then trimmed and processed for hematoxylin and eosin staining 
(Girish and Smith, 2008). 
At the end of the grower, developer and finisher phase, blood was collected from the wing 
vein (12 animals/diet) and plasma was separated as described above. 
2.5. Plasma biochemistry 
Plasma concentrations of Ca, P, total protein, albumin, globulin, albumin:globulin ratio, 
glucose, cholesterol, total bilirubin, γ-glutamyltransferase (GGT), aspartate aminotransferase 
(AST), creatine kinase (CK), amylase, lipase, uric acid, lactate dehydrogenase (LDH), bile acid 
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and glutamate dehydrogenase (GLDH) were determined by a Hitachi 911 Chemistry Analyzer 
(Roche Diagnostics, Montreal, QC, Canada). 
2.6. Quantification of DON, DOM-1 in plasma 
Detection and quantification of DON and DOM-1 in plasma was performed as described by 
Devreese et al. (2012). Briefly, 250 µL of plasma was spiked with 12.5 µL of a working 
solution (1 µg/mL) of internal standard (IS) (
13
C15-DON). This was followed by adding 750 µL 
of acetonitrile (ACN). Samples were vortexed (15 sec) and centrifugated (10 min, 2851 x g, 
4°C). The supernatant was then evaporated using a gentle nitrogen stream (40 ± 5°C). The 
dry residue was reconstituted in 200 µL of a 95/5 (v/v) mixture of mobile phase A/B. The 
mobile phase A consisted of 0.1% glacial acetic acid in water of ultra performance liquid 
chromatography (UHPLC) quality. Mobile phase B consisted of methanol of UHPLC quality. 
After vortex mixing and filtering through a Millex® PVDF-filter (0.22 µm), the sample was 
transferred to an autosampler vial, and an aliquot (10 µL) was injected onto the LC-MS/MS 
instrument. The LC system consisted of a quaternary, low pressure mixing pump with 
vacuum degassing (Surveyor MS pump Plus, Thermo Fisher Scientific, Breda, the 
Netherlands), and an autosampler (Autosampler Plus, Thermo Fisher Scientific). 
Chromatographic separation was achieved on a Hypersil-Gold column (50 mm x 2.1 mm i.d., 
dp: 1.9 mm) in combination with a guard column of the same type (Thermo Fisher Scientific, 
Louvain-la-Neuve, Belgium). A gradient elution was performed: 0–1 min (95% A/5% B), 4 min 
(linear gradient to 80% B), 4–5.1 min (20% A/80% B), 5.6 min (linear gradient to 95% A), 5.6–
8 min (95% A/5% B). The flow rate was 300 µL/min. The LC column effluent was interfaced to 
a TSQ® Quantum Ultra triple quadrupole mass spectrometer, equipped with a heated 
electrospray ionisation (h-ESI) probe (Thermo Fisher Scientific), operating in the negative 
ionisation mode. Following selected reaction monitoring (SRM) transitions were monitored 
and used for quantification: for DON m/z 355.1 > 265.1* and 355.1 >295.1, for DOM-1 m/z 
339.1 > 59.1 and 339.1 > 249.1* and for 
13
C15-DON m/z 370.1 > 279.1* and 370.1 > 310.1. 
The asterisk (*) indicates the ion used for quantification. The limit of quantification (LOQ) for 
DON and DOM-1 was 0.5 ng/mL and LODs for DON and DOM-1 were 0.09 ng/mL and 0.11 
ng/mL, respectively. 
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2.7. Immunohistochemistry analysis (CD8
+
 T-lymphocytes) 
Immunohistochemistry analysis was performed according to Girgis et al. (2010a) with some 
minor modifications. Tissue sections were fixed with ice-cold acetone for 10 min. 
Endogenous peroxidase activity was inhibited by incubating the tissues for 10 min with 3% 
H2O2 prepared in phosphate buffered saline (PBS) containing 0.3% normal goat serum. 
Blocking of nonspecific sites was done by incubating the tissues for 30 min with 5% normal 
goat serum in PBS. Sections were then incubated with anti-chicken CD8a (clone CT-8) 
primary antibodies (Southern Biotech, Birmingham, AL, USA) for 30 min, diluted 1:25 in 
blocking buffer. Biotinylated goat anti-mouse IgG (H + L) (Vector Laboratories, Burlingame, 
CA, USA) was used as the secondary antibody at a dilution of 1:250 in blocking buffer. 
Sections were incubated with the secondary antibody for 30 min. Avidin–biotin–peroxidase 
system (Vectastain® ABC kit, Vector Laboratories) was used for immunoperoxidase staining 
according to the manufacturer’s protocol. Enzyme-linked antibodies were then visualized by 
reaction with 3,3-diaminobenzidine–H2O2 solution (DAB substrate kit for peroxidase, Vector 
Laboratories). Tissue sections were counterstained with hematoxylin (Fisher Scientific),  and 
mounted with Cytoseal-60 (Richard-Allan-Scientific, Kalamazoo, MI, USA). 
Within each tissue section, 5 random fields were captured using a 5x objective lens of a 
computer-aided light microscope imager (Openlab®, Perkin Elmer, Waltham, MA, USA). 
Images were scanned using ImageScope® software (Aperio Technologies, Vista, CA, USA). 
The percentage of CD8
+
-stained area in mucosa and submucosa for each section was 
determined and the mean value was calculated for each bird. 
2.8. Morphometry analysis 
Morphometry of duodenal sections was done as described by Girgis et al. (2010b). Briefly, 
formalinized duodenal sections were trimmed, dehydrated, cleared, and paraffin embedded. 
Sections, 5 µm thick, were placed on glass slides and processed by hematoxylin and eosin 
stain. Morphometric measurements were performed on 20 axially sectioned well oriented 
villi selected from each segment, using a computer-aided light microscope image with 
Openlab® software (Perkin Elmer). Morphometric measurements included villus height (VH) 
from the tip of the villus to the crypt, crypt depth from the base of the villi to the 
submucosa, villus width (VW; average of VW at one-third and two-third of the villus) and 
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muscularis thickness from the submucosa to the serosa. Apparent villus surface area (AVSA) 
was calculated by the formula: (VW at one third + VW at two thirds of the height of the 
villus)/2 × villus height. 
2.9. Statistical analysis 
For performance, plasma biochemistry and DON/DOM-1 analysis, means were taken of each 
replicate (4 birds/replicate). These means (3 replicates/diet) were compared between 
groups using one-way ANOVA after determination of normality and homogeneity of 
variances (SPSS 19.0, IBM, Chicago, IL, USA). Data are expressed as mean of the replicate 
means ± standard error of the mean (SEM). 
Morphometry and immunohistochemistry results were analyzed in a similar way, but with 20 
and  5 measurements in each slide, respectively. 
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3. Results 
3.1. Dietary mycotoxin concentrations 
DON was the major mycotoxin contaminant detected in experimental diets. Diets also 
included lesser amounts of 15-aDON, OTA, ZON, aflatoxins and fumonisins (Table 1). 
Table 1. Dietary mycotoxin concentrations of experimental diets 
 Control Control + GMA Contaminated Contaminated + GMA 
Starter Diet     
DON (µg/g) 0.06 0.12 5.20 6.50 
15-aDON (µg/g) ND ND 0.49 0.57 
OTA (ng/g) 0.66 ND 0.61 1.10 
ZON (µg/g) ND ND 0.37 0.67 
Aflatoxins (ng/g) ND ND 1.40 1.10 
FB1+FB2 (ng/g) ND ND 29 25 
Grower Diet     
DON (µg/g) 0.39 0.38 6.50 6.10 
15-aDON (µg/g) 0.10 0.11 0.55 0.51 
OTA (ng/g) ND ND 0.77 0.77 
ZON (µg/g) ND 0.02 0.59 0.66 
FB1+FB2 (ng/g) 0.42 0.76 1.20 0.33 
Developer Diet     
DON (µg/g) 0.31 0.33 4.00 4.20 
15-aDON (µg/g) ND ND 0.45 0.55 
OTA (ng/g) 0.31 ND 0.29 0.28 
ZON (µg/g) 0.03 0.03 0.67 0.79 
FB1+FB2 (ng/g) ND 0.25 0.26 0.30 
Finisher Diet     
DON (µg/g) 0.10 0.16 4.50 5.50 
15-aDON (µg/g) ND ND 0.45 0.57 
OTA (ng/g) ND ND 0.35 0.28 
ZON (µg/g) ND ND 0.42 0.44 
FB1+FB2 (ng/g) ND 0.40 0.28 0.29 
ND = not detected (<LOD) 
LOD: DON = 0.06 µg/g, 15-aDON = 0.05 µg/g, OTA = 0.2 ng/g, ZON = 0.02 µg/g, Aflatoxins =  1.0 ng/g, FB1-FB2 = 25.0 ng/g 
Other tested mycotoxins were 3a-DON, NIV, FUS-X, NEO, DAS, T-2, HT-2. Dietary concentrations fell below the respective 
LOD of 0.05, 0.12, 0.11, 0.07, 0.06, 0.04 and 0.06 µg/g 
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3.2. Performance parameters 
Except for the starter phase, no significant differences in body weight, weight gain, feed 
intake or FCR were observed (Table 2). Birds receiving the contaminated diet showed a 
significantly higher body weight and body weight gain in the starter phase. 
Table 2. Effect of different diets on performance parameters of turkey poults 
 Control Control + GMA Contaminated Contaminated + GMA 
Starter Diet     
Body Weight (kg/bird) 0.56 ± 0.024 0.56 ± 0.064   0.59 ± 0.028* 0.55 ± 0.029 
Weight Gain (kg/bird) 0.50 ± 0.003 0.50 ± 0.006   0.52 ± 0.003* 0.49 ± 0.003 
Feed Intake (kg/bird) 0.89 ± 0.005 0.89 ± 0.020 0.94 ± 0.018 1.04 ± 0.082 
FCR 1.79 ± 0.007 1.80 ± 0.034 1.79 ± 0.029 2.12 ± 0.155 
Grower Diet     
Body Weight (kg/bird) 2.18 ± 0.055 2.26 ± 0.120 2.28 ± 0.0181 2.22 ± 0.009 
Weight Gain (kg/bird) 1.63 ± 0.031 1.70 ± 0.011 1.69 ± 0.015 1.67 ± 0.009 
Feed Intake (kg/bird) 2.69 ± 0.077 2.76 ± 0.031 2.75 ± 0.093 2.68 ± 0.022 
FCR 1.65 ± 0.035 1.62 ± 0.008 1.62 ± 0.041 1.60 ± 0.017 
Developer Diet     
Body Weight (kg/bird) 5.26 ± 0.055 5.26 ± 0.034 5.32 ± 0.046 5.38 ± 0.012 
Weight Gain (kg/bird) 3.06 ± 0.017 2.99 ± 0.026 3.04 ± 0.028 3.17 ± 0.017 
Feed Intake (kg/bird) 7.12 ± 0.157 7.15 ± 0.084 6.86 ± 0.189 6.77 ± 0.055 
FCR 2.33 ± 0.038 2.39 ± 0.046 2.25 ± 0.049 2.14 ± 0.029 
Finisher Diet     
Body Weight (kg/bird) 9.35 ± 0.133 9.33 ± 0.035 9.11 ± 0.087 9.17 ± 0.091 
Weight Gain (kg/bird) 4.09 ± 0.078 4.07 ± 0.070 3.78 ± 0.047 3.79 ± 0.088 
Feed Intake (kg/bird) 11.49 ± 0.262 10.83 ± 0.153 10.40 ± 0.453 10.40 ± 0.181 
FCR 2.81 ± 0.011 2.67 ± 0.074 2.75 ± 0.106 2.75 ± 0.046 
* significantly different compared to the control ( P<0.05) 
Values represent the overall mean of the replicate means (n=3) ± SEM 
 
3.3. Plasma biochemistry 
Differences in plasma biochemistry profiles were observed amongst the different dietary 
groups. However, no parameter was consistently altered in any rearing phase. Also no 
consistent trend between control and contaminated or contaminated + GMA diets could be 
observed. The results of the parameters showing a significant difference between groups is 
shown in Table 3. 
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Table 3. Altered plasma chemistry parameters in turkey poults fed the experimental diets  
 Control Control + GMA Contaminated Contaminated + GMA 
Starter Diet     
CK (U/L) 2584.00 ± 160.407
a
 3681.17 ± 232.031
b
 4229.08 ± 337.814
b
 4136.33 ± 62.322
b
 
Amylase (U/L) 654.33 ± 33.422
a
 663.75 ± 5.774
a,b
 757.17 ± 52.218
b
 705.67 ± 50.069
b
 
Grower Diet     
P (mmol/L) 2.53 ± 0.053
a
 2.60 ± 0.063
a,b
 2.43 ± 0.061
a
 2.93 ± 0.055
b
 
Developer Diet     
LDH (U/L) 488.33 ± 21.586
a
 597.33 ± 16.807
b
 576.33 ± 5.132
a,b
 510.33 ± 7.441
a,b
 
Finisher Diet     
Cholesterol (mmol/L) 3.52 ± 0.073
a,b
 3.23 ± 0.032
a
 3.28 ± 0.058
a
 3.74 ± 0.042
b
 
A different superscript letter indicates a significant difference (P < 0.05) 
Values represent the overall mean of the replicate means (n=3) ± SEM 
 
3.4. Morphometry of the duodenum 
Table 4 shows the results of the morphometrical analysis of duodenal sections examined at 
the end of the starter phase. Birds fed the contaminated diet showed a significantly lower 
VH and AVSA. This negative effect was prevented by addition of GMA into the contaminated 
diet. 
3.5. Immunohistochemistry 
A significant higher population of CD8
+
 T-lymphocytes was observed in the duodenum of 
turkeys fed either the contaminated or the contaminated + GMA diet after three weeks of 
feeding (Table 4). 
Table 4. Morphometrical and immunohistochemical analysis of the duodenum at the end of the starter phase 
(3 weeks) 
 Control Control + GMA Contaminated Contaminated + GMA 
Morphometry     
Villus height (µm) 2205.12 ± 35.481 2222.45 ± 30.209 1952.25 ± 23.974*** 2253.29 ± 21.949 
Crypt depth (µm) 239.59 ± 17.750 250.96 ± 6.346 243.60 ± 9.846 252.37 ± 7.486 
Submucosa thickness (µm) 29.61 ± 0.336 28.41 ± 0.659 27.58 ± 0.501 27.68 ± 0.385 
Villus width down (µm) 134.87 ± 2.452 137.75 ± 1.704 140.35 ± 2.148 132.60 ± 1.175 
Villus width up (µm) 134.79 ± 1.208 139.47 ± 1.456 136.63 ± 1.221 133.79 ± 1.012 
Mean villus width (µm) 134.83 ± 1.568 138.61 ± 1.446 138.49 ± 1.499 133.19 ± 1.015 
Apparent villus surface 
area (mm²) 
2977.03 ± 68.976 3077.88 ± 51.697 2701.71 ± 51.642* 3004.66 ± 45.027 
CD8
+
 T-lymphocytes     
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Positivity (%) 2.53 ± 0.293 2.77 ± 0.384 4.89 ± 0.391 * 6.04 ± 0.512 *** 
* and *** indicate a significant difference compared to the control at 0.05 < P < 0.01 and P <0.001 respectively 
Values represent the overall mean of the replicate means (n=12) ± SEM 
 
3.6. DON, DOM-1 concentrations in plasma 
No DON or DOM-1 was detected in any plasma samples of the birds fed the control or 
control + GMA diet. DON and DOM-1 plasma concentrations were detectable in all analyzed 
samples of birds fed the contaminated or the contaminated + GMA diet. No significant 
differences, however, were observed. The results are presented in Table 5.  
Table 5. Plasma concentrations of deoxynivalenol (DON) and de-epoxydeoxynivalenol (DOM-1) after feeding 
different experimental diets 
 Control Control + GMA Contaminated Contaminated + GMA 
Week 1     
DON (ng/mL) ND ND 1.14 ± 0.334 1.27 ± 0.337 
DOM-1 (ng/mL) ND ND 2.45 ± 0.198 2.82 ± 0.178 
Starter Diet     
DON (ng/mL) ND ND 2.09 ± 0.490 2.28 ± 0.415 
DOM-1 (ng/mL) ND ND 2.28 ± 0.043 2.40 ± 0.048 
Grower Diet     
DON (ng/mL) ND ND 3.21 ± 0.337 3.06 ± 0.409 
DOM-1 (ng/mL) ND ND 9.51 ± 0.638 9.12 ± 1.230 
Developer Diet     
DON (ng/mL) ND ND 1.71 ± 0.212 1.38 ± 0.267 
DOM-1 (ng/mL) ND ND 4.00 ± 0.210 3.73 ± 0.419 
Finisher Diet     
DON (ng/mL) ND ND 1.00 ± 0.036 1.11 ± 0.133 
DOM-1 (ng/mL) ND ND 2.11 ±  0.217 2.20 ± 0.352 
ND = Not Detected (<LOD) 
Values represent the overall mean of the replicate means (n=3) ± SEM 
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4. Discussion 
The goal of this study was to evaluate the effect of a yeast derived mycotoxin binder on 
selected unspecific parameters and specific toxicokinetic markers after feeding a naturally 
contaminated diet (± 5 mg DON/kg feed) to turkey poults. 
Trichothecenes, including DON, target the 60S ribosomal unit, where they stop the 
elongation-termination step during protein synthesis (Ueno, 1984). Trichothecenes also 
inhibit DNA and RNA synthesis, which is a secondary effect due to protein synthesis 
inhibition (Ueno, 1985). Moreover, they activate mitogen-activated protein kinases (MAPKs) 
and induce apoptosis in a process called ‘ribotoxic stress response’ (Pestka, 2007). As a 
consequence of MAPK activation, DON increases the expression and stability of 
cyclooxygenase-2 (COX-2) mRNA confirming its role in the inflammatory process (Moon and 
Pestka, 2002). The most sensitive cell types are therefore those with a high turn-over rate 
such as intestinal cells and leucocytes. 
Enterocytes are particularly exposed to the effects of DON as this mycotoxin is almost 
completely absorbed in the duodenum (Dänicke et al., 2010; Eriksen et al., 2003). The effects 
of DON on intestinal morphology, morphometry and immunology of poultry have been 
described before (Girish and Smith, 2008; Girgis et al., 2010a,b; Girish et al., 2010; Yunus et 
al., 2012a). Changes primarily occur in the duodenum, the absorption site of DON. 
In the current study, birds fed the contaminated diet showed significant reduction of the VH 
and AVSA at the end of the starter phase in the duodenum. This effect is most probably 
attributed to DON, the major contaminant of the diets. Moreover, adding GMA to the 
contaminated diet counteracted this effect. These findings were previously also described by 
Girish and Smith (2008). The reproducibility of the results confirms the pronounced 
beneficial effects of GMA on this unspecific parameter. 
CD8
+
 T-lymphocytes were selected as immunological marker in the intestine as the effects of 
feeding a DON contaminated diet already showed to alter this cell type count in cecal tonsils 
(Girish et al., 2010). The present results demonstrate a significantly higher influx of CD8
+
 T-
lymphocytes in the duodenum of turkeys fed the contaminated diet compared to the 
controls. GMA was not able to counteract this effect as no significant difference was 
observed between the contaminated and contaminated + GMA group. The dose of DON is 
Chapter VI 
188 
 
an important variable as with a lower dose (3 mg DON/kg feed), no significant differences 
between control and contaminated feeding groups were observed in a previous feeding trial 
with turkeys (Girish et al., 2010). We opted to use 5 mg/kg as it is the maximally allowed 
contamination level for poultry feed in Europe (European Commission, 2006) and Canada 
(FAO, 1997). Also, when feeding naturally contaminated diets, the entire ‘mycotoxin profile’ 
could play a role on the outcome. Next to the variation in contamination level of the major 
contaminant (DON), co-contaminants could have an additive or synergistic effect. 
Since poultry are relatively resistant to the effects of DON in terms of performance 
parameters, high concentrations are needed to cause detrimental effects (Awad et al., 
2012). It should be noted that diets containing purified DON may be less toxic than naturally 
contaminated diets due to the presence of masked mycotoxins, such as DON-3-glucoside, 
which add to the toxicity of the diet but are not detected by routine feed analyses (Sasanya 
et al., 2008). Awad et al. (2008) described that broiler chickens can tolerate up to 15 mg 
DON/kg without a decrease in BW gain. Moreover, diets contaminated with up to 10 mg 
DON/kg did not affect FCR of turkey poults (Xu et al., 2011). Also other studies did not 
observe altered poultry performance when fed DON contaminated diets (Dänicke et al., 
2001; Awad et al., 2006; Yegani et al., 2006). In contrast, Swamy et al. (2002) found 
significant linear declines in growth rate and feed consumption of broiler chickens fed 
increasing levels of grains naturally contaminated with Fusarium mycotoxins. In the present 
study, BW gain was remarkably increased in the DON contaminated group (starter phase). A 
growth promotion by moderate DON levels has already been described previously in broiler 
chickens (Kubena et al., 1985; Kubena et al., 1989) and turkeys (Xu et al., 2011). This could 
be attributed to an effect of hormesis. Hormesis represents the stimulatory effects caused 
by low levels of potentially toxic agents (Stebbing et al., 1982; Calabrese, 2008). In this 
concept, living organisms overreact on the presence of a toxin or poison at low 
concentrations. This could lead, as in the current study for example, to a transient increase 
of growth rate. 
In general, there is no simple dose-response relationship between dietary DON 
concentrations and growth performance or feed consumption in turkey poults (Dänicke et 
al., 2001; Xu et al., 2011). Therefore, animal performance parameters, including growth rate, 
feed intake and FCR, are not suitable to test the efficacy of mycotoxin detoxifiers in turkey 
poults. 
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Alterations in plasma biochemistry profile is often used as a parameter to demonstrate the 
deleterious effects of mycotoxins. Feeding diets naturally contaminated with 5 mg DON/kg 
lowered albumin concentrations and GGT activity in broiler chickens (Swamy et al., 2002). 
Another broiler study conducted with 3 mg DON/kg feed concluded that DON lowered total 
protein, albumin and P plasma concentrations (Klapacova et al., 2011). Ghareeb et al. (2012) 
did not only observe reduced protein concentrations after feeding 10 mg DON/kg feed, but 
also reduced uric acid concentrations. In turkey poults, feeding 3 mg DON/kg did not alter 
total protein, albumin, minerals or enzyme activities, but elevated uric acid concentrations in 
the plasma (Girish et al., 2008). The reduced protein concentrations observed in several 
studies on broiler chickens is attributed to the inhibitory effect of DON on protein synthesis. 
In the current study, no alterations in total protein, albumin, globulin or albumin:globulin 
ratio were observed in turkeys fed the contaminated diet, which agrees with the findings 
reported by Girish et al. (2008). For all other enzymes and minerals monitored, no trend was 
found in literature nor in this study. It can be concluded that, although significant differences 
can be observed, plasma biochemistry is not consistent enough to be considered a reliable 
parameter for efficacy testing of mycotoxin detoxifiers. 
A direct approach to evaluate the efficacy of a mycotoxin binder against DON absorption is 
measuring DON and DOM-1 levels in plasma (EFSA, 2010). After a single bolus administration 
of 0.75 mg DON/kg BW to broiler chickens, equally to 5 mg DON/kg feed, plasma 
concentrations of DON were low (maximal plasma concentration, Cmax, 26.1 ng/mL and 
absolute oral bioavailability of 19.3%), time to maximal plasma concentration (Tmax) was 
short, 35 min, and DON was rapidly excreted (elimination half-life, T1/2el, 38 min) (Osselaere 
et al., 2013). This implicates the need for very sensitive methods which quantify DON/DOM-
1 at lower ng/mL levels. This can be achieved via LC-MS/MS and such methods have been 
developed at our department (De Baere et al., 2011; Devreese et al., 2012). To our 
knowledge, the present study is the first to detect DON and DOM-1 in turkey plasma. After 
chronic feeding of DON contaminated diets to broiler chickens, plasma concentrations of 
DON may tend to be lower due to an adaptation mechanism (Yunus et al., 2012a). When 
broilers were fed 7.5 mg DON/kg feed, average plasma concentrations were 3.87 and 2.66 
ng/mL in week 1 and 2 respectively, but were <LOQ of 1.25 ng/mL after three weeks (De 
Baere et al., 2011; Osselaere et al., 2012). In the present study, plasma concentrations of 
DON and DOM-1 increased with a maximum at the end of the grower phase. This could be 
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attributed to intestinal damage, as demonstrated with the morphometry indices, leading to 
increased DON absorption. Adaptation to DON as feed contaminant, as described by 
Osselaere et al. (2012) and Yunus et al. (2012a), was observed at a later stage of the trial. In 
the developer and finisher phase, both DON and DOM-1 plasma concentrations tend to 
decrease again. When plasma concentrations are compared amongst groups, no significant 
differences between contaminated and contaminated + GMA group could be demonstrated 
at any of the sampling points. This suggests that supplementation of the contaminated diets 
with GMA did not alter DON absorption in turkey poults. 
5. Conclusions 
Feeding naturally DON contaminated diets to turkey poults altered some unspecific 
parameters such as growth rate, plasma biochemistry profile, duodenal villus height and 
apparent villus surface area and CD8
+
 T-lymphocyte count in the duodenum. A yeast derived 
mycotoxin binder, GMA, was partially effective in preventing those effects. Performance 
parameters and plasma biochemistry profiles were not found suitable to evaluate the 
efficacy of mycotoxin binders on DON absorption in turkey poults as they were not 
consistent. GMA was able to counteract the negative effects of DON on duodenal 
morphometry but did not alter the increased influx of CD8
+
 T-lymphocytes. Plasma 
concentrations of DON and DOM-1 were not altered by the addition of GMA to the diet, 
suggesting that GMA was ineffective in decreasing DON absorption. These data suggest that 
the beneficial effects of GMA are due to another mechanism than DON adsorption in the 
gut. 
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Mycotoxin detoxifying agents (mycotoxin detoxifiers) are commonly used as feed additives 
to prevent the deleterious effects of mycotoxins on animal health (Jard et al., 2011). These 
products should be evaluated for their in vitro and in vivo efficacy as well as possible 
interactions with the oral absorption of veterinary drugs. A lot of different variables have to 
be taken into account when developing models for in vitro and in vivo tests. A more general 
discussion on mycotoxin detoxifiers is presented, linked to the results obtained in this thesis. 
Mycotoxin concentration levels 
Mycotoxin binding is determined by the concentration of both the mycotoxin and the 
detoxifier. This can be demonstrated by in vitro adsorption isotherms, where a known 
amount of mycotoxin is added to a known amount of test product in an aqueous solution. 
The results are usually reported as ‘%ads’, the fraction of toxin bound to the adsorbing 
agent. At low mycotoxin concentrations, the binding of mycotoxin to the binder will depend 
on the affinity between both (affinity constant or Ka). With increasing concentration of 
mycotoxin, the amount adsorbed will increase more slowly and finally reach a point at which 
the binder is saturated, i.e. the capacity (n) of the mycotoxin binder (EFSA, 2009). When, at 
very high mycotoxin concentrations, the binder is saturated, the only way to increase the  
%ads is by increasing the amount of binder. 
In in vivo trials, high feed contamination levels are used to evoke negative effects on animal 
performance (Kolosova and Stroka, 2011). Mycotoxin levels in feedstuffs which lower 
zootechnical performance depend on both the animal species in question and on the type of 
mycotoxin. This implies that each mycotoxin at a given level of contamination can cause a 
specific sensitivity depending on the animal species: for example, pigs are more sensitive to 
fumonisin B1 (FB1), zearalenone (ZON) and deoxynivalenol (DON) than poultry. The EFSA 
states (EFSA, 2010) that maximum levels set by the EC should be used, for example 0.9 or 5 
mg DON/kg feed for pigs or poultry, respectively (Chapter IV and VI). However, these 
maximum levels are ‘safe’ values, established at a level that should not impair animal 
performance. For example, the no observed adverse effect level (NOAEL) on zootechnical 
performance of pigs is 0.04 mg/kg BW/day (Bergsjo et al., 1992). This resembles a dietary 
feed intake of 0.9 mg DON/kg feed. These maximum levels limit the use of performance 
parameters to evaluate the effect of a mycotoxin detoxifier. Other parameters should be 
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used, and as proposed by the EFSA, toxicokinetic parameters are promising in this context. If 
a mycotoxin binder adsorbs the mycotoxin in the gut, lowered concentrations will be 
detected in organ tissues and body fluids such as plasma. A prerequisite however is the 
availability of sensitive methods capable to detect and quantify mycotoxins in those matrices 
at the low ng/mL level. A specific goal of our research was developing such methods as they 
were unavailable at the time being (Chapter II and III) (De Baere et al., 2011; Devreese et al., 
2012 and 2013). The methods were successful in quantifying several mycotoxins such as 
DON, de-epoxydeoxynivalenol (DOM-1) and ochratoxin A (OTA) in animal plasma 
administered at the levels proposed by the EFSA. The methods were unsuccessful for others 
such as aflatoxin B1 (AFB1) and T-2 toxin (T-2) because of the very low maximum levels, e.g. 
0.02 mg/kg for AFB1, or a fast elimination (T1/2el of T-2 = 3.9 min in broiler chickens). Another 
issue is that for beauvericin (BEA) and enniatins (ENNs) no maximum levels in feed have 
been established by the EC. The developed method for quantifying BEA and ENNs in pig 
plasma was successful for enniatin A, A1, B and B1 at the administered dose (0.05 mg/kg) 
and may now be used for future efficacy studies. However, this dose was set arbitrarily. 
Efficacy and safety studies with such arbitrarily set contamination levels due to the lack of 
guidance levels, might not be accepted by the EFSA anymore once guidance levels are 
established. 
Furthermore, the developed methods were used to evaluate the efficacy of mycotoxin 
detoxifiers towards DON absorption in poultry (Chapter IV and VI). The maximally allowed 
guidance level of DON contamination was used (5 mg DON/kg feed). Very low DON plasma 
levels were measured, ranging between 1 and 20 ng/mL. These levels can only be quantified 
using highly sensitive LC-MS/MS equipment. As a result, this may urge the need to use 
higher contamination levels than those proposed by the EFSA when it comes to efficacy 
testing of mycotoxin detoxifiers. 
Mycotoxin standards or feed naturally contaminated with mycotoxins 
As a source of mycotoxins, both spiked feed (used in Chapter IV) or naturally contaminated 
feed (used in Chapter VI) can be used in in vivo trials. The advantage of mycotoxin standards 
is that the amount of toxin administered to the animal is exactly known. It is also easier to 
reproduce results using standards, when the exact same amount can be chosen in 
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consecutive experiments. Next, no co-contamination is present, which could exert 
synergistic or additive effects. Besides the high purchase costs, the main drawback of using 
mycotoxin standards is that it does not really represent the natural situation. 
The use of naturally contaminated feed materials is preferred by the EFSA and other 
research groups (Dänicke et al., 2003; EFSA, 2010; Girish et al., 2010). It resembles the 
situation in animal husbandry far more than using standards. Co-contaminants are often 
present which makes it harder to interpret the obtained results as a different ‘mycotoxin 
profile’ of the feed can lead to a different outcome. Also a larger variation of contamination 
level will be present as mycotoxin contamination is not homogenous throughout the entire 
feed batchv(Jard et al., 2011). Another key factor are masked mycotoxins which lead to an 
underestimation of the total mycotoxin contamination. Masked mycotoxins are usually plant 
derivatives of mycotoxins which are not detected by conventional analytical techniques 
(Berthiller et al., 2013). The plant itself modifies the mycotoxin to a less harmful compound, 
in order to reduce plant toxicity. Plant derived masked mycotoxins can be divided in two 
classes, the conjugated, such as DON-3-glucoside, and bound varieties such as protein bound 
FB1 (Park et al., 2004; Sasanya et al., 2008). Next to the plant derivatives, also food or feed 
processing can alter mycotoxins, forming masked mycotoxins. However, most of these 
compounds formed during food processing are less toxic than their precursors (Berthiller et 
al., 2013). The question remains whether these conjugated forms are hydrolyzed in vivo, 
resulting in increased exposure to the native toxin. 
Does glucomannan binds deoxynivalenol? 
Glucomannan (GMA) is an organic mycotoxin binder derived from cell wall components of 
Saccharomyces cerevisiae yeasts. Based on in vitro assays, GMA has shown to effectively 
adsorb DON, T-2, ZON, OTA and AFB1 (Bejaoui et al., 2004; Freimund et al., 2003; 
Yiannikouris et al., 2004; Yiannikouris et al., 2006). The β-D-glucan fraction of yeast cell walls 
is directly involved in the binding process with ZON, and the structural organization of β-D-
glucans modulates the binding strength. Hydrogen and van-der-Waals bonds have been 
evidenced in the glucan-mycotoxin complexes (Jouany, 2007; Shetty and Jespersen, 2006; 
Yiannikouris et al., 2004; Yiannikouris et al., 2006). These in vitro results correlate well with 
the results obtained in our in vitro model (Chapter I). In our cell culture experiments using 
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IPEC-J2 cells grown on Transwell® inserts, GMA lowered the passage of DON through the 
epithelial monolayer (37-57%). GMA was also partially effective in reducing the negative 
effects of cytotoxic DON concentrations on cellular viability and integrity (57 and 65%, 
respectively).  
The next question is whether the in vitro results could be confirmed in vivo. Several studies 
have demonstrated beneficial effects of GMA against the detrimental consequences of DON 
in both pigs and poultry. 
In pigs, feeding DON reduced brain neurochemistry hormones (dopamine, 
dihydroxyphenylacetic acid and norepinephrine) (Swamy et al., 2002). It also increased 
serum IgA and IgM concentrations and altered performance parameters (reduced feed 
intake and weight gain). In a study by Diaz-Llano and Smith (2007), GMA addition was able to 
counteract the alterations of serum biochemical parameters induced by DON in sows. 
However, no positive effect on feed intake and body weight gain was seen. Also Dänicke et 
al. (2007) did not observe improved productive parameters in pigs following GMA addition in 
a DON contaminated feed. 
Furthermore, GMA has shown to counteract most of the alterations in plasma biochemical 
parameters caused by a DON contaminated diet in chickens (Faixova et al., 2010). In a study 
by Swamy et al. (2004), GMA could also prevent the decrease in B-cell count induced by 
DON. GMA also promoted the growth of villi and intestinal recovery after coccidial challenge 
of broiler chickens (Girgis et al., 2010). It has preventive effects on alterations in brain 
neurochemistry of turkeys (Girish et al., 2008a). Also in turkeys, GMA counteracted the 
effects of DON on intestinal morphology (Girish and Smith, 2008), animal performance, 
some alterations in plasma biochemistry and the effects of CD8
+
 T cell-mediated delayed-
type hypersensitivity response (Girish et al., 2008b). 
 
In conclusion, GMA is able to counteract many effects induced by DON on animal 
performance, blood biochemistry, histology, immunology and other parameters in several 
animal species. May these effects be attributed to the binding of DON by GMA in the 
intestinal tract or are other mechanisms involved? To elucidate this, GMA was included as 
mycotoxin detoxifier in our in vivo model based on the toxicokinetics of DON. In Chapter IV, 
oral bolus models were developed in which DON with or without GMA was given as an intra-
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crop bolus to broiler chickens. In the first model, a significant higher AUC0-inf, Cmax, ka and 
relative oral bioavailability (OBB) and a shorter T1/2a were found in the DON + GMA group 
compared to the group only administered DON. No significant differences in toxicokinetic 
parameters between both groups in bolus model 2 and 3 were observed. Another trial was 
performed with DON and GMA in turkey poults (Chapter VI). Birds were reared for twelve 
weeks and fed different diets: control (minimally contaminated), control + GMA, DON 
contaminated (5 mg/kg) and contaminated + GMA. Several unspecific parameters were 
monitored, as well as DON and DOM-1 plasma concentrations. GMA was able to counteract 
some effects of DON on unspecific parameters, however the feed additive was not able to 
lower plasma concentrations of DON or DOM-1 in any of the rearing phases. 
 
As a general conclusion, it was shown in this work that GMA is partly effective in adsorbing 
DON in vitro, but the in vivo situation is complicated by many other variables. Although GMA 
exerts beneficial effects, they cannot be attributed to binding of DON by GMA in vivo. What 
other mechanism is involved, is not clear up to day. GMA is composed of mannan 
oligosaccharide (MOS) and β-glucan. MOS has a distinct effect on the intestinal microflora. 
Spring et al. (2000) demonstrated a reduction of prevalence and concentration of Salmonella 
strains in broiler chickens ceca when fed MOS. Besides, it is often used as a prebiotic to 
increase animal performance. Addition of MOS to the diet of broiler chickens and turkeys 
increased their growth rate and decreased their feed conversion (Hooge, 2004a, 2004b; 
Rosen, 2007). MOS would also have an advantageous effect on intestinal morphology and 
function. It enhances the nutrient digestibility, increase villus surface area and stimulates 
mucus production (Yang et al., 2008; Baurhoo et al., 2009). The second compound of GMA, 
namely β-glucan, can promote the immune system by activating T-lymphocytes (Rop et al., 
2009) (Chapter VI). It also stimulates intestinal recovery after coccidial challenge in poultry 
(Girgis et al., 2010), increases the intestinal cell rate proliferation leading to changes in 
mucosal structure (Iji, 1999), sequesters bile acids in the gut (Chen and Huang, 2009), and 
even exerts anti-tumoral activity (Yalin et al., 2005). All these, and other factors, may 
account for the beneficial effects of GMA, indirectly counteracting the effects of DON. 
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Specific biomarkers to evaluate the efficacy of mycotoxin detoxifiers 
To evaluate the efficacy of mycotoxin detoxifiers, measuring specific biomarkers in tissues or 
body fluids is the method of choice according to the EFSA (EFSA, 2010). For DON, the parent 
compound in plasma has demonstrated to be a sensitive biomarker for exposure and for 
efficacy testing in broiler chickens (Chapter II and IV). Its main metabolite DOM-1 was not 
suited as a biomarker in broiler chickens, in contrast to turkeys, where plasma levels of 
DOM-1 were higher and less variable compared to DON (Chapter VI). This demonstrates that 
biomarkers should be assessed for each species individually and cannot be generalized. Also 
phase II metabolites might be suited as biomarker for DON. At least in humans, DON-
glucuronides were validated as biomarker (Warth et al., 2012). The hepatic glucuronidation 
pattern of DON is species dependent, therefore the suitability of DON-glucuronide as 
biomarker will be species dependent as well. Humans and pigs extensively glucuronidate 
DON, in contrast to poultry species (Maul et al., 2012). 
Suitable biomarkers for assessing the efficacy of mycotoxin detoxifiers towards other 
mycotoxins should be investigated as well. For T-2 for example, 70% of the metabolite 
residue is present in its glucuronide form (Corley et al., 1985). This metabolite might 
therefore be more suited as biomarker compared to T-2 itself or HT-2. This is acknowledged 
by our results since no plasma levels of the T-2 nor HT-2 could be detected after oral 
administration of a relatively high dose of T-2 to pigs (0.05 mg/kg BW) (Chapter II). 
Next to the parent compound or its metabolites, biomarkers can also include compounds 
related to the mode of action of the mycotoxin. This is the case for fumonisin B1 (FB1). FB1 
specifically acts as an inhibitor of the ceramide synthesis, leading to altered levels of 
sphinganine (Sa) and sphingosine (So) in tissues and body fluids. The Sa:So ratio was suited 
as biomarker for fumonisin exposure in mammals and avian species (Haschek et al., 2001). 
Efficacy and safety testing of mycotoxin detoxifiers: involvement of different stakeholders 
Since in vitro and in vivo models are now available to evaluate the efficacy of mycotoxin 
binders and modifiers and to investigate possible interactions with oral absorption of 
veterinary drugs, the next question arises: who should evaluate the efficacy and safety of 
both types of products? 
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Several partners are involved: governmental instances, academia and manufacturers of 
those feed additives. 
The outline on how new detoxifiers should be evaluated has to be provided by governmental 
instances. However, they should take the available know-how and equipment into account. 
When the EFSA proposed their guidelines for in vivo efficacy and safety testing of mycotoxin 
detoxifiers in 2010 (EFSA, 2010), no models were available at that time. Such guidelines 
should be drafted in agreement with the involved manufacturers. To our knowledge, since 
the launch of their guidelines one registration dossier was submitted, demonstrating the 
ability of bentonite clay to bind AFB1, to be used in all animal species. The efficacy on 
ruminants could be demonstrated by an altered excretion profile, lower aflatoxin M1 (AFM1) 
excretion in milk due to lowered AFB1 absorption from the intestinal tract. For the other 
animal species, the manufacturer provided numerous studies to demonstrate the efficacy. 
However, they were based on unspecific parameters including zootechnical parameters, 
blood proteins, organ weights and histopathology. The EFSA concluded (EFSA, 2011) that the 
data provided were insufficient to currently prove the efficacy of bentonite clays as no 
evidence based on specific toxicokinetic parameters was given. 
It was up to the academia to fill the gap between what legislators want and the know-how 
available to manufacturers. The models described in this thesis are in close relation to the 
EFSA guidelines and provide an added value for the involved manufacturers which can adopt 
them. It does require some efforts as manufacturers are used to evaluate their products 
using adsorption studies and/or feeding trials evaluating performance parameters. For new 
registration dossiers, manufacturers should also demonstrate that their products can be 
safely used in combination with medicated feed or drinking water. Another option is to 
prohibit the use of the detoxifier in combination with additives from the group of antibiotics, 
chemotherapeutics, coccidiostats and other frequently used medical substances in poultry 
and pig industry. 
On the other hand, a huge variety of mycotoxin detoxifiers are commercially available today, 
without fully evaluating the safety of those products. In our opinion, it is up to the academia 
to draw attention on these interactions and consequences for animal health, microbial 
resistance and even public health. Evaluating all available drugs and all available commercial 
detoxifiers is, however, out of the scope of the academia. 
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Future perspectives 
A first future perspective could be developing an ex vivo model using the Ussing chamber 
technology. An Ussing chamber consists of two halves clamped together with an insert 
containing a full-thickness intestinal sample. Similar parameters can be evaluated as in the 
developed in vitro model, namely tissue integrity based on transepithelial electrical 
resistance (TEER) and passage through the intestinal tissue explant. This ex vivo model can 
be used for efficacy and safety testing of mycotoxin binders. It leads to a higher throughput 
compared to in vivo trials, but it is more labor intensive than the developed in vitro model. 
Mycotoxin modifiers are supposed to biotransform mycotoxins into less toxic metabolites. 
The Simulator of Human Intestinal Microbial Ecosystem (SHIME) is a dynamic ex vivo model 
simulating the gastro-intestinal tract by consecutive reactors each containing stable 
microbial communities. The SHIME could be used to evaluate the efficacy (biotransformation 
capability) and safety (identification and characterization of the formed metabolites) of 
these products in the presence of the intestinal microbiota. 
The in vitro and in vivo efficacy models described in this thesis were validated with DON. It 
would definitely be interesting to use the developed models with other mycotoxins. The 
most appropriate biomarkers should be selected first. These biomarkers can be the 
mycotoxin itself, metabolites or compounds related to the mode of action (as stated above). 
The in vitro and in vivo safety models developed were based on a direct interaction between 
mycotoxin detoxifier and veterinary drugs. However, as stated above, a more complex 
interaction between detoxifier, veterinary drug and mycotoxin was described by means of 
the in vivo model (Goossens et al., 2012; Osselaere et al., 2013). It would be of interest to 
investigate if the results of this more complex interaction could be reproduced with the in 
vitro model. 
Future research should not only focus on adsorption of veterinary drugs by mycotoxin 
detoxifiers but also enhanced oral bioavailability, as demonstrated with doxycycline in pigs 
(Goossens et al., 2012) and oxytetracycline in broilers (Osselaere et al., 2012). Enhanced oral 
bioavailability, leading to increased tissue concentrations might impair the withdrawal time 
of veterinary drug formulations and possibly lead to the occurrence of undesirable residues 
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(above the Maximum Residue Limit, MRL) of the antibiotic in edible tissues. On the other 
hand, if the detoxifier leads to increased plasma concentrations, this could, from a 
theoretical point of view, be compensated by reducing the dosage of the antibiotic. 
In Chapter III, a sensitive LC-MS/MS method for simultaneous determination and 
quantification of BEA and ENNs in pig plasma was described. At the time being, little is 
known about the in vivo toxicokinetics and toxicodynamics of these mycotoxins. The 
presented method can now be applied to conduct a comprehensive animal experiment to 
elucidate the toxicokinetics of these mycotoxins in swine. Eventually, this would provide a 
better understanding on their in vivo effects. 
Recently, there are indications that mycotoxins and mycotoxin detoxifiers could also 
interfere with the pathogenesis of infectious disease. More specifically, DON and T-2 
potentiate Salmonella Typhimurium in pigs (Vandenbroucke et al., 2011; Verbrugghe et al., 
2012). Moreover, the addition of GMA to T-2 contaminated diet (87 µg T-2/kg feed) did not 
only alleviate the reduced body weight gain of the pigs, it also reduced the intestinal 
colonization of S. Typhimurium, although not significantly. Nevertheless, in vitro findings 
suggests that GMA binds Salmonella bacteria (Verbrugghe et al., 2012). These results open 
new research perspectives regarding the interaction between mycotoxins, mycotoxin 
detoxifiers and infectious agents.  
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Mycotoxins are considered a major issue worldwide because of their harmful effects on 
animals. This leads to great economic losses, especially in pig and poultry industry. The most 
commonly used method to counteract the negative impact of mycotoxins on animals is 
adding mycotoxin detoxifying agents (mycotoxin detoxifiers) to feed. These feed additives, 
so-called mycotoxin binders or mycotoxin modifiers, either adsorb or biotransform 
mycotoxins in the gastrointestinal tract, respectively. 
These products should be tested on their ability to bind or modify mycotoxins in vitro as well 
as in vivo (efficacy). At the time being, no reliable in vitro models were available which were 
both high-throughput and mimic the gastrointestinal tract nor were there in vivo models 
available which evaluate the efficacy of mycotoxin detoxifiers based on specific toxicokinetic 
parameters. 
Next to the efficacy of these products, questions have been raised on possible interactions 
with the oral absorption of veterinary drugs. Furthermore, no in vitro nor in vivo models 
were available to evaluate the safety, regarding drug absorption, of these products. 
The general introduction of this thesis starts with an overview of the most toxic and 
prevalent mycotoxins. Next, pre- and postharvest methods to reduce the impact of 
mycotoxins is provided including mycotoxin detoxifiers. Finally, regulations of the European 
Commission (EC) and the European Food Safety Authority (EFSA) are summarized, focusing 
on maximum levels of mycotoxin contamination in feed and guidelines to evaluate the 
efficacy and safety of mycotoxin detoxifiers, respectively. 
The general aim of this doctoral research was to develop in vitro and in vivo models for 
testing the efficacy of mycotoxin detoxifiers and their possible interactions with the oral 
absorption of veterinary drugs. 
In Chapter I an in vitro model was developed to evaluate the efficacy of mycotoxin binders 
and possible interactions with veterinary drug adsorption. Intestinal porcine epithelial cells 
derived from the jejunum (IPEC-J2) were cultivated on Transwell® cell culture inserts. In the 
first experiments, deoxynivalenol (DON) was added at 0.5 µg/mL or 1 µg/mL, with or without 
activated carbon (AC) or a commercially available glucomannan binder (GMA). A 
concentration of 1 µg/mL decreased cellular viability (based on a neutral red cytotoxicity 
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assay) and cellular integrity (based on measurements of transepithelial electrical resistance, 
TEER). On the other hand, a concentration of 0.5 µg/mL DON did not exert any cytotoxic 
effect nor did it damage the cellular integrity. AC was used as a positive control binder and 
completely alleviated the negative effects of 1 µg/mL DON. Furthermore, it almost 
completely (>99%) reduced the passage through the epithelial monolayer, mimicking 
intestinal absorption, at both 1 and 0.5 µg/mL DON. These results prove that our model is 
effective in demonstrating the ability of mycotoxin binders to bind DON. The commercial 
binder, GMA, was partially effective in preventing the cytotoxic effects and cellular integrity 
damage of DON. Moreover, it reduced the transepithelial passage of DON with 37% to 57% 
compared to AC, at both cytotoxic and non-cytotoxic concentrations of DON. 
In the second experiments, a drug interaction model was developed. The interaction 
between tylosin (20 µg/mL) and mycotoxin binders was investigated as some authors 
suggest binding of macrolide antibiotics to bentonite clays. Indeed, a bentonite clay, used as 
positive control, decreased the passage of tylosin through the epithelial monolayer with 
82%, indicating binding of tylosin by bentonite. This indicates that the combined use of 
bentonite and tylosin in the feed could lead to therapy failure. GMA did not alter the 
passage of tylosin, indicating safe combined use. 
 
The next step after introducing the in vitro model was to develop in vivo models based on 
specific pharmaco- or toxicokinetic parameters. In order to do so, sensitive methods were 
needed to detect and quantify mycotoxins in animal plasma. 
In Chapter II a sensitive and reliable multi-mycotoxin method was developed for the 
identification and quantification of several toxicological important mycotoxins such as DON, 
de-epoxydeoxynivalenol (DOM-1), T-2 toxin (T-2), HT-2 toxin (HT-2), zearalenone (ZON), 
zearalanone (ZAN), α-zearalenol (α-ZOL), β-zearalenol (β-ZOL), α-zearalanol (α-ZAL), β-
zearalanol (β-ZAL), ochratoxin A (OTA), fumonisin B1 (FB1) and aflatoxin B1 (AFB1) in pig 
plasma using liquid chromatography combined with heated electrospray ionization triple 
quadrupole tandem mass spectrometry (LC-h-ESI-MS/MS). Sample cleanup consisted of a 
deproteinization step using acetonitrile, followed by evaporation of the supernatant and 
resuspension of the dry residue in water/methanol (85/15, v/v). Each plasma sample was 
analyzed twice, i.e. once in the ESI+ and ESI- mode, respectively. For the performance of 
toxicokinetic studies with individual mycotoxins, even more sensitive analyte-specific LC–
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MS/MS methods were developed. The multi-mycotoxin and analyte-specific methods were 
in-house validated: matrix-matched calibration graphs were prepared for all compounds and 
correlation and goodness-of-fit coefficients ranged between 0.9974–0.9999 and 2.4–15.5%, 
respectively. The within- and between-run precision and accuracy were evaluated and the 
results fell within the ranges specified. The limits of quantification for the multi-mycotoxin 
and analyte-specific methods ranged from 2 to 10 ng/mL and 0.5 to 5 ng/mL, respectively, 
whereas limits of detection fell between 0.01–0.52 ng/mL and < 0.01–0.15 ng/mL, 
respectively. 
 
Several Fusarium spp. are capable of producing well-known mycotoxins like trichothecenes, 
fumonisins and/or ZON, but also other mycotoxins including beauvericin (BEA) and enniatins 
(ENNs) such as enniatin (ENN) A, A1, B and B1. Several studies have reported cytotoxic 
effects of ENNs and BEA on several cell types. Data on their in vivo toxicity are however 
lacking. To investigate their toxicokinetic properties and to evaluate the possible effects of 
mycotoxin binders on adsorption of BEA and ENNs, methods to detect and quantify these 
compounds in plasma are again mandatory. Therefore, in Chapter III a sensitive and reliable 
method was developed for the identification and quantification of BEA, ENN A, A1, B and B1 
in pig plasma using LC-h-ESI-MS/MS. The same sample preparations was used as for the 
previously described mycotoxins except for the resuspension solvent (acetonitrile/water, 
80/20, v/v). The method was in-house validated: matrix-matched calibration graphs were 
prepared for all compounds and correlation and goodness-of-fit coefficients ranged between 
0.9980 and 0.9995 and between 5.2% and 11.3%, respectively. The within- and between-run 
precision and  accuracy were evaluated and the results fell within the ranges specified. The 
limits of quantification were 0.1 ng/mL for enniatin A and A1 and 0.2 ng/mL for BEA, ENN B 
and B1, whereas limits of detection were ≤ 10 pg/mL for all analytes. The method has been 
applied for the analysis of incurred plasma samples from one pig that received an oral bolus 
(0.05 mg/kg BW) of the investigated mycotoxins. At the applied dosage, the results indicated 
the suitability of the method for use in toxicokinetic studies with ENNs. 
 
Another specific aim was to develop in vivo models based on toxicokinetic parameters using 
the described analytical methods. In Chapter IV, three bolus models were developed, 
assessed using DON in broiler chickens. In the first model, DON was given to broiler chickens 
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as an intra-crop bolus together with a mycotoxin detoxifier in order to study the plasma 
concentration–time profile of DON. In the second model, the same oral bolus was given, 
preceded by an oral bolus of mycotoxin detoxifier, to make sure the detoxifier was present 
in the whole intestinal tract when the mycotoxin was administered. In the third model, the 
mycotoxin detoxifier was mixed in the feed of broiler chickens, and after 1 week feeding, 
DON was given as an oral bolus. In order to evaluate the efficacy of these detoxifiers, plasma 
concentration–time profiles were set up and the main toxicokinetic parameters were 
compared. Two commercially available mycotoxin detoxifiers were tested, but they were not 
able to lower the oral availability of DON. As a positive control, AC was used. We showed 
that AC significantly reduced the absorption and oral availability of DON in all three models. 
It was concluded that these models are able to demonstrate the efficacy of mycotoxin 
detoxifiers in relation to EFSA guidelines. 
 
After the in vivo efficacy model, a similar bolus model for testing the interaction of 
mycotoxin detoxifiers with oral absorption of veterinary drugs was developed in Chapter V. 
As an interaction between tylosin and bentonite clay was observed in vitro, these 
compounds were used to develop the in vivo model. The interaction between bentonite and 
tylosin was investigated in broiler chickens, based on pharmacokinetic characteristics. 
Simultaneous oral administration of bentonite and tylosin significantly lowered plasma levels 
of tylosin and reduced the area under the plasma concentration–time curve (AUC0-inf), 
maximal plasma concentration (Cmax), time to maximal plasma concentration (Tmax) and 
relative oral bioavailability. The results proved unambiguously the binding of tylosin by 
bentonite. Simultaneous administration of tylosin (in the drinking water or feed) and 
bentonite (mixed in the feed as a mycotoxin binder) should therefore be avoided. A 
commercially available GMA binder was also evaluated in this study. It did not alter the oral 
absorption of tylosin and can therefore be safely co-administered with tylosin in animal 
feed. 
 
The final goal for in vivo modeling was to evaluate the correlation between unspecific and 
specific parameters for efficacy testing of mycotoxin detoxifiers. In Chapter VI, an 
experiment was conducted to investigate the effects of grains naturally contaminated with 
Fusarium mycotoxins and a yeast derived mycotoxin binder (G
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and specific parameters in turkey poults. Two hundred-forty 1-day-old male turkey poults 
were fed diets up to twelve weeks, formulated with minimally contaminated grains (control), 
control + 0.2% GMA, contaminated grains, or contaminated grains + 0.2% GMA. DON was 
the major contaminant of the contaminated grains and concentrations varied around 5 
mg/kg feed. Following unspecific parameters were selected: performance parameters, 
plasma biochemistry profile, morphometry and CD8
+
 T-lymphocyte count of the duodenum. 
Plasma concentrations of DON and DOM-1 were used as specific parameter and were 
correlated to the unspecific parameters. 
Zootechnical and plasma biochemistry parameters were altered by DON and/or GMA but 
were not consistent along the trial and cannot be used as parameters for efficacy testing of 
the mycotoxin detoxifier in turkey poults. DON reduced the villus height and apparent villus 
surface area in the duodenum. This effect was prevented by GMA addition to the diet. DON 
elevated the total CD8
+
 T-lymphocyte count in the duodenum but this effect was not 
prevented by GMA. No significant differences in plasma concentrations of DON and DOM-1 
between contaminated and contaminated + GMA groups were observed, concluding that 
GMA did not prevent DON absorption. The effect of GMA on morphometry parameters can 
therefore not be attributed to DON adsorption in the gut. As the CD8
+
 T-lymphocyte count in 
the duodenum correlates well with DON and DOM-1 plasma concentrations it can be 
concluded that this unspecific parameter is suitable to evaluate the efficacy of the mycotoxin 
binder on adsorption of DON in turkey poults. 
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Mycotoxines worden wereldwijd beschouwd als een belangrijk probleem omwille van hun 
schadelijke effecten op mens en dier. Dit leidt tot beduidende economische verliezen, 
voornamelijk in de varkens- en pluimveehouderij. De meest toegepaste methode om de 
schadelijke effecten van mycotoxines tegen te gaan, is het inmengen van mycotoxine 
detoxificerende producten in veevoeder. Deze voederadditieven kunnen onderverdeeld 
worden in mycotoxine binders, die de mycotoxines in het gastro-intestinaal stelsel 
adsorberen, en mycotoxine modifiërs, die mycotoxines in het gastro-intestinaal stelsel 
transformeren en gedeeltelijk of totaal onschadelijk maken. 
Deze voederadditieven dienen getest te worden op hun mogelijkheid om mycotoxines te 
detoxificeren zowel in vitro als in vivo. Bij de aanvang van het onderzoek waren er geen 
betrouwbare in vitro modellen beschikbaar, die zowel een grote verwerkingscapaciteit 
hebben als de omstandigheden van het gastro-intestinaal stelsel nabootsen. Bovendien 
waren er geen in vivo modellen voorhanden die de efficaciteit van deze producten toetsten 
gebaseerd op specifieke toxicokinetische parameters. Naast het testen van de efficaciteit 
van deze producten zijn er ook bedenkingen bij hun veiligheid, vooral wat betreft mogelijke 
interacties met de orale absorptie van veterinaire geneesmiddelen. Er waren eveneens noch 
in vitro noch in vivo modellen beschikbaar die de veiligheid van deze producten konden 
evalueren. 
De algemene inleiding van dit proefschrift vangt aan met een overzicht van de meest 
toxische en relevante mycotoxines. Vervolgens worden methoden beschreven die de impact 
van mycotoxines kunnen tegengaan, zowel vóór als na het oogsten. Mycotoxine 
detoxificerende producten vallen hier ook onder. Uiteindelijk wordt de belangrijkste 
Europese regelgeving, uitgaande van de Europese Commissie (EC) en de Europese Autoriteit 
voor de Voedselveiligheid (EFSA), beschreven. Daarbij werd uitgegaan van maximaal 
toegelaten gehaltes van mycotoxines in veevoeder en richtlijnen om de efficaciteit en 
veiligheid van mycotoxine detoxificerende producten te evalueren. 
De algemene doelstelling van dit doctoraatsonderzoek was om in vitro en in vivo modellen 
te ontwikkelen die de efficaciteit van mycotoxine detoxifiërs kunnen bepalen, evenals hun 
mogelijke interacties met de orale absorptie van veterinaire geneesmiddelen. 
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In Hoofdstuk I werd een in vitro model ontwikkeld om de efficaciteit van mycotoxine binders 
na te gaan, evenals de mogelijke interacties ervan met veterinaire geneesmiddelen. 
Darmepitheelcellen van het jejunum van varkens (IPEC-J2) werden gekweekt op Transwell® 
celcultuur inserts. Tijdens de eerste experimenten werd 0,5 of 1 µg/mL deoxynivalenol 
(DON) aan de inserts toegevoegd met of zonder actieve kool (AK) of een commercieel 
beschikbare glucomannaan binder (GMA). Een concentratie van 1 µg/mL gaf aanleiding tot 
een significante daling van de cellulaire leefbaarheid (vastgesteld aan de hand van de 
neutraal rood cytotoxiciteitstest) en cellulaire integriteit (vastgesteld aan de hand van 
transepitheliale elektrische weerstandsmetingen, TEER). Een concentratie van 0,5 µg/mL 
daarentegen, had geen invloed op de cellulaire leefbaarheid of integriteit. AK werd gebruikt 
als een positieve controle en was inderdaad in staat om de schadelijke effecten van 1 µg/mL 
DON volledig teniet te doen. Meer zelfs, AK verminderde de passage van DON doorheen de 
epitheliale monolaag bijna volledig (>99%), zowel bij 0,5 als 1 µg/mL. Deze resultaten tonen 
aan dat het model in staat is om de efficaciteit van mycotoxine detoxificerende agentia in 
vitro aan te tonen. GMA was in staat om de negatieve effecten van DON op de cellulaire 
viabiliteit en integriteit deels te verhinderen. Het additief verminderde de transepitheliale 
passage van DON met 37% tot 57% in vergelijking met AK en dit zowel bij cytotoxische als 
niet-cytotoxische concentraties, respectievelijk. 
In een tweede reeks experimenten werd een veiligheidsmodel ontwikkeld. De interactie 
tussen het macrolide antibioticum tylosine (20 µg/mL) en mycotoxine binders werd 
geëvalueerd aangezien sommige auteurs voorafgaandelijk mogelijke interacties tussen 
macrolide antibiotica en bentoniet klei rapporteerden. Bentoniet werd gebruikt als positieve 
controle en dit additief reduceerde de passage van tylosine doorheen de epitheliale 
monolaag met 82%, ten gevolge van tylosine-bentoniet binding. Het gecombineerd gebruik 
van tylosine en bentoniet klei in veevoeder kan bijgevolg tot therapiefalen van tylosine 
leiden. De GMA binder had geen effect op de transepitheliale tylosine passage, zodat beiden 
samen veilig gebruikt zouden kunnen worden in veevoeder. 
 
Een volgende specifieke doelstelling na de ontwikkeling van het in vitro model bestond er in 
in vivo modellen te ontwikkelen gebaseerd op farmaco- of toxicokinetische parameters. 
Daarvoor werden eerst gevoelige analysemethoden op punt gesteld om mycotoxines te 
kunnen detecteren en kwantificeren in dierlijk plasma.  
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In Hoofdstuk II werd een multi-mycotoxine analyse methode ontwikkeld voor identificatie 
en kwantificatie van verschillende toxicologisch belangrijke mycotoxines zoals DON, de-
epoxydeoxynivalenol (DOM-1), T-2 toxine (T-2), HT-2 toxine (HT-2), zearalenone (ZON), 
zearalanone (ZAN), α-zearalenol (α-ZOL), β-zearalenol (β-ZOL), α-zearalanol (α-ZAL), β-
zearalanol (β-ZAL), ochratoxine A (OTA), fumonisine B1 (FB1) en aflatoxine B1 (AFB1) in 
varkensplasma gebruik makende van vloeistofchromatografie gecombineerd met 
elektrospray ionisatie triple quadrupool tandem massaspectrometrie (LC-h-ESI-MS/MS). 
De staalvoorbereiding bestond uit een deproteïnizatie stap met acetonitrile, gevolgd door 
evaporatie van het supernatans en heroplossen van het droog residu in water/methanol 
(85/15, v/v). Elk plasmastaal werd tweemaal geanalyseerd, in ESI+ en ESI- modus. Voor de 
uitvoering van specifieke toxicokinetische studies met individuele mycotoxines, werden 
meer gevoelige analiet-specifieke LC-MS/MS methoden ontwikkeld. De multi-mycotoxine en 
analiet-specifieke methoden werden gevalideerd: matrix-afgestemde calibratiecurven 
werden opgesteld voor elke analiet en correlatiecoëfficiënten en goodness-of-fit 
coëfficiënten varieerden, respectievelijk, tussen 0,9974-0,9999 en 2,4-15,5%. De precisie en 
accuraatheid binnen één analyse en tussen verschillende analysen viel binnen de 
aanvaardbare grenzen. De kwantificatielimieten voor de multi-methode en analiet-specifieke 
methoden varieerden, respectievelijk, tussen 2 en 10 ng/mL en 0,5 en 5 ng/mL. De 
detectielimieten varieerden, respectievelijk, tussen 0,01–0,52 ng/mL en < 0,01–0,15 ng/mL. 
 
Verschillende Fusarium spp. kunnen welgekende mycotoxines zoals de trichothecenen, 
fumonisinen en/of ZON produceren, maar ook minder gekende toxines zoals beauvericine 
(BEA) en enniatines (ENNs), waaronder enniatine (ENN) A, A1, B en B1. Verschillende studies 
hebben de cytotoxische effecten van ENNs en BEA reeds aangetoond op verschillende 
celtypes. Gegevens in verband met hun in vivo toxiciteit daarentegen ontbreken. Om de 
toxicokinetische eigenschappen te onderzoeken en het effect van mycotoxine 
detoxificerende voederadditieven op de absorptie van ENNs of BEA te evalueren, zijn 
methoden noodzakelijk om deze componenten te identificeren en kwantificeren in plasma. 
Bijgevolg werd er een methode ontwikkeld voor identificatie en kwantificatie van BEA, ENN 
A, A1, B en B1 in varkensplasma gebruik makende van LC-h-ESI-MS/MS, zoals beschreven in 
Hoofdstuk III. De staalvoorbereiding was identiek aan deze vermeld in het voorgaand 
hoofdstuk, met uitzondering voor wat het heroplossingsolvens betreft (acetonitrile/water, 
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80/20, v/v). De methode werd opnieuw gevalideerd: matrix-afgestemde calibratiecurven 
werden opgesteld voor elke analiet en correlatiecoëfficiënten en goodness-of-fit 
coëfficiënten varieerden, respectievelijk, tussen 0,9980-0,9995 en 5,2-11,3%, respectievelijk. 
De precisie en accuraatheid binnen één analyse en tussen verschillende analysen viel binnen 
de aanvaardbare grenzen. De kwantificatielimiet was 0,1 ng/mL voor ENN A en A1 en 0,2 
ng/mL voor BEA, ENN B en B1. De detectielimiet was ≤ 10 pg/mL voor alle componenten. De 
methode werd succesvol toegepast op biologische stalen afkomstig van een varken dat een 
orale bolus (0,05 mg/kg LG) van de onderzochte mycotoxines toegediend kreeg. De 
resultaten bevestigden de toepasbaarheid van de methode voor toxicokinetische studies 
met ENNs, althans wanneer deze worden toegediend aan de geteste dosering. 
 
In de volgende fase was het de bedoeling om, met behulp van de op punt gestelde 
analysemethoden, in vivo modellen te ontwikkelen gebaseerd op toxicokinetische 
parameters. Daarom werden drie orale bolus modellen ontwikkeld, getoetst aan de hand 
van DON bij mestkippen (Hoofdstuk IV). In het eerste model werd DON oraal in de krop 
toegediend met of zonder een mycotoxine detoxifiër om het plasmaconcentratie-tijdsprofiel 
van DON op te stellen. In het tweede model werd dezelfde orale bolus toegediend, echter 
voorafgegaan door een orale bolus van de mycotoxine detoxifiër zodat het additief reeds in 
het gastro-intestinaal stelsel aanwezig was vóór toediening van DON. In het derde model 
werd het mycotoxine detoxificerende additief ingemengd in het voeder en werd, na 1 week 
voederen, DON als bolus toegediend. Om de efficaciteit van de additieven na te gaan 
werden plasmaconcentratie-tijdsprofielen van DON opgesteld en de belangrijkste 
toxicokinetische parameters onderling vergeleken. Twee commercieel beschikbare 
mycotoxine detoxifiërs werden onderzocht, maar deze waren niet in staat om de orale 
absorptie van DON te verminderen. Als positieve controle werd opnieuw AK ingesloten in de 
proefopzet. AK was effectief in het verlagen van de orale absorptie en biologische 
beschikbaarheid van DON in alle modellen. Aldus kan men concluderen dat de ontwikkelde 
modellen in staat zijn de efficaciteit van mycotoxine detoxificerende producten aan te 
aantonen, in relatie met de richtlijnen van de Europese Autoriteit voor de Voedselveiligheid. 
 
Een volgende doelstelling, na de ontwikkeling van in vivo efficaciteitsmodellen, bestond erin 
een gelijkaardig bolus model te ontwikkelen om de interactie tussen mycotoxine detoxifiërs 
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en de orale absorptie van veterinaire geneesmiddelen na te gaan (Hoofdstuk V). De 
interactie tussen tylosine en bentoniet werd reeds in vitro aangetoond en werd vervolgens 
getoetst in vivo. Mestkippen kregen een orale bolus van tylosine toegediend, al dan niet 
gecombineerd met bentoniet klei. Gelijktijdige toediening van bentoniet en tylosine 
verlaagde de plasmaconcentraties van tylosine significant. Dit bleek uit de verminderde 
oppervlakte onder het plasmaconcentratie-tijdsprofiel (AUC0-inf), maximale 
plasmaconcentratie (Cmax), tijd tot maximale plasmaconcentratie (Tmax) en relatieve orale 
biologische beschikbaarheid. Deze resultaten toonden ondubbelzinnig aan dat tylosine 
interageert met door bentoniet. Simultane toediening van beide producten in het voeder of 
drinkwater is daarom niet aangewezen. GMA werd ook ingesloten in de proefopzet, maar dit 
additief veranderde de farmacokinetische parameters van tylosine niet. Bijgevolg kunnen 
tylosine en GMA veilig samen in voeder ingemengd worden. 
 
De finale doelstelling van in vivo modellering bestond er in om de correlatie na te gaan 
tussen niet-specifieke en specifieke parameters voor efficaciteitsstudies van mycotoxine 
detoxifiërs. Daarom werd een experiment uitgevoerd om het effect na te gaan van granen 
natuurlijk gecontamineerd met Fusarium mycotoxines en een mycotoxine binder (GMA), op 
zowel specifieke als niet-specifieke parameters bij kalkoenen. Dit werd beschreven in 
Hoofdstuk VI. Tweehonderd veertig eendagskuikens kregen verschillende diëten, namelijk 
controle (minimaal gecontamineerd), controle + 0.2% GMA, gecontamineerd of 
gecontamineerd + 0.2% GMA. DON was de voornaamste contaminant met een gehalte van 
ongeveer 5 mg/kg. De volgende niet-specifieke data werden geëvalueerd: zoötechnische 
prestaties, biochemisch plasmaprofiel, duodenale morfometrie en CD8
+
 T-lymfocytenaantal 
in het duodenum. De gemeten plasmaconcentraties van DON en DOM-1 werden gebruikt als 
specifieke parameter en gecorreleerd aan de niet-specifieke data. 
De zoötechnische gegevens en het biochemisch plasmaprofiel werden gewijzigd ten gevolge 
van DON en/of GMA, maar dit bleek niet consistent te zijn gedurende de ganse fokperiode 
zodat deze parameters niet kunnen gebruikt worden om de efficaciteit van mycotoxine 
detoxifiërs bij kalkoenen na te gaan. DON zorgde voor kortere villi en verminderde 
schijnbaar villus oppervlakte in het duodenum. Dit effect werd teniet gedaan door GMA 
toevoeging in het voeder. DON zorgde tevens voor een toegenomen influx van CD8
+
 T-
lymfocyten in het duodenum maar dit effect bleef gehandhaafd in aanwezigheid van GMA. 
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Er werden geen significante verschillen in DON of DOM-1 plasmaconcentraties aangetoond, 
waaruit kan geconcludeerd worden dat GMA niet in staat is om de absorptie van DON te 
verlagen. Het positieve effect van GMA op villuslengte en schijnbaar villus 
absorptieoppervlak kon daarom niet te wijten zijn aan adsorptie van DON aan GMA. Het 
aantal CD8
+
 T-lymfocyten in het duodenum correleerde met de plasmaconcentraties van 
DON en DOM-1, zodoende kan deze niet-specifieke parameter als kandidaat merker 
beschouwd worden om de efficaciteit van de mycotoxine binder tegen DON in kalkoenen te 
evalueren. 
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Frank Pasmans voor mogelijkheid om de experimenten met de IPEC-J2 celcultuur uit te 
voeren. Ook jouw deur stond altijd open voor mij. Prof. dr. Lynn Vanhaecke, bedankt voor de 
vlotte samenwerking met de HR-MS planning. En samen met Dr. Alfons Callebaut van harte 
bedankt voor de opbouwende kritiek, waardevolle opmerkingen en suggesties aan dit 
proefschrift. 
Wie heeft mij in de wondere wereld van LC-MS/MS geïntroduceerd? Siegrid. Zonder jouw 
hulp en input zouden de 2 LC-MS/MS papers niet tot stand gekomen zijn, hele dikke merci 
daarvoor! Eveneens bedankt om altijd ter hulp te schieten als de TSQ weer eens haar kuren 
had en niet wou meewerken. Telkens opnieuw kon ik op jou rekenen! 
Toen ik hier in september 2010 arriveerde, waren mijn bureaugenoten nog 3 dames, die 
evenwel hun mannetje stonden. Virginie, het ga je goed in DGZ! Joline, de combinatie van al 
die langdurige varkensproeven en professioneel koersen was zeer lastig, maar je hield met 
verve stand, chapeau daarvoor! Ann O., succes met de nieuwe job.  
Als het over dierproeven gaat, kunnen we uiteraard niet om Anja heen. ’s Avonds en tijdens 
het weekend, altijd stond je met de glimlach klaar om mee te helpen met de beestenboel. 
Heel erg bedankt! 
Ondertussen zijn de bureaugenoten 2 mannelijke collega’s geworden. Nathan en Thomas, 
gelukkig kon ik met jullie over iets anders praten als het ‘weer maar eens’ over baby’s ging. 
Hopelijk kunnen we de niet-werk gerelateerde activiteiten, zoals LAN-parties, squashen en 
de vrijdagavond-pint, nog lang volhouden. 
De nieuwste ‘mytoxer’, Sophie. Hopelijk heb je je draai al gevonden op de vakgroep. We 
zullen die Alternaria toxines wel klein krijgen! De (ex-)mytoxer aan de overkant, Elin, 
bedankt voor de hulp en raadgeving met de celculturen. Eind dit jaar terug afspraak op het 
Kerstbal. Gunther, ook jij stond altijd klaar voor hulp bij de dierproeven. Ik ben er van 
overtuigd dat je de geheime samenwerking tussen Clostridium en mycotoxines zal 
ontrafelen. Elke G., als tijdelijk mytoxer heb jij ook je steentje bijgedragen aan mijn 
onderzoek, bedankt! 
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Het LPS-team: Elke, Anneleen en Heidi. Bij jullie kon ik altijd terecht voor een babbel of voor 
een helpende hand, bedankt! Elke, uiteindelijk ben je van die kalverproeven vanaf. Ook al 
zijn ze heel schattig, ze willen soms toch echt niet echt meewerken. Maar als het er toch nog 
eens van zou komen, weet je me te vinden! Anneleen, succes met de verbouwingen, maar 
met zo’n klusser in huis zal dat wel geen probleem zijn. Heidi, de vele varkensproeven zijn 
zeker en vast niet voor niets geweest. Het doctoraat loert om de hoek, succes met de laatste 
loodjes! 
Voor de GLP bureau zou ik graag Ann S. willen bedanken om mij in te leiden in het GLP 
gebeuren. An M., bedankt voor raad en daad ivm de TSQ. De KELA-boys: Kris DK., Kris B. en 
Marc, bij jullie kon ik ook altijd terecht om over koetjes en kalfjes te praten, hetgeen het 
onderzoek aangenamer maakte. En Kris B., gelukkig weet jij meer van computers dan ikzelf, 
zodat de redder in PC-nood niet ver te zoeken is! 
Nathalie, bedankt om de berg paperassen en de ganse papierwinkel op jouw te nemen. 
Dankzij jou hoeven we ons daar niet te veel van aan te trekken! 
Jelle, ook al sta je dikwijls alleen in het labo en ben ik meestal een toevallige passant, toch 
konden we dikwijls een praatje slaan. Eveneens succes met de verbouwingen en bedankt 
voor alle hulp bij de labo analyses en dierproeven. 
Zo zijn we bij de biochemie gekomen en daar is er toch iemand die veel meer is dan een 
collega. Koen, amigo from the first minute! Van in het begin hebben we samen opgetrokken, 
en ondertussen hebben we veel dingen meegemaakt die ik niet zal vergeten. Memorabele 
galabals, uitstapjes naar Flanders Expo, sleepovers of gewoon samen één (?) gaan drinken. 
Thanks! Ik vind het nog altijd sjiek dat je de halve wereld rondgereisd hebt om mij te 
bezoeken! Hopelijk blijf je nog een tijdje aan de vakgroep.. 
Prof. dr. Meyer, Evelyne, bedankt voor uw interesse in het mycotoxine onderzoek. Uw 
goedgemutstheid en vriendelijkheid zorgen voor een positieve sfeer op de vakgroep. 
Jella, welkom terug van nooit helemaal weggeweest. Donna en Jorien, succes met de, 
respectievelijk, laatste en eerste loodjes van het onderzoek. Kristel, jij vrolijkt altijd de resto-
bezoeken op met nieuwe weetjes van binnen en buiten de vakgroep. 
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Niet enkel binnen de vakgroep maar ook daarbuiten heb ik steun gehad bij mijn 
doctoraatsonderzoek. En niet in het minste van mijn ouders. Al meer dan 26 jaar steunen 
jullie mij in alles wat ik doe en helpen jullie mij om te bereiken wat ik wil. Ook al zeg ik het 
niet genoeg: bedankt voor alles! 
Mamies, ik weet dat jullie heel trots zijn op je kleinzoon. Beide papies zouden dit ook zijn. 
Hetgeen jullie voor mij gedaan hebben en voor mij betekenen is teveel om op te noemen. 
Bedankt voor alles! Er zullen nog vele avonturen volgen en ik hoop echt dat jullie daar nog 
bij zullen zijn. 
Dirk en Christine, bedankt voor de uitgebreide interesse in mijn doctoraatsonderzoek! Eva 
en Yves, voor jullie is de eindstreep van het studeren heel dichtbij, go for it! Yves, sjiek dat 
onze wegen na al die jaren opnieuw kruisen! 
Mijn nauwste vrienden, Jannes, Diederik, Floris, Goussey, Leander, Lieven, Craene, Laleman, 
Pauwels en Strubbe, bedankt voor alle zalige momenten. Ook in de post-universitaire tijd zijn 
we blijven afspreken en moeten we blijven doen! 
Stefanie en Koen, bedankt voor de kippen die ik bij jullie mocht ophalen. Zoals je ziet hebben 
ze hun steentje bijgedragen aan de wetenschap. 
And last but not least, Joke. Jij betekent alles voor mij. Samen gaan we een mooie toekomst 
tegemoet in Oekene. Er zijn nog zoveel momenten die ik samen met jou wil beleven! 9 mei 
2014… ik kijk er al naar uit! 
 
Mathias 
